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ABSTRACT 
Adjuvants are critical components of vaccines because they enhance antigen-specific 
immune responses to protect against disease. However, the mechanisms of action (MOA) of 
most adjuvants are not well understood and they particularly are under-investigated in large 
animal species including pigs and cattle. This knowledge gap may limit our ability to design 
effective vaccines for livestock. Understanding the mechanisms by which adjuvants mediate 
their effects could provide critical information on how innate immunity influences the 
development of adaptive immunity. Furthermore, knowledge on the MOA of adjuvants may 
inform vaccine the safety. In the present investigations, we studied the MOA of the experimental 
adjuvant polydi(sodium carboxylatoethylphenoxy)phosphazene (PCEP) in pigs. First, we 
administered PCEP by intradermal (i.d.) injection into pigs and assessed its impact on the 
expression of select immune response genes known as ‘adjuvant response genes’ over time. We 
observed that PCEP induced the expression of chemokine (C-C motif) ligand 2 (CCL-2), 
proinflammatory cytokine interleukin (IL)-6, IL-13 and macrophage scavenger receptor 1 
(MSR1) genes at the site of injection. Next, we evaluated whether these gene expressions 
translate to protein transcription by accessing local and systemic production of cytokines after 
intradermal injection of PCEP into piglets and whether the cytokines produced induces 
recruitment of immune cells at the site of injection and in the draining lymph nodes.  We 
observed that, at the site of injection, PCEP induced increased production of IL-1β and IL-13 
cytokines, increased cellular infiltration of macrophages, T and B cells, and other leucocytes 
especially neutrophils as well as showing necrotic debris which might cause release of damage 
associated molecular patterns (DAMPs) and activate the inflammasome. In the draining lymph 
nodes, the cytokines IL-1β and IL-6 were elevated and there was increased leucocyte infiltration. 
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No changes in cytokine levels were detected in the blood after PCEP injection indicating that the 
immunostimulatory effect of PCEP is local but not systemic.   
   Because i.d. injection of PCEP induced signs of necrosis (cell death), we investigated 
whether reduction of the adjuvant dose reduced tissue damage without negatively impacting 
antigen-specific immune responses. We conducted two studies to address this issue. In the first 
study, we injected piglets i.d with varying doses of PCEP alone as follows: 500 µg, 100 µg,  or 
20 µg PCEP into piglets and evaluated the inflammatory responses. The four parameters 
evaluated were granuloma formation, lymphocytic infiltration, necrosis, and suppurative 
inflammation at the injection site and the draining lymph nodes over 14 days. When PCEP was 
injected alone, we observed that only 500 µg consistently induced significant necrosis and 
suppurative inflammation. However, the medium dose (100 µg) PCEP did induce significant skin 
granulomas and lymphocyte infiltration, where as the only significant response induced in the 
skin by the lower dose (20 µg) PCEP was lymphocyte infiltration. In the draining lymph nodes, 
only 500 ug PCEP significantly higher suppurative inflammation. No necrosis or granuloma was 
observed in the lymph nodes in all the doses. Thus, the high dose of adjuvant triggered the most 
significant pathological signs of tissue damage at both sites (skin and draining lymph nodes). In 
the second study, we co-injected i.d varying doses of PCEP 500 µg, 100 µg, 20 µg, or 4 µg co-
formulated with inactivated swine influenza virus (SIV) H1N1 antigen and measured the four 
parameters of inflammatory response (granuloma formation, lymphocytic infiltration, necrosis, 
and suppurative inflammation) at days 20 and 41 after a single injection at each sites and also 
assayed SIV H1N1-specific antibody titers.  We observed that the highest dose of the adjuvant 
PCEP (500 µg) induced significant inflammatory responses in 3 of the 4 parameters assessed at 
day 20, and by day 41, this high dose of adjuvant had caused significant tissue response in all the 
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four parameters assessed. Interestingly, only 500 µg of PCEP induced significant granuloma 
formation and necrosis (the more severe lesions) at both time points. Of the lower doses, 100 µg 
and 20 µg of PCEP both induced significant lymphocytic infiltration compared to 4 µg of PCEP, 
SIV and PBS groups. The lowest dose, 4 µg of PCEP did not induce any significant 
inflammatory response in any of the four parameters assessed. When SIV H1N1-specific 
antibody titers were assessed in immunized animals, only 500 µg, 100 µg and 20 µg of PCEP 
induced significant antibody responses when compared to SIV H1N1, confirming that these 
doses of PCEP had adjuvant activity. In contrast, 4 µg of PCEP did not induce any significant 
SIV H1N1-specific antibody titers, indicating that this dose did not have adjuvant activity.  
These results suggest that induction of inflammatory responses at the site of injection is 
necessary for adjuvant activity. However, not all responses assessed may be required for 
adjuvant activity as induction of very severe inflammatory responses was not associated with any 
additional increase in antigen-specific antibody titres. Thus, the quality of the inflammatory 
response is important but severe inflammation was not beneficial to antigen-specific immune 
responses 
Together, our data indicate that in pigs, the adjuvant PCEP stimulated early inflammatory 
responses at the injection site, creating an immunocompetent environment that led to activation 
of innate immune response genes, production of cytokines and chemokines, and recruitment of 
various immune cells. These events contribute to the adjuvant activity of PCEP. We propose a 
MOA model whereby PCEP induces tissue damage at the site of injection and the subsequent 
release of damage associated molecular patterns (DAMPs) which may activate the 
inflammasome and contribute to increased immunogenicity of the co-administered antigens. 
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CHAPTER 1: LITERATURE REVIEW 
1.1 The immune system  
The immune system is a framework of cells, tissues, and organs that cooperate to shield 
the body against infection by "outside" invaders (Medzhitov & Janeway, 1997). These foreign 
invaders are principally microorganisms such as bacteria, parasites or fungi. To ensure that 
individuals are adequately protected against infections, the immune system should be able to 
perform the following function: 1) Immunological recognition of the pathogen or antigen, 2) 
Containment of the infection and possibly killing of the infectious agent through effector 
functions, 3) Immune regulation that limits harm to the host, 4) Establish immunological 
memory. Immunity is divided into two parts dictated by the speed and specificities of the 
responses induced (Abbas et al., 2014b). These are named the innate and the adaptive immune 
responses, in spite of the fact that there is much association between them. 
1.1.1. Overview of innate immunity 
The innate immune system is present since birth and it is the initial response by the body 
to eliminate microbes and to prevent infection (Akira et al., 2001; Kawai & Akira, 2010). Innate 
immunity is an antigen-nonspecific defense mechanisms that is activated immediately or within 
hours after exposure to microbes and antigens (Medzhitov, 2001).  
Innate immune cells such as neutrophils, epithelial cells, fibroblast and monocytes and 
tissue phagocytic cells such as macrophages recognize pathogen-associated molecular patterns 
(PAMPs) present in infectious agents which bind to pattern-recognition receptors (PPRs) 
expressed by mammalian cells (Akira et al., 2001). Pathogenic microorganisms are remarkably 
different but they have some basic patterns in segments of their structures, for example, the cell 
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wall or nucleic acids. PRRs can react to PAMPs including proteins, lipids, and sugars, DNA and 
RNA. Various PAMPs have been depicted for some classes of pathogenic microorganisms, for 
example, Gram-negative organisms, Gram-positive microbes, viruses, fungi, and protozoa as 
described in Table 1. The cooperation among PRRs and PAMPs include the initial reactions to 
outside or foreign substances and are basic for pathogen regulation and amplification of the full 
repertoire of the immune response (Mogensen, 2009). The innate immune cells release 
chemokines and cytokines that trigger inflammation to contain the infection and immune cell 
recruitment to kill the invading pathogen. Recruited defense cells include phagocytic cells such 
as blood-derived neutrophils, macrophages, mast cells, basophils, eosinophils and natural killer 
(NK) cells are recruited and release inflammatory mediators that augment more inflammation and 
recruitment of immune cells (Takeda & Akira, 2005)  
1.1.1.1 Innate immune receptors and their respective ligands.  
PRRs are developmentally moderated receptors on different types of innate immune cells 
and are equipped for reacting to PAMPs (Akira et al., 2001). PRRs can reside on the cell surface 
as well as in the cytosol (Akira et al., 2001; Medzhitov, 2007). Their classifications include Toll-
like receptors (TLRs) which are communicated on the cell surface or on the endosome’s plasma 
layer, C -type lectin receptors (CLRs) and scavenger receptors which are just present on the cell 
surface (Figdor et al., 2002), and cytosolic PRRs such as NOD-like receptors (NLRs) and RIG1-
like receptors (RLRs) which can aggregate to form inflammasomes (Bryan et al., 2010; Compan 
et al., 2015; Figdor et al., 2002). RLRs have a place with the RNA helicases family that explicitly 
distinguishes RNA species got from infections by viruses in the cytoplasm and facilitate anti-
viral suppression through induction of type I interferons (Yoneyama & Fujita, 2008). NLRs 
establish a vast group of intracellular PRRs, for example, NOD1, NOD2 and NALP3 {NACHT 
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[neuronal apoptosis inhibitory protein (NAIP), CIITA, HET-E and TP-1]}, LRR (leucine-rich 
repeat) and PYD (pyrin domain containing protein 3)} (Martnon et al., 2009; Schroder & 
Tschopp, 2010; Ting et al., 2008). NOD1 and NOD2 bind to intracellular bacterial cell products, 
and NALP3 reacts to different stimuli to frame a multi-protein complex named the NALP3 
inflammasome. Together, they initiate caspase-1 activation, which thus cleaves pro-IL-1β, pro-
IL-18, and pro-IL-33 and releasing their bioactive components (Fritz et al., 2006; Martnon et al., 
2009). In addition, intracellular double stranded DNA (dsDNA) discharged by DNA viruses or 
bacteria work as PAMPs to initiate type I IFN through unidentified pathways (Ishii & Akira, 
2006). In addition to PAMPs, endogenous molecules discharged by host cells due to damage, 
pathogen invasion, and harm, can also be recognized by TLRs, NLRs, RLRs (Shi et al., 2003). 
Molecules related with tissue damage, for example, uric acid, nucleotides, adenosine triphosphate 
(ATP), reactive oxygen species, and cytokines are discharged at the site of injection if tissue 
injury happens (Shi et al., 2003). Particulate vaccine adjuvants cause local tissue damage and cell 
death at the injection site hence can activate inflammmasomes (Kool et al., 2008). TLRs are the 
most studied PRRs in pigs but many other PPRs are not well understood. Because PRRs tend to 
share high sequence homology among species, synthetic/purified PAMPs used in murine or 
human studies are also presumed to stimulate innate immune receptors in swine. For instance, 
pigs respond to peptidoglycan (PGN) and lipoteichoic acid that stimulate TLR2, poly I:C 
stimulates TLR3 (Auray et al., 2010), lipopolysaccharide (LPS) stimulates TLR4 (Islam et al., 
2012; Uddin et al., 2012), imiquimod (which belongs to a group of drugs called immune response 
modifiers) and ssRNAstimulate TLR7/8 (Calzada-Nova et al., 2010), CpG ODN stimulates TLR9 
(Auray et al., 2010; Calzada-Nova et al., 2010; Dar et al., 2010) and muramyl dipeptide (MDP) (a 
constituent of both Gram-positive and Gram-negative bacteria) stimulates NOD receptors (Jozaki 
et al., 2009). This high degree of homology may facilitate research on the other PRR members. 
4		
However, NLRs, RLRs and CLRs have not been described in pigs. 
 
 
Table 1.1 Pattern Recognition Receptors, localization, their ligands, and origin in humans, mice 
and pigs. 
TLRs (Toll-like 
receptors) (present 
in mice, human and 
pig) 
Localization Ligands 
(PAMPs or 
DAMPs) 
Origin of the ligands 
TLR 1 (mice, human) Plasma 
membrane 
Triacyl 
lipoprotein 
Bacteria (Takeuchi et al., 2002) 
TLR 2 (mice, human 
and pig) 
Plasma 
membrane 
Lipoprotein Bacteria, viruses, parasites, self (Auray et 
al., 2010; Schröder et al., 2003) 
TLR 3 (mice, human 
and pig) 
Endolysosome dsRNA Virus (Auray et al., 2010; Sen & Sarkar, 
2005) 
TLR 4 (mice, human 
and pig) 
Plasma 
membrane 
LPS Bacteria, viruses, self (Islam et al., 2012; 
Tapping et al., 2000; Uddin et al., 2012) 
TLR 5 (mice, human) Plasma 
membrane 
Flagellin Bacteria (Hayashi et al., 2001) 
TLR 6 (mice, human) Plasma 
membrane 
Diacyl 
lipoprotein 
Bacteria, viruses (Henneke et al., 2005) 
TLR 7 (mice, human 
and pig) 
Endolysosome ssRNA Virus, bacteria, self (Calzada-Nova et al., 
2010; Crozat & Beutler, 2004) 
TLR 8 (mice, human 
and pig) 
Endolysosome ssRNA Virus, bacteria, self (Calzada-Nova et al., 
2010; Heil et al., 2004) 
TLR 9 (mice, human 
and pig) 
Endolysosome CpG-DNA Virus, bacteria, protozoa, self (Auray et al., 
2010; Bauer et al., 2001; Calzada-Nova et 
al., 2010; Dar et al., 2010) 
TLR 10 (only in 
human) 
Endolysosome Unknown Unknown (Hasan et al., 2005) 
TLR 11 (only in mice) Plasma 
membrane 
Profilin-like 
molecule 
Protozoa (Yarovinsky et al., 2005) 
TLR 12 and 13 only in 
mice 
Endolysosome Unknown Unknown (Andrade et al., 2013) 
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1.1.1.2 Innate immunity in the skin 
Before discussing innate immunity in the skin, a brief anatomy of the porcine skin will be 
provided. 
1.1.1.2.1 Brief anatomy of porcine skin 
The skin is the biggest organ of the body making up approximately 20% of the total body 
weight and it receives approximately 33% of all blood circulating through the body. The skin 
protects against environmental injuries such as biologic, physical, or chemical substances. 
Porcine skin has been broadly utilized as a substitute for human skin in different fields of 
dermatological research as they share certain similarities (Klíma et al., 2009; Laurent et al., 
2007). Similar to human skin, porcine skin is partitioned into three histological layers from top to 
bottom namely: the epidermis, the dermis and the hypodermis (or subcutis) as described in figure 
1, each with a particular role in the general skin functions (Laurent et al., 2007).  
The most superficial layer of the skin is the epidermis, which is the first barrier of protection 
from the invading of foreign substances. The epidermis is composed of layers of flattened, 
anucleated cells and keratin filaments, interfilament matrix and glycolipid. A basal, cuboidal cell 
layer of epithelia settles upon thick basal lamina which protects the germinal cells that are 
important to the recovery of the layers of the epidermis. These germinal cells are isolated from 
the dermis by the basement membrane (Cartlidge, 2000). Epidermal turn-over is very high and is 
estimated to occur every 14-30 days based on the skin region. 
The dermis is the thickest of three layers of skin and it contains elements necessary for 
thermoregulation and it supports the vascular system by supplying the avascular epidermis with 
supplements. The dermis contains fibroblasts, which emit collagen, elastin and ground substance 
that give the skin structural support and flexibility. Likewise present are immune cells that 
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protect against foreign antigens penetrating the epidermis. The hypodermis is the deepest layer of 
the skin comprised of a system of fat and collagen cells. It works as both a cover, preserving the 
body's warmth, and as a safeguard to the internal organs through shock absorption. It likewise 
stores fat as energy reserves for the body. The veins, nerves, lymph vessels, and hair follicles 
likewise cross through this layer (Cartlidge, 2000) 
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Figure 1.1 Comparative histological aspect of porcine (left) and human (right) skin 
(haematoxylin-eosin-saffron staining). HF: hair follicle, Mu and arrowhead: Arrector pili muscle, 
SwG: Sweat gland, SG: sebaceous gland, Ad: Adipocytes (hypodermis) adopted from (Debeer et 
al., 2013) 
 
Skin innate immunity 
The skin innate immune systems help to protect against pathogen colonization and 
invasion. The uppermost layer of the epidermis and the corneal layer in the eyes are unique layers 
not present in other epithelia that are exposed to the external environment (such as the gut and 
lung epithelia) (Kupper & Fuhlbrigge, 2004; Nestle et al., 2009). Dead keratinocytes in the 
epidermis and corneal layer provide the skin and eye with a physical barrier (Kupper & 
Fuhlbrigge, 2004; Nestle et al., 2009). Keratinocytes (sometimes referred to as "basal cells" or 
"basal keratinocytes”) constitute 90% of the cells in the epidermis, the outermost layer of the skin 
(Baroni et al., 2012; Hsu, Li, & Fuchs, 2014). Keratinocytes produce antimicrobial peptides 
(AMPs) in response to infection including human β-defensins, cathelicidins and RNases (Otto, 
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2010; Pivarcsi et al., 2004; Schauber & Gallo, 2008) but the pig lacks α-defensins (Sang et al., 
2009). DCs of the epidermis are known as Langerhans cells and they express PRRs which can 
detect invading microorganisms via PAMPs expressed on the invading microorganism cell 
surface; this interaction initiates early immune responses in the skin (Fournier & Philpott, 2005). 
The underlying dermis is anatomically more complicated, with greater cell diversity (Basset et 
al., 2003) including the granular, spinous and basal layers. The basal layer is primarily comprised 
of basal keratinocytes and undifferentiated cells, which can be viewed as the undeveloped cells of 
the epidermis. They develop into keratinocytes of the stratum spinosum, which then relocate 
externally. Other cell type also found inside the basal layer which incorporate melanocytes 
(pigment generating cells), Langerhans DCs, and Merkel cells (that have touch receptors) (Härle-
Bachor & Boukamp, 1996; Jensen et al., 1999).  
Immune cells present in the dermis include Langherham DCs, macrophages, mast cells, B 
and T-cells, plasma cells, NK cells, fibroblasts and innate γδ T-lymphocytes and invariant natural 
killer T-cells (iNKTcells) (Kupper & Fuhlbrigge, 2004; Nestle et al., 2009). These skin immune 
cells all express PRRs to detect invading pathogens. The skin is constantly exposed to external 
factors (e.g., ultraviolet radiation, pollution, topical medications, skin care products) that can alter 
the balanced relationship between the skin and its microbiome. Such disruptions may result in 
increased risk for infections, chronic inflammatory skin disease (e.g., atopic dermatitis, psoriasis, 
rosacea, and acne), pruritic, and irritated skin (Zeeuwen et al., 2013). 
While an essential capacity of immune cells present in the skin is discovery of invading 
microorganisms through PRRs, another imperative capacity is to maintain the harmony between 
the host and the skin microbiome. It is thought that like commensal microorganisms found in the 
gastro-intestinal (GI) tract, skin microorganisms assume a crucial role in keeping pathogenic 
organisms from colonizing the skin’s microenvironments. Bacteria are present on the skin 
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surface, the deeper layers of the epidermis, the dermis, and dermal adipose tissue (Weyrich et al., 
2015). The majority of the microorganisms in the skin are harmless or beneficial, providing 
protection against pathogens modulating the host’s cutaneous innate and adaptive immune 
systems (Baldwin et al., 2017). Commensal species of microorganisms that naturally reside on 
the surface of the skin are an integral part of the innate immune system. These bacteria protect 
against pathogen growth by competing for nutrients and space. Some bacteria directly restrict the 
growth of competitors via production of antimicrobial compounds that can inhibit reproduction of 
closely related species without affecting the organisms producing them.   
Staphylococcus epidermis reside on normal skin and they have been shown to suppress 
inflammation by inducing secretion of the interleukin-10 by APCs (Chau et al., 2009; Lai et al., 
2009). Staphylococcus epidermis also secretes a unique lipoteichoic acid that acts through a 
TLR2-dependent mechanism to inhibit inflammatory cytokine release from keratinocytes and 
induction of inflammation triggered by injury (Gallo & Nakatsuji, 2011; Lai et al., 2009). The 
balanced interactions between the host cells and bacterial populaces are influenced by host and 
environmental factors and this imbalance may contribute to chronic inflammatory skin diseases, 
such as atopic dermatitis, psoriasis, brosacea, or acne (Rosenthal et al., 2011; Schommer & Gallo, 
2013). 
1.1.1.3.2 APCs activation on the skin and migration to the draining lymph node. 
DCs (Langerhans cells and macrophages) present antigens to naive T cells. Epidermal 
Langerhans cells utilize their dendrites (arm-like projections) to survey the environment, 
particularly in the stratum corneum. Langerhans cells recognize PAMPs by PRR interaction then 
migrate to the lymph nodes draining the site of infection and present antigens to naive T-
lymphocytes. DCs express explicit attachment molecules and develop chemoattractant receptors 
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that enable them to react to an assortment of ligands (Sozzani et al., 1997; Sozzani et al., 1995), 
which control their movement. For instance, to migrate towards and to invade non-lymphoid 
peripheral tissues, juvenile DCs (and a portion of their precursors, especially monocytes) use 
explicit chemokine receptor-ligand pathways, for example, CCR2-CCL2 (Geissmann et al., 2003; 
Merad et al., 2002), CCR5-CCL5 (Stumbles et al., 2001), and CCR6-CCL20 (Le Borgne et al., 
2006). Once they take up antigen, DCs undergo a maturation process to become specialized 
APCs. Specifically, these mature DCs have reduced endocytic abilities, reduced expression of 
CCR5 and CCR6 and increased expression of CCR7, which helps to traffic to the draining lymph 
nodes and show expanded capacity to display and present antigen (Ohl et al., 2004; Willimann et 
al., 1998). Mature DCs have enhanced expression of MHC class II and co-stimulatory molecules 
(CD80, CD86 and CD40), development marker (CD83), CCR7 and CXCR4 (Lechmann et al., 
2001; Ohl et al., 2004) and increased ability to secrete cytokines and chemokines. Antigen 
presentation and recognition by DCs plays a vital role in connecting innate and adaptive immune 
responses. Communication to T cells by DCS about the type of immune response that should be 
induced (i.e. Th1-type, Th2-type, etc.) is dependent upon the pathogen or antigen that has been 
presented, the local tissue condition at the site of infection and maturation signals.  
Antigen presentation requires internalisation of the antigen, processing inside the cell, and 
display of a short peptide on the surface of the APC on an MHC molecule. There are two kinds of 
MHC: MHC class I and II. MHC class I is found on nucleated cells in the body and is utilized to 
present endogenous substances, for example, viral or tumor proteins to cytotoxic T cells. MHC 
class II is present on APCs (dendritic cells, monocytes/macrophages and B cells) and is utilized 
to present foreign non-self antigens to CD4+ T cells. Exogenous pathogens are endocytosed and 
displayed chiefly on MHC class II peptides on DCs. In the endoplasmic reticulum (ER) of DCs, 
recently formed MHC class II molecules are associated with preformed invariant chain (Ii, also 
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called CD74), which possesses the peptide-binding site (Lamb & Cresswell, 1992; Roche et al., 
1991). Ii binds the MHC class II peptide-restricting notch with a locale in its luminal space that is 
called CLIP (for class-II-related invariant chain peptide). Ii is cleaved by numerous proteases in 
characterized successive cleavage steps, beginning at the carboxy-terminal luminal area, until just 
the CLIP part is left possessing the peptide-binding groove of MHC class II (Bryant & Ploegh, 
2004). The cleavage of proteins and stacking onto MHC class II for presentation requires 
augmented acidification of endosomal compartments by the enactment of a proton pump within 
the mature DCs (Trombetta et al., 2003). The antigen-stacked MHC class II complexes are then 
transported to plasma membranes through tubular organelles (Kleijmeer et al., 2001; Savina & 
Amigorena, 2007). 
Endogenous antigens (viral proteins, intracellular bacterial proteins, flawed cell products) 
and exogenous antigens that are processed inside the cell are only presented on MHC class I 
molecules (Savina & Amigorena, 2007). Intracellular proteins frequently have ubiquitin joined to 
them. These ubiquitin-conjugated proteins are broken down into short peptides of eight to ten 
amino acids by multifunctional proteases known as proteasomes. MHC class I proteins overlap 
and amass inside the ER lumen and peptide binding is a fundamental part of the assembly 
process. Peptides are translocated from the cytosol into the ER lumen, which is performed by the 
transporter associated with antigen processing (TAP) (Yewdell & Nicchitta, 2006). The gathering 
of this complex requires multiple chaperones, for example, calnexin, calreticulin, ERp57 and 
tapasin that help with collapsing and stacking of peptides on the MHC class I peptide-binding 
groove (Cresswell et al., 2005; Rock et al., 1990). After peptide stacking, MHC class I molecules 
separate from TAP and cluster at the export sites on the ER layer where they are specifically 
enlisted into cargo vesicles for transport to the Golgi apparatus. MHC class I molecules at that 
point traffic through the Golgi apparatus to the plasma membrane. 
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Upon antigen exposure and processing, DCs traffic to secondary lymphoid organs where 
they induce adaptive immune responses. The DC migration process starts with 1) recognition of 
mobilizing signals such as various inflammatory signals including PAMPs, DAMPs and pro-
inflammatory cytokines such as TNF-α and IL-1β. Pro-inflammatory cytokine exposure induces 
expression of CCR7 (Antonopoulos et al., 2001; Cumberbatch et al., 1999; Enk & Katz, 1992) 
which induces maturation of DCs which is manifest as rearrangement of their chemokine receptor 
expression, altered expression of adhesion molecules and eventually induced mobilization 
(Granucci et al., 1999). 2) Separation from the encompassing tissues where attachment 
molecules, for example, epithelial cadherin, maintain DCs in the peripheral tissues. Local TGF-β 
triggers an aberrant role in DC maintenance as it upregulates the expression of E-cadherin on 
DCs and represses its development and CCR7 expression (Geissmann et al., 1999). Pro-
inflammatory cytokines TNF-α and IL-1β instigate DC separation by diminishing E-cadherin 
expression (Jakob & Udey, 1998). 3) Interstitial relocation where DCs are segregated from tissue 
and move through the extracellular framework of proteins (collagens, fibronectins and laminins) 
and basement membranes before entering the lymphatics. To counter these obstructions, DCs up-
regulate matrix metalloproteinases (MMP)-2 and MMP-9 (Ratzinger et al., 2002), and down-
regulate tissue inhibitors of metalloproteinases (TIMPs) (Darmanin et al., 2007). DC passage into 
lymphatics is controlled by chemokine CCR7 and its ligands, CCL19 and CCL21 (Ohl et al., 
2004) and also CXCR4 and its ligand CXCL12 (Kabashima et al., 2007). Secretion of TNF-α 
further enhances CCL21 expression by lymphatic endothelial cells, which guides DCs towards 
lymph vessels (Martín-Fontecha et al., 2003). 4) DC migration through afferent lymphatic 
endothelium is a steady state migration guided by a chemokine scavenging receptor, D6 and 
CCX-CKR1 expressed on the lymphatic endothelium (Heinzel et al., 2007; Mantovani et al., 
2006). 5) DCs travel through the afferent lymphatics into lymph nodes which are bolstered by the 
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intercellular adhesion molecules (ICAM)-1 and vascular cell adhesion (VCAM)-1 on the 
lymphatic endothelium (Johnson et al., 2006). 6) When DCs undergo maturation following 
activation, they downregulate their responsiveness to inflammatory chemokine pathways and 
migrate to the draining LNs by upregulating CCR7, which responds to CCL19 and 
CCL21expressed by the lymphatic vessels draining the site of infection (Dieu et al., 1998; 
Sallusto et al., 1998; Sozzani et al., 1998).  DC movement in lymph node is guided by CCR7-
CCL19/CCL21 while CCR8 and its ligand CCL1 control DC movement in the lymph node 
parenchyma (Qu et al., 2004). DCs also have high-affinity for CCL19 and CCL21, which are 
uniquely involved in DCs homing to T cell zones of lymphoid tissues. The main source of 
CCL19 and CCL21 is fibroblast reticular cells within the T cell zone. Additionally, naive T cells 
express CCR7, and this is the reason naive T cells circulate through similar areas of lymph nodes 
where antigen-bearing DCs are concentrated. The co-localization of antigen bearing activated 
DCs and naive T cells augment the opportunity of T cells with receptors for the antigen finding 
that antigen. 
Follicular dendritic cells (FDCs) are conspicuous stromal cell constituents of B cell 
follicles with the capacity to hold complement fixed antigens on their cell surface for expanded 
time frames (McCloskey et al., 2011). FDCs secrets the B cell attracting chemokine CXCL13 
(McCloskey et al., 2011). Germinal centre (GC) B cells express the CXCL13 binding chemokine 
receptor CXCR5 and are thereby attracted towards the B cell follicle (McCloskey et al., 2011). 
FDCs produce B-cell activating factor (BAFF), which is involved in regulating GC B cell 
survival (Borhis et al., 2017). FDCs present antigen to GC B cells where antigen-explicit GC B 
cells perceive the antigen through their BCR, endocytose and process it into peptides then present 
to T follicular helper cells (TFH cells) in the type of peptide-MHC II ( Zhang et al., 2005). TFH 
cells at that point supply related B cells with survival signals. It is expected that after each round 
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of somatic hypermutation, B cells with high-affinity BCRs can recognise antigen introduced by 
FDCs and, subsequently can interact with TFH cells.  This prompts the positive selection of 
protective T and B cells, while others bearing lower affinity receptors cannot compete for limited 
antigens and hence undergoes apoptosis. To avoid autoimmunity, these cells must be cleared 
effectively. FDCs discharge the apoptotic cell binding protein Mfge8 that are then recognized and 
cleared by macrophages.  
The innate immune system can be activated through ligand binding to a number of 
conserved PRRs, such as the TLRs (Underhill & Ozinsky, 2002), NLRs, RLRs and CLRs (Stahl 
& Ezekowitz, 1998) which can be stimulated by many adjuvants. Targeting the host innate 
immune system through activation of immune receptors constitutes an important approach in the 
development of immunostimulatory adjuvants. Hence, adjuvants that stimulate PRRs may 
enhance the protective immune response and promote memory to a specific antigen (Cox & 
Coulter, 1997).  
1.1.2 Overview of adaptive immunity 
Adaptive (acquired) immunity refers to antigen-specific defense mechanisms that react to 
and eliminate a specific antigen and is designed to take several days to become fully activated 
(Abbas et al., 2014a). There are two noteworthy parts of the adaptive immune responses: humoral 
and cell-mediated immunity. Humoral immunity is mediated by macromolecules found in 
extracellular fluids such as secreted antibodies, complement proteins, and certain antimicrobial 
peptides. Cell-mediated immunity is mediated by T lymphocytes and involves the activation of 
cytotoxic T lymphocytes and Th1-type T or Th2-type T cells that promote macrophages and NK 
cell activation (Abbas et al., 2014a; Itano et al., 2003).  
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Substances that are targeted by antibody molecules and antigen receptors on lymphocytes 
are called antigens while an immunogen is an antigen that is recognized by the body as non-self 
and activates an adaptive immune response (Abbas et al., 2014a). During adaptive immunity, 
antigens are taken up by APCs then transported to lymphoid organs where they are recognized by 
naive B-lymphocytes and T-lymphocytes. The activated B and T lymphocytes then proliferate 
and differentiate into effector cells.  
1.1.2.1 Naïve T and B cell activation in draining lymph nodes 
T cells are unable to recognise pathogens directly (Mackay et al., 2012). Generation of 
activated effective T cell requires three vital signals. Recognition of antigen displayed on MHC 
molecules through TCR on T cells is the first signal. The receptor on the surface of a CD4+ T cell 
binds to the peptide presented on MHC class II complex on the surface of APCs while CD8+ T 
cell binds to the peptide presented on MHC I complex on the surface of the APCs (Banchereau & 
Steinman, 1998). Effective antigen presentation leads to maturation of naïve T cells to effector T 
cells, which then differentiate into two cytotoxic CD8+ T cells and CD4+ T cells. The state of 
activation of DCs and the presentation of antigen on MHC I or II are critical factors in 
determining the outcome of T cell responses (Mellman & Steinman, 2001). Additionally, 
immunological synapse formed by prolonged and dynamic interaction of DCs and T cells is 
necessary for effective activation of T cell. At first, ICAM-1 found on DCs forms a limited 
interaction with leukocyte function associated antigen 1 (LFA-1) on the T cells (Dustin et al., 
2006). The co-stimulatory molecule CD80/CD86 form a ligation with CD28 on T cells provides 
the second signal, which further stabilises the interaction (Lotze & Thomson, 2001). 
Furthermore, cooperation between CD40 on the T cells and CD40L on the DCs activates DCs to 
enhance up-regulation of co-stimulatory molecules that aids in stabilizing the immunological 
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synapse (Lanzavecchia & Sallusto, 2001). DCs release cytokines to provide the third signal 
which then determines the differentiation status of the T cells.  
Two distinct signals are required for B cell activation and differentiation into memory B 
cells or plasma cells. The first signal of activation occurs when antigen binds to BCRs. After 
binding to the BCR, the antigen is taken up by receptor-mediated endocytosis, broken down into 
small peptides, and incorporated into MHC class II molecules on the surface of B cells (Batista et 
al., 2001). Introduction of an antigen on MHC II molecule on a B cell empowers the B cell to 
presents antigen to T cells (Foy et al., 1994; Lederman et al., 1992).  
The second activation signal occurs via either a thymus-dependent or a thymus-
independent mechanism (Lederman et al., 1992). T helper cells, which are mainly follicular T 
helper (TFH) cells, initially activated with similar antigen recognize and bind MHC-II-peptide 
complexes via T cell receptor. T cells express the surface protein CD40L which acts as an 
essential co-stimulatory factor for B cell activation (Dubois et al., 1997). CD40L binding to 
CD40 promotes B cell proliferation, immunoglobulin class switching and somatic hypermutation 
as well as helps sustain T cell growth and differentiation. This activates the BCR to form 
microclusters and trigger downstream signalling cascades (Depoil et al., 2008). The microcluster 
undergoes a contraction phase to form an immunological synapse which helps in the stable 
interaction between B and Th2-type T cells to give a bidirectional activation signals (Depoil et 
al., 2008; Fleire et al., 2006).  
To produce antigen-specific antibodies, B cells require cytokine signalling and 
stimulatory signals from Th T cells in the lymph node (Kaliński et al., 1999). Th2-type T cells 
produce IL-4 following their recognition of specific ligand on the surface of the B-cell, which 
interact with CD40L and synergizes the clonal expansion that precedes antibody production 
(Dubois et al., 1997). IL-4 secreted by the Th2-type T cells is directed at its site of contact with 
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the B cell hence acts specifically on the antigen-specific target B cell (Andrew et al., 1998). The 
combination of B-cell receptor and ligation of CD40 along side with IL-4 in addition to MHC 
and T-cell receptor  derived from direct T-cell contact prompts the B-cell proliferation (Rathmell 
et al., 1996). 
In contrast, some antigens that can directly give the second B cell activation signal 
(thymus-independent activation). These antigens may include components of some bacterial cell 
wall such as lipopolysaccharide or antigens containing exceedingly repetitious molecules such as 
bacterial flagellin (Edwards et al., 2002; Wortis et al., 1995). Upon activation, B cells proliferate 
and form germinal centers where they differentiate into memory B cells or plasma cells (Foy et 
al., 1994; Paus et al., 2006). Expansion of B cells leads to the generation of a specific antibody 
such as IgG, IgA or IgE, depending on the nature of the antigen (Batista & Harwood, 2009). This 
process leads to the generation of memory B cells and long-lived plasma cells that confers long-
lasting immunity from infection (McHeyzer-Williams et al., 2012; Penna et al., 1996). Following 
differentiation into plasma cells, additional signals initiate plasma cell antibody class switching 
and regulate antibody secretion (Reimold et al., 2001).  
CD4+ cells can differentiate into two kinds of memory cell with very different 
characteristics of activation. One sort of these cells are called effector memory cells since they 
can quickly develop into effector CD4+ T cells and discharge copious amount of IFN-γ, IL-2, IL-
4, and IL-5 early after restimulation. The effector memory cells lack the chemokine receptor 
CCR7 though they express β-1 and β-2 integrins in high levels and inflammatory chemokines 
receptors suggesting that effector memory cells are highly specialized for quickly entering 
inflamed tissues. The other kinds of memory cells are called central memory cells and they 
express CCR7 that allows them to recirculate more easily to secondary lymphoid tissues T cell 
zones. These central memory cells are highly sensitive to cross-linking by T-cell receptor and 
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rapidly upregulate CD40L in response to it. Be that as it may, they take more time to separate 
into effector cells and in this way do not discharge as much cytokine as do effector memory cells 
early after restimulation.  Activated Th2-type T cells trigger B cell stimulation and production of 
antibodies. Th2-type T cells secretes IL-4, IL-5, IL-6 and IL-10 cytokines. They likewise initiate 
activation of eosinophils (Mosmann & Sad, 1996). Th2 cells are associated with atopic dermatitis 
in the skin. Th17-type T cells secrete IL-17 and IL-22 which are important in protection from 
bacterial and parasitic infections in the skin (Louten et al., 2009). 
Th cells can be Th1, Th2, and Th17-type T cells. Each has explicit signalling cytokines 
and effector capacities (Walsh & Mills, 2013). Th1-type T cells are involved in a cell-mediated 
immune responses that function to kill intracellular pathogens through production of IFN-γ which 
activate macrophages and NK cells (Biswas & Mantovani, 2010). Th1-type T cells lead to 
increased cell-mediated responses, Th1-type T effector cells utilize two signs to initiate 
macrophages activation. They specifically produce IFN-γ, which binds to IFN-γ receptors on the 
surface of macrophage, and also display the costimulatory protein CD40 ligand, which binds to 
CD40 molecule on the macrophage. When activated, the macrophage can kill the phagocytosed 
organisms by allowing the lysosomes fuse more promptly with the phagosomes, releasing a 
hydrolytic attack, and also the activated macrophages makes oxygen radicals and nitric oxide, the 
two of which are very harmful to the organisms. Because DCs likewise express CD40, the Th1-
type T cells at locales of infection can likewise aid in their activation. Thus, the dendritic cells 
increase expression of MHC class II molecules, B7 (CD80/86) costimulatory proteins, and 
different cytokines, particularly IL-12. This makes them increasingly successful in stimulation 
and development of Th1-type T effector cells in peripheral lymphoid organs by providing a 
positive feedback loop that leads to the generation of Th1-type T cells, which then activate the 
macrophages.  
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Other T cell populations, for example, regulatory T cells (Tregs), modify the immune 
cell’s response to foreign and self-antigens thus preventing autoimmune diseases. Several 
suppression mechanisms of Treg include local secretion of immunosuppressive cytokines such as 
IL-10 and TGF-β, cell-contact-dependent suppression, and modification of function or killing of 
APCs. For example, depletion of Treg-secreting IL-10 and TGF-β contribute to inflammatory 
bowel disease in mice (Read, Malmström, & Powrie, 2000). Tregs coexpressing Foxp3 and IL-10 
at a solitary-cell level are found in lamina propria of the intestine and blood but not in the spleen 
(Maynard et al., 2007; Uhlig et al., 2006). TGF-β may mediate direct suppression of the immune 
responses by conditioning responder T cells to be sensitive to suppression, maintaining Foxp3 
expression and increasing Tregs suppressive activity. Foxp3+ characteristic Tregs produce 
immunosuppressive IL-35, a recently recognized member from the IL-12 family (Collison et al., 
2007).  
Alternatively, assimilation of cytokines by Tregs may cause apoptosis in responder T 
cells (Pandiyan et al., 2007). Granzyme or perforin-dependent cell-to-cell mechanism by Tregs, 
or delivery of a negative signal to responder T cells might also kill responding T cells or APCs. 
Some of these negative signals include upregulation of intracellular cyclic AMP, which impedes 
T cell proliferation and secretion of IL-2, or Treg-expressed generation of pericellular adenosine 
catalyzed by CD39 (ectonucleoside triphosphate diphosphohydrolase1) and CD73 (ecto-5′-
nucleotidase). Activated Tregs may likewise down regulate expression of CD80/86 on APC or 
modulate dendritic cells to form the enzyme indoleamine 2, 3-dioxygenase that catabolizes the 
essential amino acid tryptophan to kynurenines which are then toxic to T cells; both of these 
mechanisms are reliant on the expression of CTLA-4 by Tregs. 
Cytotoxic CD8+ T cells recognise and bind to MHC class I molecules on all nucleated 
cell types, which present antigen. They bind to the Fas death receptor, a protein on the cell 
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membrane on the surface of the target cell thus starts the perforin–granzyme pathway and 
cytokine-mediated pathways to initiate apoptosis, which specifically executes virally infected 
cells or tumour cells (Cao et al., 2007; Rouvier et al., 1993). 
 
1.1.2.1.1 Function of activated lymphocytes  
Clearance of intracellular pathogens and tumours cells depends on the cell-mediated 
immune response. CD8+ effector T cells play an important role with their function distinguished 
by antigen-specific cytotoxicity restricted by MHC class I and the killing is Fas-Fas perforin 
mediated. Upon recognizing a cell that is presenting its cognate antigen on MHC class I, CD8+ T 
cells secretes perforin and granzymes,which are cytotoxic proteins at the point of contact with the 
target cell leading to killing of specific cell. Perforin is a membrane-disrupting protein, which 
increases apoptosis induced by granzymes on the target cell. The cytotoxic synapse of CTL often 
referred to as a ‘the kiss of death’ because of it ability to cause death of the target cell. There are 
two described mechanisms of CTL-mediated killing which are 1) Ca2+-dependent killing by 
perforin and granzymes, and 2) Ca2+-independent killing mediated by binding of Fas ligand 
(FasL) to Fas (CD95) on target cells (Dustin et al., 2006; Fooksman et al., 2010). Apoptosis 
triggers death in both though the perforin pathway is more expedient. Perforin-mediated killing is 
progressively broad and depends on exceedingly conserved membrane responses to injury and 
lysis of endosomal membranes leading to introduction of granzymes into the cytoplasm of the 
target cell with consequently no requirement of a particular receptor (Dustin et al., 2006; 
Fooksman et al., 2010). Since perforin and granzymes are released from the cell, the formed 
synaptic cleft improves the function via high local concentration and further preventing exposure 
to bystander active perforin in the vicinity. Fas, likewise, requires cell-cell contact, since FasL 
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and Fas are proteins membranes with a restricted reach (~15 nm). FasL present in the granules of 
CTLs that co-express perforin and granzymes to be exocytosed into the synaptic cleft because of 
TCR activation (Fooksman et al., 2010). In addition to cytolysis, CD8+ effectors cells produce 
IFN-γ and TNF-alpha that activate macrophages to kill the infected cell (Intlekofer et al., 2005). 
CD4+ T-cell priming ends up in different subsets recognized by the generation of specific 
cytokines and effector capacities. Traditionally, CD4+ effectors were classified as Th1/Th2-type 
T cells however different subsets exist including IL-17 secreting T cells (Th17-type T cells) and 
Tregs have since been characterised (Weaver et al., 2006).  
Th2-type T cells secrete IL-4, IL-5 and IL-13 that are necessary for B-cell antibody 
production (note that IL-4 is not expressed by pigs). These cytokines drive B-cell multiplication 
by secretion of IL-4 and contact-dependent CD40 ligand on DCS and CD40 on the T-cells 
binding, which augments humoral guards against extracellular pathogens. Besides, these 
cytokines empower IgE generation and eosinophilic inflammation, imperative for the protection 
against helminthic infection, also profoundly pertinent to the allergic immune responses 
(Soumelis et al., 2002). 
Th1-type T cells are necessary for activation of macrophages through IFN-γ secretion and 
also contact-dependent stimulation by utilizing an assortment of cell surface costimulatory 
ligands. Th1-type helper T cells hence assume a crucial role in clearance of intracellular 
pathogen, delayed type hypersensitivity reactions and down regulation of B-cell responses 
(Jankovic et al., 2007). Th1-type T cells differentiation is directed by IFNs generated by the 
innate response to infection. 
Th17-type T cells secrete IL-17, IL-17F, IL-6, and TNF, and are currently viewed as a 
particular CD4+ T-cell subset in mice, human, cattle and canines. IL-17 is a powerful 
inflammatory cytokine associated with the proliferation and recruitment of neutrophils. Th17-
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type T cells differentiation and survival requires TGF-β, IL-6, and IL-23 (Bettelli et al., 2007). 
CD4+ T cells can likewise differentiate into cells with the capacity for suppression of T cell 
responses which prevent autoimmunity commonly referred to as Tregs (Sakaguchi, 2005). 
Memory T cells are categorized into 2 subsets termed central memory (TCM) and effector 
memory. TCM cells express CD45RO, CD62L, and CCR7, and are sequestered in lymphoid 
tissue (Broli, 2013; Sallusto et al., 2004). They react to antigen by undergoing rapid division to 
differentiate into effector cells; however all by themselves without the antigen they have almost 
no effector function. TEM cells express CD45RO but neither CD62L nor CCR7 (Sallusto et al., 
2004), circulate in the peripheral tissues and have limited proliferative ability but increasingly 
more effector functions. In this way, TEM cells performs surveillance of the peripheral tissues for 
fast effector responses, though TCM cells rapidly create reinforcement effector cells. At the point 
when the immune responses turn out to be increasingly localized, the immune synapse establishes 
a lineage toward effectors, and the daughter cell distal establishes a lineage toward TEM 
(Klebanoff et al., 2005; Sallusto et al., 1999). B-cells once activated by antigen in secondary 
lymphoid tissues, generate memory B cells and antibody-secreting plasma cells (Odendahl et al., 
2005). 
1.1.2.2 Humoral immunity in the skin 
B memory cells are effector cells that have already been exposed to antigens to guarantee 
a quicker and long-lasting immune response. B cells secrete specific antibodies 
(immunoglobulins) that can bind to explicit antigens (Martin & Kearney, 2000). Immune 
response effector capacities induced by antibodies are 1) Neutralization where antibodies bind to 
the pathogen and counteract adherence to the target cells, 2) Opsonisation wherein antibodies 
coat the antigen or microorganism surface and increase the consequent take-up by phagocytic 
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cells (Burton, 2002), 3) Activation of complement which leads to cleavage of C3 by enzyme C3 
convertase to generate C3b. Next, C3b advances cleavage of C5 convertase to deliver C5b which 
is trailed by the commencement of the terminal common complex (Shishido et al., 2012). The 
whole process results in the membrane attack complex (MAC) formation, which causes lysis of 
the host or pathogenic cells by the development of pores in the cell membrane. C3b opsonisation 
enhances the recognition of pathogens by complement receptor 3 (CR3) expressed on the surface 
of neutrophils and macrophages. Cleavage products recognized by complement receptor 2 (CR2) 
on the B cell triggers production of antibodies (Molina et al., 1996). CR2 is one of several 
receptors for human CD23 (Aubry et al., 1994; Aubry et al., 1992). CD23 is an 
immunoregulatory protein discovered both on cell membrane and as a soluble protein. CD23 
communicates with CR2 to enhance production of IgE with the help of IL-4 (Aubry et al., 1992), 
rescue germinal-center B cells from apoptosis (Bonnefoy et al., 1993), provide T cell-activating 
signals by B cell APCs (Grosjean et al., 1994), and promote T-B cell adhesion (Björck et al., 
1993). The C3a and C5a released from their respective convertases are potent mediator of 
anaphylatoxin reactions. 
1.1.2.3 Cell mediated immunity (CMI) in the skin  
The skin contains resident T cells and recruited circulating T cells. The skin is home to 
approximately 20 billion T cells, about double the number present in the whole blood volume 
(Clark et al., 2006). CD8+ T cells that are found in the epidermal region of the skin are of memory 
phenotype (Gebhardt et al., 2009) and live together with keratinocytes with particular localization 
close to LCs (Foster et al., 1990). Equal numbers of CD4+ and CD8+ cells are restricted to 
capillaries and the epidermal–dermal junction which are characteristic for the dermis (Mueller et 
al., 2013; Nomura et al., 2014). Large portions of the lymphocyte population are memory cells 
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communicating cutaneous lymphocyte-related antigen. Skin memory T cells hold key position 
and make the primary line of protection against pathogen challenge (Schenkel & Masopust, 
2014). The Th17, Th1 and Th2-type T cells are important effector cells in inflammatory skin 
pathology such as allergic inflammation (Conrad et al., 2007; Honda et al., 2013) or psoriasis 
(Conrad et al., 2007). IL-17 together with IL-22 produced by Th17-type T cells induces abnormal 
differentiation of keratinocytes in psoriasis but Th17-type T cells shield skin from bacteria and 
fungal infections, for example, Candida albinos, Klebsiella pneumonia, and Staphylococcus 
aureus (Kashem et al., 2015; Kurebayashi et al., 2013). The extent of immune responses in skin 
is effectively controlled by Tregs which constitutes 5– 10% of all inhabitant skin T cells (Clark et 
al., 2006). Together with other resident skin T cells, Tregs effectively move between the skin and 
lymph nodes amid immune response as well as in the steady state (Clark, 2010; Tomura et al., 
2010). In skin, Tregs regulate responses of T cells, APCs such as DCs and macrophages, as well 
as neutrophil accumulation during early stages of inflammation (Richards et al., 2010; Tiemessen 
et al., 2007). Tregs induces anti-inflammatory functional profile in macrophages and inhibit 
macrophage TNF-α production in the skin (Tiemessen et al., 2007)  
The goal of vaccination is induction of protective immune memory that is long lasting and 
can respond rapidly to future infections. This is accomplished by exploiting the adaptive portion 
of the immune system usually characterized by durability and specific recognition of pathogens. 
Be that as it may, the magnitude, quality and duration of adaptive responses are exceedingly 
impacted by the innate portion of the immune system, which is characterized by limited 
specificity and immune memory. Activating the innate receptors tweaks the ‘‘immunogenic 
conditions’’ in which APCs and CD4+ T cells engrave the adaptive responses 
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1.2 Conventional vaccines 
All vaccines contain an active component (the antigen), which is the target of the 
(hopefully) protective immune response. The main types of vaccines can be classified according 
to the following: attenuated (live), inactivated, toxoid, subunit vaccines, conjugate, DNA and live 
vectored vaccines. 
1.2.1 Live, and/or attenuated vaccines 
Live, attenuated vaccines are comprised of microbes that are living but have been passaged in 
culture to reduce replicating ability and pathogenicity (Meeusen et al., 2007). Being very similar 
to the microbe that causes natural infection, these vaccines are generally highly immunogenic and 
may not require addition of adjuvants (with some exceptions) to induce protective immune 
responses (da Costa et al., 2015; Makoschey, 2012; Rizzi et al., 2012). These vaccines tend to 
elicit strong cellular and antibody responses and often confer lifelong immunity with only one or 
two doses. These classes of vaccines have been very successful. Measles, mumps, and rubella 
(MMR) vaccine is a good example of attenuated live viral vaccine which has been used in the 
United States since 1971 (Ravanfar et al., 2009). Priorix ® is an MMR vaccine marketed by 
GlaxoSmithKline and contains these attenuated virus strains, measles (the Schwarz strain), 
mumps (the RIT 4385 strain), and rubella (the Wistar RA 27/3 strain) which are independently 
obtained by chick embryo tissue cultures of mumps and measles or MRC5 human diploid cells in 
the case of rubella (Wellington & Goa, 2003). Other examples of live, attenuated vaccines 
include smallpox, polio, yellow fever, tuberculosis, typhoid, anthrax, varicella (chickenpox), 
rotavirus and influenza vaccines (Flushield ®). For example, the virtual eradication of rinderpest 
virus from the globe is widely believed to have been critically dependent on the use of the 
“Plowright” vaccine. This is an attenuated vaccine produced from the Kabete O strain 
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passaged 90 times in tissue culture. However, the attenuated microbe have a small probability of 
reverting to a virulent form and cause infections, which may be particularly harmful to 
individuals who have damaged or weakened immune systems (immunocompromised hosts) such 
as those infected with HIV/AIDs, children and the elderly 
1.2.2 Inactivated vaccines 
Inactivated vaccines are produced by inactivating the microbe with chemicals, heat, or radiation 
(Meeusen et al., 2007). The fundamental characteristic of killed or inactivated vaccines over live 
attenuated vaccines is that they are safe. Since the pathogens are killed/inactivated the 
possibilities of reverting back to a virulence form to cause infections are obviated. However, this 
forms a gigantic drawback since the absence of replication results in quick clearance from the 
body prompting a diminished immunogenicity compared to the live vaccines. Killed/inactivated 
vaccines in comparison to subunit vaccines give rise to a more complex or greater inflammatory 
immune response since high amount pathogenic components and possibly some tertiary 
structures are preserved. Inactivated vaccines are widely used because they are not likely to revert 
to virulence in the non-immunocompromised and are therefore considered safe in addition to low 
doses of antigen. An example of such a vaccine is the Hepatitis A vaccine Epaxal® from Crucell 
where the strain RG-SB of hepatitis A virus is formalin inactivated and adsorbed onto a virosome 
formulation containing the adjuvant system (Bovier, 2008). Other examples of killed/inactivated 
vaccines have been developed for Typhoid, cholera, polio and rabies.. For example, a one-dose 
inactivated porcine circovirus type 2 (PCV2) vaccine has recently been licensed in the United 
States for the prevention of postweaning multisystemic wasting syndrome in pigs. However they 
are not as immunogenic as live, attenuated vaccines and they often require the addition of 
adjuvants and/or require two or more doses to induce protective immune response (Makoschey, 
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2012).  
1.2.3 Convectional subunit Vaccines 
Subunit vaccines, like inactivated whole-cell vaccines, do not contain live components of the 
pathogen. Instead of the entire microbe, subunit vaccines only include the antigen components of 
the microbe that best stimulate a protective immune system (Dintzis, 1992). By selecting only 
one or a few antigens as targets, these vaccines are must be extensively tested to ensure that the 
particular combinations of antigens and adjuvants generate an effective immune response. Like 
inactivated vaccines, subunit vaccines do not contain live components and are considered very 
safe. Bordetella pertussis vaccine is a good example of a subunit vaccine and contains inactivated 
Bordetella pertussis toxin (protein) with at least one other bacterial components. The pertussis 
toxin is detoxified by chemical treatment or by utilising molecular genetic techniques which may 
impact recognition by the immune system.  In other examples, subunit vaccines use epitopes that 
are very precise regions of a protein that are recognised by T cells. A recombinant baculovirus 
producing the protective ORF2 protein of PCV2 has recently become available as a vaccine for 
pigs. These peptides are poorly immunogenic thus require addition of adjuvants to induce 
protective immune responses (Reed et al., 2009). Examples of subunit vaccines are hepatitis B 
and pertussis (whooping cough).  
1.2.4 Toxoid Vaccines 
The immune system produces antibodies that bind to and can potentially block bacterial toxins. 
Toxoid vaccines are made from toxins (poisons) that are produced by specific organisms (e.g. 
tetanus or diphtheria) that attack the circulatory system and are, to a great extent, responsible for 
manifestation of the disease. The toxin is rendered harmless by formalin fixation or another 
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means then included as an antigen in the vaccine to evoke an immune response. To increase the 
immunogenicity, the toxoid can be adsorbed to adjuvants. Toxoid vaccines are often considered 
safe because they do not have the ability to revert to virulent form that can cause. Further, toxoids 
tend to be stable, as they are less susceptible to changes in temperature, humidity and light 
(Baxter, 2007). However, because they are poorly immunogenic, they require addition of 
adjuvants to induce protective immune responses (Arimitsu et al., 2004). Vaccines against 
diphtheria and tetanus are examples of toxoid vaccines. 
1.2.5 Conjugate Vaccines 
Some components of the organisms e.g polysaccharides that coat bacteria can disguise or hide 
surface antigens so that they escape recognition by the immune system. Conjugate vaccines, a 
special type of subunit vaccine, overcome this problem (Dintzis, 1992). In comparison to plain 
polysaccharide vaccines, the polysaccharide is bound to a carrier protein to enhance their 
immunogenicity. When incorporated in the vaccine, the linked polysaccharide-carrier protein 
helps the immature immune system react to polysaccharide coatings and defend against the 
disease-causing bacteria. Conjugate vaccines also create a response against the molecules in the 
pathogen's capsule. Different protein transporters are utilized for conjugation, including 
diphtheria and tetanus toxoid. Conjugate vaccines have not been related with any uncommon, 
progressively extreme immune responses but continued surveillance for possible unexpected 
effects as with the introduction of any new vaccine is necessary. A vaccine that protects against 
Haemophilus influenzae type B (Hib) is a conjugate vaccine. However, they are poorly 
immunogenic thus require addition of adjuvants to induce protective immune responses but the 
benefits of using conjugates type of vaccines would depend on the antigen and adjuvant used, 
which may limit the scope of the application. 
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1.2.6 DNA Vaccines 
DNA vaccines are comprised of genes that code antigens. DNA vaccines are an attractive 
class of new generation of vaccines because of their simplicity and for the many benefits they 
have over conventional vaccines. The fundamental principle behind DNA vaccines is that 
plasmid DNA (pDNA) encodes the antigen which transduces host cells instead of infusing 
antigen as peptide or protein (Bins et al., 2013). Upon DNA vaccination, host cells produce the 
protein (antigen) encoded by the DNA and immunity against this particular protein is 
subsequently induced. The major benefits related with DNA vaccines are that they are relatively 
inexpensive to produce, and they can evoke both humoral and cellular immune responses (Bins et 
al., 2013). In addition, pDNA is fairly stable at room temperature hence they do not require cold 
chain storage.  
A DNA vaccine can elicit a strong antibody response to soluble antigens in addition to 
stimulating a strong cellular response to the microbial antigens present on surfaces of the cell. 
Poor immunogenicity remains the single biggest obstacle to human DNA vaccines achieving 
their potential. Adjuvants or delivery methods are required to enhance the immunogenicity of 
DNA vaccines (Meeusen et al., 2007). DNA vaccines targeting influenza and herpes viruses are 
being tested in clinical trials.  
1.2.7 Recombinant Vector Vaccines 
Recombinant vector vaccines are exploratory vaccines like DNA vaccines, yet they utilize an 
attenuated microbe to introduce and/or carry microbial DNA into cells. (Rizzi et al., 2012). 
Recombinant vector vaccines have a few attributes that make them proficient in initiating 
humoral and cell-mediated immune responses, including their capacity to infect cells and persist 
in the body. They can infect APCs, and the viruses’ proteins can act as adjuvants. . Recombinant 
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vector vaccines such as adenoviruses (Ads) can be attenuated to reduce pathogenicity, such as 
replication-deficient mutants. They can be administered by the oral or nasal route to promote 
immunity on the mucosal surfaces (Abbink et al., 2007). Contrasted with other viral delivery 
systems, Ads have limited cloning capacity and human Ads have a confined range of hosts which 
frequently makes testing in animal models troublesome (Abbink et al., 2007). Various organisms 
have been utilized for vector vaccines including adenoviruses, attenuated poliovirus and vaccinia 
virus. Meanwhile, a subunit vaccine capable of preventing Newcastle disease virus (NDV) in 
poultry was successfully registered. Hemagglutinin-neuraminidase (HN) protein, a protective 
antigen, of NDV was produced in plant cells and demonstrated to protect a vaccinated chicken 
once challenged with wild type virus. These vaccines are highly immunogenic and do not 
necessarily require addition of adjuvants to induce protective immune responses as the carrier 
vector used for delivery of the vaccine may as well act as an adjuvant.  
1.3 History of vaccine adjuvants 
The overall goal of vaccination is to generate strong immune responses to the administered 
antigen so that any future encounter with the antigen (likely as part of an invading pathogen) will 
trigger a protective memory immune response. Unlike natural infections or in response to 
vaccines comprised of live-attenuated pathogens, subunit vaccines or vaccines comprised of 
killed pathogens often require the addition of immune enhancing additives commonly known as 
adjuvant (Bomford, 1998). The word adjuvant comes from the Latin word adjuvare meaning “to 
help” or “to enhance” (Brown, 1998). Hence, adjuvants are broadly defined as compounds that 
enhance the specific immune response against co-inoculated antigens. Most of the initial studies 
that have contributed to the advancement of adjuvants for use in vaccines incorporated antigen 
and adjuvants both derived from the bacteria (Ramon, 1925, 1926; Ramon, 1940). The first 
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documented study with a substance that acted as a depot for the antigen at the site of delivery was 
lanolin and this adjuvant was administered with a killed salmonella bacterial vaccine in 1916 
(Kensil et al., 2004).  
There are four recognised periods for development of adjuvants including: a period for 
studying adjuvants for toxoid vaccines (1920s-1940s), utilization of oils and aluminum 
compounds as adjuvants (1940s-1970s), a period for synthetic adjuvants development and 
second-generation delivery depot systems (1970s-1990s), and development of receptor-related 
adjuvants that stimulate innate immune system (1990s-Present) (Petrovsky &Aguilar, 2004). 
1.3.1 Development of adjuvants for toxoid vaccines  
The concept of adjuvants in vaccines advanced significantly in the 1920s with Ramon et 
al. taking note that horses that had a boil at the vaccination site of diphtheria toxoid produced 
higher antibody titres (Ramon, 1925, 1926). It was later discovered that abscesses created by the 
addition of substances (adjuvants) alongside the diphtheria toxoid generated robust immune 
responses against the toxoid (Ramon, 1925, 1926).  
The first vaccine adjuvanted with alum was made by co-precipitation of diphtheria toxoid 
with aluminum dissolved in carbonate buffer (pH 8.0), resulting in a co-precipitate of aluminum 
hydroxide and diphtheria toxoid (Glenny, 1926; Glenny & Barr, 1931). Inclusion of aluminium 
salts in subcutaneous injection triggered more rapid induction of humoral immunity and 
significant anti-toxoid antibody without local reactions when studied in guinea pigs (Ramon, 
1925, 1926) and these salts were  generally, but not correctly, referred to as alums (Glenny, 1926; 
Glenny & Barr, 1931). Since then aluminum salts, such as aluminum hydroxide, aluminum 
phosphate, and aluminum potassium sulfate have been used safely in vaccines as adjuvants due to 
their ability to strengthen the body’s immune response to these vaccines.  
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1.3.2 Use of oils and aluminum adjuvants  
As observed by Freund: “Interest in promoting antibody formation by addition of 
unrelated substances to antigens has never been lacking” (Freund, 1947). In 1937, Freund 
developed an emulsion of water and mineral oil containing killed mycobacteria called  Complete 
Freund's Adjuvant (CFA), which is a standout amongst the most intense adjuvants developed up 
to date (Freund et al., 1937). Despite being the gold standard adjuvant, CFA was shown to cause 
serious local responses and has since been classified as unreasonably dangerous for use in human 
and animal vaccines. Similar oil-in-water emulsion with no mycobacteria is known as Freund's 
Incomplete Adjuvant; it is less harmful and has been utilized in human vaccines formulations. 
During the 1950s, Johnson et al. confirmed that lipopolysaccharides (LPS) from Gram-negative 
bacteria displayed adjuvant activity (Johnson et al., 1956) but it is not used in human vaccines 
because it can trigger septicemia (Stefanova et al., 1993) 
1.3.3 Synthetic adjuvants and second-generation delivery depot systems 
A broad measure of work was finished during the 1990s undertaken to improve the adjuvant 
impacts of liposomes, PEG [poly(ethylene glycol)]lated lipids. PEG-modified lipids are typically 
added to phospholipid vesicles used for drug delivery to provide a steric coating on the surface of 
the membrane to hinder clearing of the particles by the reticuloendothelial system (RES) thereby 
prolonging the circulating plasma half-life. Utilization of liposomes for delivery of DNA 
vaccines has been considered. However, it is generally considered that liposomal delivery of 
subunit protein peptide antigen alone does not improvement of immunogenicity (Ott & Van Nest, 
2007). 
A second lipid-based particle with extensive application is the ISCOM/ISCOMATRIX system, 
based on Quillaja saponin, cholesterol, and phospholipids. Immunostimulatory complexes 
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(ISCOMs) are particulate antigen delivery systems composed of antigen, cholesterol, 
phospholipid and saponin, while ISCOMATRIX is a particulate adjuvant comprising cholesterol, 
phospholipid and saponin but without antigen. The combination of an antigen with 
ISCOMATRIX is called an ISCOMATRIX vaccine. ISCOMs and ISCOMATRIX combine the 
advantages of a particulate carrier system with the presence of an in-built adjuvant (Quil A) and 
consequently have been found to be more immunogenic, while removing its haemolytic activity 
of the saponin, producing less toxicity. Research has shown that Immune stimulating complexes 
(ISCOMs) are lipid-based particles that have shown potential as adjuvants and carriers for 
antigens. They have been used as prophylactic or therapeutic vaccines injected into the muscle as 
well as via mucosal and cutaneous administration. Both cellular and humoral immune responses 
have been reported after vaccination with antigens co-administered with ISCOM adjuvants 
(Nielsen et al., 2015; Ott & Van Nest, 2007). 
1.3.4 Development of receptor-associated adjuvants that activate the innate immune system 
Components of bacteria and viruses that are PAMPs that bind to PRRs on innate immune 
cells can act as vaccine adjuvants. For example, immunostimulatory CpG oligodeoxynucleotides 
(ODNs) are unmethylated cytosine-guanine dinucleotides found in bacterial DNA but absent in 
mammalian DNA (Aguilar & Rodriguez, 2007; Krieg, 2002). Overall, several hundred natural 
and synthetic compounds have been identified to have adjuvant activity (Krieg et al., 2001). CpG 
ODN bind to TLR9 causing simultaneous maturation of immature DC and activation of mature 
DC to produce cytokines and acts as adjuvants for Th1-type T cell responses and cytotoxic T cell 
responses(Sparwasser et al., 1998)  
Although LPS is a very robust adjuvant, it is not considered safe for use in human vaccines 
because it can cause septicemia. Detoxified LPS or related compounds such as lipid A are a much 
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safer adjuvant alternative to LPS. Monophosphoryl lipid A has been used since 2009 in one 
vaccine in the US, Cervarix (Einstein et al., 2009) and it has been tested for safety in tens of 
thousands of people and found to be safe. Polyinosinic:polycytidylic acid (Poly I:C) that 
stimulates TLR3. RIG1 and MDA-5 is another adjuvant that enhances immunity to vaccines and 
experimental antigens by a variety of mechanisms. The focal element of potency associated with 
Poly I:C is by binding to TLR3 hence directly activating DCs and type I IFNs through MDA-5 
(Tritto et al., 2009) 
1.4 Classification of adjuvants 
Criteria for classifying adjuvants can include those that act as delivery systems and those that act 
as immunostimulatory adjuvants (Cox & Coulter, 1992). Adjuvants that act as delivery vehicles 
generally act as a depot and/or promote the slow release of antigen from the site of injection. This 
slow release leads to sustained stimulation of the immune system for production of elevated 
antibody titers. Many adjuvants such as alum, liposomes, emulsions, ISCOMs and numerous 
particulate vaccine adjuvants are thought to exert part of their adjuvant activity through depot 
formation (Cox & Coulter, 1997; Mosca et al., 2008) 
.  
Immuno-stimulatory adjuvants activate innate immune cells leading to secretion of cytokines and 
chemokines that enhance immune cell recruitment at the injection site, APC maturation and 
antigen presentation to effector T cells (Cox & Coulter, 1997). These adjuvants include CpG 
ODNs, muramyl dipeptide (MDP) and monophosphoryl A (MPL).	Adjuvants such as the 
aluminum compounds (alum) have been dominantly used in many vaccines due to their 
immunopotentiation and safety records since 1920s. However, how these mineral agents 
influence the immune response to vaccination remains elusive. Many hypotheses exist as to the 
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mode of action of these adjuvants, such as depot formation, antigen (Ag) targeting, and the 
induction of inflammation. Recent advances in immunobiology have provided evidence that 
adjuvants initially characterized as delivery systems can actually activate innate immunity (Guy, 
2007; Magiri et al., 2018b).	
1.5 Adjuvants selection consideration 
Some considerations for adjuvant choice includes the type of antigen type to be used, the 
species to be immunized, the injection route and the probability of adverse reactions (Byars & 
Allison, 1990; Gupta, 1998). Ideally, adjuvants should be steady with long shelf half-life, 
biodegradable, not induce immune responses against themselves and induce desired immune 
responses (for example humoral or cellular mediated depending upon prerequisites for protection) 
(Edelman, 1980) .  
Reports demonstrate that aluminium is a weak adjuvant for induction of antibody 
responses to recombinant vaccines and prompts a Th2-type T cells, as opposed to a Th1-type T 
cells response (HogenEsch, 2012). Some other adjuvants including oil emulsions, 
lipopolysaccharides, polymers, saponins, liposomes, cytokines, ISCOMs, CFA, IFA, alums, 
bacterial poisons and so forth, have been assessed and clinical preliminaries are under scrutiny, in 
spite of the fact that MOA of adjuvants frequently remain inadequately studied (Edelman & 
Tacket, 1990). Safety is perhaps the single most important impediment in introducing most such 
adjuvants to human use. Synthetic adjuvants have numerous drawbacks, for example, side 
effects, severe injection site reactions and carcinogenesis, in addition to complicated preparations 
or inability to expand immunogenicity of the feeble antigen (Edelman & Tacket, 1990).  
1.6 Adjuvants approved for human use  
Not many vaccine adjuvants have been authorized for prophylactic use in human. Among them, 
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alum (aluminum salts) has been generally utilized for over 70 years and up to this point it is the 
main adjuvant approved in the United States. Oil-in water-emulsions (MF59 and AS03) are 
authorized for flu vaccines in Europe. AS04, a blend adjuvant made out of MPL adsorbed to 
alum is endorsed for HBV and HPV vaccines in Europe and has been as of late authorized in the 
USA (Mbow et al., 2010; O’Hagan & De Gregorio, 2009) 
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Table 1.2 Licensed adjuvants for human use  
Adjuvant  Year 
licenced 
Country/ 
region 
Company Class Indication  
Alum 1924 United 
states 
Various Mineral salts 
(potassium aluminum 
sulfate, ammonium 
aluminum sulfate, 
and sodium 
aluminum sulfate. 
Potassium aluminum 
sulphate) 
 
Various 
MF59 1997 Europe Novartis Oil in water emulsion Influenza 
(Fluad)/pandemic 
flu 
ASO3 2009 Europe  GSK Oil in water emulsion 
+ α- tocopherol 
Pandemic Flu 
(Pandemrix 
AS04 2000 Europe 
and 
United 
states 
GSK MPL + alum HBV (Fendrix), 
HPV (Cervarix) 
Liposomes 2005 Europe Crucell Oil in water emulsion HAV, Flu (EU) 
 
1.7 Mechanisms of Action   
The MOA by which adjuvants mediate their responses may include depot formation at the site of 
injection leading to sustained release of antigen and continuous stimulation of immune system. 
Water-in-oil emulsion adjuvants such as CFA create such depots (Herbert, 1968; Lambrecht et 
al., 2009). Other MOA include cytokines and chemokines upregulation, induction of recruitment 
of immune cells at the injection site, increased uptake and presentation of antigen to APCs and 
induced APC activation and maturation by increasing their expression of MHC class II and co-
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stimulatory molecules (Cox & Coulter, 1997; Fraser et al., 2007; Hoebe et al., 2004). 
Upregulation of cytokines and chemokines promote local immune cell recruitment at the site of 
injection causing uptake of the vaccine and antigen by the recruited immune cells that then traffic 
to the draining lymph nodes to induce adaptive immune responses. Alum, CpG, MF59 and PCEP 
have been shown to activate “adjuvant core response genes” which are genes expressed 
commonly for all three of these adjuvants (Awate, 2012; Magiri et al., 2016; Mosca et al., 2008). 
Activation of adjuvant core response genes is known to increase cytokine-cytokine receptor 
interaction, host-pathogen interaction and defence immune protein activity (Mosca et al., 2008). 
MF59 promotes recruitment of neutrophils, monocytes, macrophages and DCs to the site of 
injection in mice (Calabro et al., 2011). The adaptive immune response relies on antigen 
presentation on APCs. Although it is not fully understood how it works, antigen absorbs onto 
alum and interacts with lipids on DCs through an abortive phagocytosis then the DCs take up the 
antigen leading to antigen processing, presentation and DC activation (Calabro et al., 2011). 
Although alum is able to induce antigen presentation by enhancing surface expression of MHC 
class II and costimulatory molecules on the surfaces of macrophages and monocytes, it does not 
directly affect APC maturation (Seubert et al., 2008; Sun et al., 2003). AS04 is able to stimulate 
DC activation through TLR4 pathway signalling (Didierlaurent et al., 2009). CpG ODNs can 
promote signaling in APCs through TLR9, LPS promotes signaling through TLR4 while Poly I:C 
activates TLR3 signaling (Chow et al., 1999; Klaschik et al., 2009; Klinman et al., 1996) which 
induces maturation and activation of DCs such as induced expression of costimulatory molecules 
and cluster of differentiation molecules. Cytokines such as IL-2, IL-6, IL-7, IL-13, IL-15 and 
hepatocyte growth factor (HGF), in combination or even, in some cases, alone, can contribute to 
the maturation of DCs (Didierlaurent et al., 2009; Kerkmann et al., 2003; Werninghaus et al., 
2009).  
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The inflammasome is an important component of the innate immune response that can be 
a target for many adjuvants (Awate et al., 2013; Martinon et al., 2009). The inflammasome is 
expressed in myeloid cells and it is a complex assembly of proteins that are activated by NLRs 
family members (Awate et al., 2013) or DAMPs by components released from dying cells 
(Matzinger, 1994). Danger signals such as uric acid, nucleotides, adenosine triphosphate (ATP), 
reactive oxygen intermediates, and cytokines released from damaged cells can activate the 
inflammasome leading to release of pro-inflammatory cytokine such as IL-1β (Kool et al., 2008). 
Molecules such as (Krysko et al., 2011). This sterile/semi-sterile inflammation can be induced in 
response to injection of adjuvants and release of these endogenous molecules can attract 
inflammatory cells and promote induction of innate immunity (Chen et al., 2007; Kono et al., 
2014; Shi et al., 2003) 
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Figure 1.2 Diagrammatic representation of MOA of adjuvants: Adjuvants have a variety of 
mechanisms of action including forming a depot, secretion of chemokines and cytokines, and 
immune cell recruitment at the injection site, activation and maturation of antigen-presenting 
cells including activation of the inflammasome as well as shaping the type of immunity during 
antigen presentation in the lymph node (Awate et al., 2013). 
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1.8 How adjuvants link innate and adaptive immune responses 
Janeway (1989) described adjuvants as “immunologist’s dirty little secret” (Janeway, 
1989) which means that in spite of the wide utilization of adjuvants in billions of dosages of both 
human and animal vaccines, the MOA by which they potentiate their activity was not known at 
the time.  
Recent advances in immunobiology have contributed to a greater understanding of the 
innate and adaptive type of immune responses. The innate immune system is acted upon by 
adjuvants binding to a number of conserved PRRs, such as the TLRs (Underhill & Ozinsky, 
2002), NLRs, RLRs and CLRs (Stahl & Ezekowitz, 1998). These receptors function by specific 
recognition of PAMPs and/or DAMPs (Medzhitov & Janeway, 1997) leading to activation of a 
variety of transcription and translation factors and a downstream immunological pathways which 
enhance genes and secretion of proinflammatory cytokines (Medzhitov & Janeway, 1997). Hence 
adjuvants that stimulate PRRs may enhance the protective immune response and promote 
memory to a specific antigen (Cox & Coulter, 1997)  
Effective vaccines formulations need to stimulate multiple PRRs to both enhance the 
magnitude and the quality of immune responses to the vaccine antigens.  Many adjuvants signal 
through PRRs on various immune cells resulting in increased NF-kB. Proinflammatory cytokines 
and/or type I interferon (IFN) production, which subsequently leads to an up-regulation of 
chemokines and cytokines leading to recruitment of immune cells such as DCs and other APCs to 
the site of injection. The recruited DCs express various PRRs both on the surface (TLRs, CLRs) 
and intracellularly (NLRs and RLRs), which are recognized and/or are activated by the adjuvants 
needed for maturation of dendritic cells (DCs) and improved antigen uptake and presentation to 
antigen presenting cells (APC), activation and maturation of APC [increased major 
histocompatibility complex (MHC) class II and co-stimulatory molecules expression]. Mature 
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APCs up-regulate the expression of MHC and co-stimulatory molecules. They are also 
characterized by increased capacity for antigen processing and presentation. Mature APCs then 
migrate to the draining lymph nodes to interact with antigen-specific B or T cell to activate potent 
antibody secreting B cells and/or effector CD8+ T cell responses (Cox & Coulter, 1997, Hoebe et 
al., 2004) 
Therefore effective adjuvants can improve the immunogenicity of inactivated or 
recombinant antigens, and they can lessen the quantity of antigen per dose or the number of 
inoculations required to accomplish protective immunity. They may specifically improve the 
efficacy of vaccines in newborns, the elderly or immunocompromised persons, enhance the speed 
and duration of the immune response, modulate antibody avidity, specificity, isotype or subclass 
distribution, stimulate cell mediated immunity, promote the induction of mucosal immunity, and 
to help overcome antigen competition in combination vaccines (Rajput et al., 2007; Singh & 
O'Hagan, 2003). 	
1.9 Recent advances in experimental polyphosphazenes (PZs) adjuvants and their 
mechanisms of action (Cell and Tissue Research, December, 2018: 374(3), 465-471) 
Royford Magiri1,2, George Mutwiri1,2 and Heather L. Wilson1,2, 
1Vaccinology & Immunotherapeutic Program, School of Public Health at the University of 
Saskatchewan, Canada 
2Vaccine & Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac), 
University of Saskatchewan, Canada	
1.9.1 PZs as immunostimulatory adjuvants 
PZs are high molecular weight, water-soluble, synthetic polymers that have been shown to 
enhance the magnitude, quality and duration of immune responses when co-administered with 
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bacterial and viral antigens in mice, pigs and cattle (Andrianov et al., 2009; Andrianov et al., 
2011; Andrianov et al., 2006; Dar et al., 2012; Eng et al., 2010; Garlapati et al., 2010; Garlapati 
et al., 2011; Magiri et al., 2018a; McNeal et al., 1999; Mutwiri et al., 2008; Mutwiri et al., 2007). 
. The two most investigated PZs are poly [di(carboxylatophenoxy)phosphazene] (PCPP) and 
PCEP (Mutwiri & Babiuk, 2009a).  
Changes in synthesis (such as reduction in the reduction of acid groups) and formulation as a 
soluble adjuvant or microparticle impacts how they influence the immune response (Andrianov et 
al., 2004). PCEP has been shown to have a significantly higher adjuvant activity compared to 
PCPP (Mutwiri et al., 2008) and also to induce1000-fold higher antibody titres compared to alum 
when co-administered subcutaneously with an influenza antigen in mice (Mutwiri et al., 2007). 
Relative to PCPP, PCEP also promotes a significantly stronger mixed Th1/Th2 type T cell 
response leading to broad-spectrum immunity (Mutwiri et al., 2007). 
 
 
 
Figure 1.3 The structures of the polyphosphazenes adjuvants, PCEP and PCPP (Andrianov et al., 
2006; Teasdale & Brüggemann, 2013). Image recreated from Motifolio.com	
PCEP PCPP
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1.9.2 Regulation of innate immune response genes, induction of cytokines and chemokines, and 
recruitment of immune cells to the site of injection by PZs in mice and pigs 
Studies with mice and pigs revealed species-specific differences in PZ-induced 
stimulation of innate immune responses (Awate et al., 2012; Magiri et al., 2016). Intramuscular 
injection of PCEP induced time-dependent changes in the gene expression of many “adjuvant 
core response genes” (Mosca et al., 2008) such as chemokine genes CCL-2, CCL-4, CCL-5, 
CCL-12 and CXCL-10 in mice (Awate et al., 2012) and CCL2 and CXCL10 (but not CCL- 5) in 
pigs (Magiri et al., 2016). Major transcription factor NF-kB gene and the inflammatory cytokine 
TNF-α gene were up-regulated in response to PCEP in mice (Awate et al., 2012) but not in pigs 
(Magiri et al., 2016). At the protein level, PCEP promoted significant local production of Th1-
type proinflammatory cytokines (IL- 1β, Il-6, IL-18 IFN-γ and TNF-α) and Th2-type cytokines 
(IL-4 and monocyte chemoattractants CCL-2 and CXCL-10) at the site of injection in mice but 
not systemically (Awate et al., 2012). Further, in vitro studies showed that PCEP activated the 
NLRP3 inflammasome in a Caspase 1-depedent manner which lead to the processing of 
interleukin IL-1β, IL-18 and IL-33 stimulated splenic DCs in mice (Awate et al., 2014). 
However, in pigs, PCEP induced IL-6 gene expression but not IL-10, IL-17 or IFN-α (Magiri et 
al., 2016). PCEP injection in mice increased the expression of TLR4 and TLR9 at the site of 
injection (Awate et al., 2012) whereas PCEP did not induce significant expression any of the 
TLR genes in pigs suggesting differences in activation of immune responses in different animal 
species may be due to cell recruitment and differences in PPRs expression (Magiri et al., 2016). 
These results suggest that PCEP may modulate antigen-specific immune responses by activating 
early innate immune responses and promoting a strong immunostimulatory environment at the 
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site of injection. Our studies provide evidence that the effect that adjuvants have on the innate 
immune response can differ remarkably between species.  
Intramuscular (i.m.) injection of PCEP promoted recruitment of largely neutrophils but 
also macrophages, CD4+ T cells, CD8+ T cells and CD19+ B cells, monocytes and DCs to the 
injection site and the draining lymph nodes in mice (Awate et al., 2014a). Confocal analysis 
revealed that many recruited myeloid cells (but only a few lymphocytes) showed evidence of 
intracytoplasmic lysosomal localization of PCEP (Awate et al., 2014b). These findings suggest 
that the recruitment of distinct immune cells to the site of injection site may be an important 
mechanism by which PCEP potentiates immune responses. 
1.9.3 Activation of immune cells by PZs 
Even in the absence of antigens, PCPP and PCEP have strong avidity to soluble immune 
receptor proteins such as Mannose Receptor and endolysosome membrane-associated PRRs such 
as TLR7, TLR8, and TLR9 (Andrianov et al., 2016a; Sasai & Yamamoto, 2013). Other studies 
revealed direct activation of immune cells by PCPP and PCEP through TLR signaling pathway, 
both on the external cell surface (TLR4) and endosome (TLR3 and TLR9) receptors (Reed et al., 
2013; Sasai & Yamamoto, 2013). Incubation of primary mouse splenocytes with PCEP or PCPP 
triggered production of IL-4 and IL-12, but only PCEP induced significant IFN-γ production 
suggesting that activation of innate immunity may be important in mediating PZ adjuvant activity 
(Mutwiri et al., 2008). Others have demonstrated that PCPP induced activation and maturation of 
DCs (Andrianov et al., 2006; Andrianov et al., 2016a). In the presence of antigen, PCPP has been 
shown to promote activation and maturation of human adult and newborn DCs by upregulating 
co-stimulatory molecules and cytokine production and was as induction of an innate immune 
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transcriptome (Palmer et al., 2014) which may suggest that PZ may be an appropriate adjuvant to 
include in early life immunization. 
1.9.4. Vaccine carrier adjuvants  
Vaccine carriers have been traditionally viewed as particulate delivery vehicles capable of 
facilitating physical uptake of the antigen by APCs (De Temmerman et al., 2011; Storni et al.,, 
2005). Generally, it was thought that delivery systems tend to induce Th2-type immune responses 
which are not effective against many intracellular pathogens, while immunostimulatory adjuvants 
were traditionally thought to induce Th1-type immune responses by strongly activating the innate 
immune system (Ryan et al., 2001). However, these classifications are no longer appropriate 
since there is growing evidence that some delivery systems can activate innate immunity as well.  
1.9.4.1 PZs as vaccine carriers 
PZs have been exploited as protein carriers due to their versatile molecular structures and 
wide-spectrum of chemical and physical properties including biodegradability and matrix 
permeability (Andrianov & Payne, 1998; Teasdale & Brüggemann, 2013). PZ can bind vaccine 
antigens as well as TLR ligands or other sites on immune cells leading to cell maturation and 
more effective antigen processing which supports the idea that PZs macromolecules have dual 
antigen carrier and immunostimulant functions (Andrianov et al., 2016a; Andrianov et al., 2005; 
Palmer et al., 2014). Further, PZs can form stable water-soluble, complexes with antigenic 
molecules spontaneously and thus do not require chemical conjugation (Andrianov et al., 2005; 
Palmer et al., 2014). These non-covalent interactions with proteins stabilize proteins in solution 
and during drying processes and they have been correlated with immunoadjuvant activity 
(Andrianov et al., 2005; Marin et al., 2010).  
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Aqueous PZs can be transformed to microparticles by cross-linking them with divalent 
cations. Microencapsulation of antigens by PZs can be achieved under remarkably mild 
physiological conditions (which avoids denaturation or loss of biological activity of encapsulated 
material) giving them tremendous potential as matrices for sustained antigen release (Andrianov 
& Payne, 1998). For example, immunogenicity of influenza antigen and tetanus toxoid were 
dramatically enhanced when microencapsulated in PCPP microparticles (Payne et al., 1995). 
Further, by varying polymer ratios and using PZ of reduced molecular weight, it can form 
macromolecular assemblies at the nanoscale level to cross-linked hydrogels while maintaining 
protein-binding ability (Andrianov et al., 2016b). Microparticles are more effective in mucosal 
delivery of antigens (Shim et al., 2010) which should be taken into consideration for vaccine 
development. 
1.9.5 Adjuvant potential of PZs in combination with other adjuvants 
Due to challenges in vaccine development, increased regulatory hurdles and/ for purely 
economic reasons, the vaccine industry has historically used one adjuvant per vaccine. However, 
evidence has accumulated over the last decades that multiple adjuvant components in the same 
vaccine may act synergistically (Ciabattini et al., 2016; Didierlaurent et al., 2017; Kindrachuk et 
al., 2009; Levast et al., 2014; Madan-Lala et al., 2017; Mount et al., 2013; Mutwiri et al., 2011; 
Salvador et al., 2012). Combination adjuvants are particularly suited to only enhance and/or 
direct the immune responses towards a Th1-, Th2- or Th17-type immune responses (Kindrachuk 
et al., 2009; Levast et al., 2014; Salvador et al., 2012).  
Due to the short half-life of most immunostimulatory adjuvants in vivo, combining a delivery 
vehicle adjuvant with an immunostimulatory adjuvant may increase the magnitude and modulate 
the quality of immune responses (Weiner et al., 1997). Mice vaccinated subcutaneously with 
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PCPP microparticles encapsulating OVA and CpG ODN generated higher antigen-specific 
antibody responses compared to antigen alone (Garlapati et al., 2010; Wilson et al., 2010). 
Studies by several investigators at VIDO-InterVac have demonstrated that PZ as part of a triple 
adjuvant combination (TriAdj) consisting of PCEP or PCPP plus TLR agonist (CpG or polyIC) 
plus Host Defense Peptide (HDP) is a robust adjuvant combination in multiple species and 
multiple routes of delivery. For example, subcutaneous immunization of mice with of hepatitis B 
surface antigen (HBsAg) plus TriAdj resulted in enhanced production of HBsAg-specific 
antibody responses compared with the mice immunized with HBsAg plus any of the three 
adjuvants alone (Mutwiri et al., 2008). Relative to mice immunized with OVA plus the adjuvants 
alone, mice vaccinated with OVA plus TriAdj showed enhanced antibody and cell mediated 
responses via both MHC class I and II pathways, promoting a more balanced antibody-mediated 
and type1-biased cell-mediated immune response (Kovacs-Nolan et al., 2009a). Mice vaccinated 
subcutaneously with Bordetella pertussis antigen plus TriAdj had significantly reduced bacterial 
load after challenge and increased antigen-specific IL-17 secreting cells relative to vaccine 
comprised of one or two adjuvants alone (Garlapati et al., 2011). Formulation of pertussis toxoid 
(PTd) with TriAdj increased IgG1 responses in adult mice and induced superior serum IgG2a 
antibody titers in both adult and neonatal mice compared to mice immunized with each adjuvants 
alone (Gracia et al., 2011). Recombinant truncated bovine respiratory syncytial virus (BRSV) 
fusion protein (DeltaF) plus TriAdj showed enhanced secretion of antigen-specific serum 
antibody titres when compared with mice immunized with antigen alone (Kovacs-Nolan et al., 
2009b). Intranasal vaccination with a formalin-inactivated BRSVs vaccine plus TriAdj resulted 
induced systemic and mucosal immunity in mice (Mapletoft et al., 2010) and significant 
reduction in viral replication upon BRSV virus challenge (Mapletoft et al., 2008). Cattle 
immunized subcutaneously on days 0 and 90 with TriAdj with hen egg lysozyme antigen 
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produced superior antigen-specific humoral responses and cell-mediated immune responses 
relative to cattle immunized with Emulsigen (Kovacs-Nolan et al., 2009c). Intramuscular or 
intrauterine immunization of rabbits with a single dose of OVA, truncated glycoprotein D (tgD) 
from bovine herpesvirus, and a fusion protein of porcine parvovirus protein VP2 and bacterial 
thioredoxin (rVP2-TrX) formulated with TriAdj induced antigen-specific humoral responses 
systemically and within the local (uterus) and distal mucosa (lungs and vagina) (Pasternak et al., 
2017). Thus, PZ as part of the TriAdj combination dramatically enhanced the magnitude of 
immune responses resulting in a balanced immunity for broader protection.  
1.9.6 Antigen dose sparing effect of PZs adjuvants 
The implementation of antigen stabilization and dose-sparing technologies is an important 
step in improving availability of vaccines and is a critical feature for effective vaccine 
development at the time of a pandemic outbreak. PZ have the potential to significantly reduce the 
cost of vaccination by reducing the number of immunizations or reducing the minimal doses of 
antigen required to induce significant immunity. Indeed, lethal challenge studies in ferrets 
demonstrated 100% protection for low-antigen dose PCPP-adjuvanted formulations and at least a 
10-fold antigen-sparing effect with improved thermal stability of H5N1 influenza vaccine in 
solutions (Andrianov et al., 2011)Additionally, reducing the dose of antigen by 25-fold had no 
effect on antibody responses in mice immunized with PCPP and PCEP in mice (Mutwiri et al., 
2007). When used as part of an intradermal delivery system for hepatitis B surface antigen, PCPP 
demonstrated superior induction of immunity in pigs compared to i.m. administration and 
significant antigen sparing potential (Andrianov et al., 2009). Further development of PZ as an 
adjuvant may therefore have a great impact in the vaccine industry. 
50		
1.9.7 The safety profile of PZs adjuvants 
Many potential immunological adjuvants are not licensed for use in humans or veterinary 
species due to safety and/or toxicity concerns (Eng et al., 2010; Petrovsky, 2015; Sivakumar et 
al., 2011). PZs have been shown to be a safe and effective adjuvant at doses up to 1 mg when 
injected in sheep and cattle (Kovacs-Nolan et al., 2009c) without adverse reactions such as 
pathological inflammatory reactions,  swelling or pain, (Kovacs-Nolan et al., 2009c). In pigs, up 
to 500 µg PCEP was tolerated with fewer injection site reactions and reduced delayed type 
hypersensitivity in pigs (Dar et al., 2012;Magiri et al., 2016; Magiri et al., 2018a).  
In human Phase I clinical trials for three influenza viral strains (A/H3N2, A/H1N1 and B strain) 
targeted towards both young and elderly adults, up to 500 µg PCPP was shown to be safe 
showing sterile abscesses, and non-ulcerative necrosis at the site of inoculation. (Le Cam et al., 
1998). Phase I and Phase II clinical trials of a vaccine formulated with PCPP and HIV-1 antigens 
did not result in either abscess at injection site, immune dysfunction, anaphylaxis, or allergy, 
whereas a vaccine formulated with CFA and HIV-1 was associated with definable long-term 
adverse events (Gilbert et al., 2003). Together, the results suggest that polyphosphazenes are well 
tolerated in humans and animals but detailed safety and toxicity studies per vaccine are still 
required. 
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CHAPTER 2. RATIONALE, HYPOTHESIS, OVERALL OBJECTIVE AND AIMS 
2.1 Rationale and hypothesis 
Vaccination continues to be a very important public health tool in the control of infectious 
diseases in the world. Subunit vaccines containing even inactivated antigens consequently are 
ineffectively immunogenic and require the addition of adjuvants to generate protective immune 
responses. Despite their crucial role, the MOA of numerous adjuvants remain ineffectively 
understood. The lack of detailed information on how adjuvants work is a barrier to their rational 
use in vaccines especially the development of safe and effective vaccines. Although adjuvants 
have been used in billions of doses of vaccines, little is known regarding some of their MOA. 
PZs are high-molecular weight, water-soluble polymer that have been shown to enhance 
long lasting immune responses with a variety of viral and bacterial antigens in mice pig and cattle 
(Mutwiri et al., 2008, McNeal et al., 1999, Eng et al., 2010). The two most investigated PZs are 
PCPP and PCEP; PCEP has been shown to possess significantly stronger adjuvant activity than 
PCPP because of its ability to promote mixed Th1/Th2 type of immune responses hence giving a 
broad spectrum immunity (Mutwiri et al., 2007). Recent advances in immunobiology in mice 
suggest that most adjuvants including PCEP act by stimulating the innate immune response 
leading to induction of cytokine and chemokine production at the site of injection (Mutwiri et al., 
2008), recruitment of immune cells and transport of antigen to the draining lymph node (Awate et 
al., 2014a), increased antigen uptake by DCs and activation and maturation of antigen 
presentation cells. It was recently reported that some adjuvants injected into murine muscle 
induced a set of at least 56 "adjuvant core response genes" at the site of injection (Awate et al., 
2012). In vitro, PCEP induces secretion of innate cytokines IL-12 and IFN-γ suggesting that 
activation of innate immunity may be crucial in mediating its adjuvant activity (Mutwiri et al., 
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2008). These studies were carried out in mice and there is little information as to its MOA in 
large animals. 
Since most adjuvants act by stimulating innate immunity, we will focus on investigating how 
PCEP activates innate immunity as a means to understand its mechanism of action in pigs.  
 
Hypothesis 
1. PCEP is a strong activator of innate immune responses (inflammation) in pigs.  
2. Strong inflammatory responses are not required for adjuvant activity of PCEP. 
2.2 Overall Objective  
The overall objective was to investigate innate immune responses activated by adjuvant PCEP in 
pigs by addressing the following specific aims 
2.3 Aims 
1. To investigate the immune response genes induced by PCEP at the injection site 
2. To determine inflammatory responses induced by PCEP at the injection site and in the 
draining lymph node  
3. To investigate the local and systemic cytokine and chemokine concentrations after 
PCEP injection 
4. To examine whether reduction of dose of PCEP reduces inflammatory responses at 
the site of injection 
5. To determine whether reduction in dose of PCEP reduces tissue reaction to the 
vaccine without compromising the immune response to swine influenza virus antigen. 
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CHAPTER 3. Response of immune response genes to adjuvants poly [di (sodium 
carboxylatoethylphenoxy) phosphazene](PCEP), CpG Oligodeoxynucleotide and Emulsigen 
at intradermal injection site in pigs  
 (Veterinary Immunology Immunopathology 2016. 175: 57-63) 
R.B. Magiri, K. Lai, A.M. Chaffey, H. L. Wilson, W.E. Berry, M.L. Szafron, G.K. Mutwiri 
Vaccinology & Immunotherapeutic Program, School of Public Health at the University of 
Saskatchewan, Vaccine & Infectious Disease Organization- International Vaccine Centre (VIDO-
InterVac) 
Relationship of this study to the dissertation  
Adjuvants are critical component of vaccines. Despite being a critical component of many 
vaccines, the MOA are not fully understood and particularly in regard to large animals. This lack 
of understanding limits our ability to design effective vaccines. PCEP has shown great potential 
as a candidate for an experimental vaccine adjuvant with different viral and bacterial antigens in 
mice pigs and cattle. However, the MOA of PCEP is not well studied. In this study, we 
investigated the capacity of a novel adjuvant PCEP to induce “adjuvant core response genes” 
(cytokines, chemokines, innate immune receptors, interferon-induced genes and adhesion 
molecules) when injected intradermal in pigs. This study suggests that PCEP ehnance its adjuvant 
activity by strongly activating early innate immune responses genes that may induce immune cell 
recruitment which promote a strong immuno-stimulatory environment at the site of injection. 
In this manuscript, my primary role was conduct of data analysis and interpretation of the 
work which led to the paper, writing the initial draft of the manuscript, and revising it based on 
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feedback from the other authors. Additionally, I responded to reviewer’s comments appropriately 
before final publication. 
 
3.1 INTRODUCTION 
Vaccination continues to be a very important public health tool to control infectious 
diseases in human and animals (Drummond et al., 2007). Many modern vaccines contain highly 
purified antigens, which tend to be poorly immunogenic and therefore require the addition of 
adjuvants to induce protective immune responses. Recent evidence suggests that adjuvants may 
mediate their effects by modulating a variety of innate immune events including the production 
of cytokines and chemokines, the recruitment of immune cells, the enhancement of antigen 
uptake and presentation, and the promotion of antigen transport to draining lymph nodes. The 
type of innate response induced by adjuvants can impact the quality and quantity of adaptive 
immune responses. Understanding the mechanisms by which adjuvants mediate their effects will 
provide critical information on how innate immunity influences the development of adaptive 
immunity and may lead to the rational development of new, safe, and effective vaccines in large 
animal species.  
PZs adjuvants are high-molecular weight, water-soluble polymers that, when coupled 
with many viral and bacterial antigens, have been shown to enhance long-lasting immune 
responses (Eng et al., 2010; Garlapati et al., 2010; McNeal et al., 1999; Mutwiri et al., 2008). 
When co-administered with influenza virus X:31 antigens, PCEP has been shown to induce a 
robust Th1/Th2 type, broad spectrum immune response in mice (Mutwiri et al., 2007). Other 
studies have demonstrated that PCEP promotes the induction of cytokine and chemokine 
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production (Awate et al., 2012; Mutwiri et al., 2008), which leads to immune cells being 
recruited to the injection site, as well as the transport of antigens to draining lymph nodes. 
Results from in vitro experiments with splenic DCs indicate that PCEP stimulated significant 
production of the innate immune response cytokines IL-12 and IFN-γ (Garlapati et al., 2011; 
Mutwiri et al., 2008). PCEP has been shown to activate B-cells and CD4⁷ and CD8⁷ T cells 
respectively, leading to a significant production of IgM and the induction of IFN-γ (Awate et al., 
2014b). Our research group recently reported that CpG ODN and PCEP induced expression of a 
number of ‘adjuvant core response genes’ at the intramuscular injection site in mice (Awate et al., 
2012). These data suggest that the powerful adjuvant activity of PZs and CpG are a consequence 
of the strong activation of innate immunity (Mutwiri et al., 2008). 
To our knowledge, no studies have explored how a PCEP adjuvant mediates its activity in 
large animals. To obtain a better understanding on the adjuvant’s mechanism of action in large 
animals, we evaluated how the adjuvants PCEP, CpG ODN and Emulsigen injected intradermally 
into pigs modulated local expression patterns of immune response genes. 
3.2 Materials and Methods 
3.2.1 Animal experiments 
Four groups (n=6/group) of three to four weeks old commercial cross breed pigs were 
administered a 250 µl volume i.d. injection at the subcutis of phosphate-buffered saline (PBS), 
100 µg PCEP, 10 µg CpG 2395, or 20% Emulsigen. Each animal was injected at five different 
injection sites five centimeters apart and an 8 mm skin punch plug biopsy was collected from one 
site at each time point (1, 6, 24, 48 and 96-hours). The animal experiments were approved by the 
University of Saskatchewan’s Animal Research Ethics Board for humane animal use.  
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3.2.2 Adjuvant preparation 
PCEP was synthesized as detailed in (Awate et al., 2012). ssRNA CpG 2395 (Merial 
Pharmaceuticals, CA, USA) and Emulsigen (MVP Laboratories, OM, USA) were dissolved in 
endotoxin-free, sterile PBS at the pH 7.4 (Life Technologies, Carlsbad, CA, USA) prior to 
injection.  
3.2.3 Quantitative real-time PCR (qRT-PCR) for gene expression 
Skin tissue biopsies were collected at each time point for total RNA isolation using 
TRIzol (Life Technologies, Carlsbad, CA, USA) as per the manufacturer’s instructions with the 
addition of a second isopropanol (Commercial Alcohols, Inc., Brampton, ON, Canada) 
precipitation to remove phenol and other contaminants. The biopsies were homogenized as 
detailed in (Awate et al., 2012). 
RNA was quantified and checked for quality by using an Agilent RNA 6000 nano kit 
5056-4476 (Agilent Technologies, Waldbronn, Germany) and run on the Agilent Bioanalyser. 
Before cDNA synthesis, the RNA samples were treated with DNase I (Life Technologies) for 20 
minutes at room temperature. One milligram of the total RNA was used to synthesize cDNA.  
 The cDNA was prepared by using random hexamer and oligo(dT) primers and 
Superscript III reverse transcriptase (Life Technologies) using the manufacturer recommended 
concentrations. cDNA was then diluted in nuclease-free water to 10 ng/µL equivalent cDNA. 
qRT-PCR was performed in duplicate using 20 ng of equivalent cDNA, KappaFast Universal 
Mastermix (Kappa Biosystems, Wilmington, MA USA) with a primer concentration of 1 µM. 
The differential expression of selected cytokine and chemokine genes was assessed using the 
Bio-Rad iCycler detection system (Hercules, California, USA). The specificity of the amplified 
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products was determined by visualising on a 1.8% Agarose gel (Life Technologies). The melt 
curve was used to test the primer product specificity by determining whether primer pairs (Table 
1) were amplifying a single product (data not shown). As controls, we included a ‘No Template 
Control (NTC)’ reaction, wherein no cDNA was included, and a ‘No RT control’, where RNA 
samples were not reverse transcribed (data not shown). The PCR for the housekeeping genes β-
ACTIN, RPL-19, and HPTR1 and the genes of interest from each sample were run in parallel 
over several PCR plates. The PCR efficiency for the primer probe set was evaluated against a 
serial dilution of pooled samples and found to be greater than 95% for all genes (data not shown). 
Target gene expression Ct values were first normalised using the iCycler iQ™ real-time PCR 
detection system as outlined in (Vandesompele et al., 2002). The increase in target gene 
expression levels in stimulated skin tissues were calculated as the fold change increase (2-ΔΔCT) 
relative to PBS and normalized against the geometric mean of the time-matched HPTR1 gene, 
which was the most stable for all time points.  
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Table 3.1 List of primers 
Gene 
symbol 
Forward sequence (5’-3’) Reverse sequence (5’-3’) 
CCL-2 AGTCACCTGCTGCTATACAC 
 
GCGATGGTCTTGAAGATCAC 
 
CCL-5 TGCCCTTGCTGTCATCCTC 
 
CACACCTGGCGGTTCTTTC 
 
CXCL-10 AGAACTGTTCGCTGTACC CATGTGGGCAAGATTGAC 
IL-17 CTCTCGTGAAGGCGGGAATC GTAATCTGAGGGCCGTCTGG 
IFN-γ GCTCTGGGAAACTGAATGAC TCTCTGGCCTTGGAACATAG 
IFN-α CTCCTGGCACAAATGAGGAG CTGAAGAGCTGGAAGGTCTG 
IL-1β AGAAGAGCCCATCGTCCTTG 
 
GAGAGCCTTCAGCTCATGTG 
 
IL-6 ATCAGGAGACCTGCTTGATG 
 
TGGTGGCTTTGTCTGGATTC 
 
TNF-α CCAATGGCAGAGTGGGTATG 
 
TGAAGAGGACCTGGGAGTAG 
 
IL-10 GGTTGCCAAGCCTTGTCAG AGGCACTCTTCACCTCCTC 
IL-13   
NF-kappa B GGCCATCAATCAGCGCATCCAG AGCAGAGCCGCACAGCATTCAG 
TLR4 TGTGCGTGTGAACACCAGAC 
 
AGGTGGCGTTCCTGAAACTC 
 
TLR9 GGCCTTCAGCTTCACCTTGG 
 
GGTCAGCGGCACAAACTGAG 
 
IFIT2 CAGAAGGCGGCAGAGAATG ACAGAGGCAGGCGAGATAG 
IFIT3 CTCGCCAAACAGATGTCC GGATTCCAGTGCCGTTAG 
IFNAR2 TCCGCCTGGGTATTTCCTG CGCTATCGCTGTCGCTTTC 
MX1 AGTGTCGGCTGTTTACCAAG TTCACAAACCCTGGCAACTC 
MX2 CCGACTTCAGTTCAGGATGG ACAGGAGACGGTCCGTTTAC 
IRF7 TGCGATGGCTGGATGAAG TAAAGATGCGCGAGTCGG 
LGAL3 GACCCAAGGCGTGAAAGAC CGTTCCTGAAGCCCAAAGC 
PMSB8 TTGTGGCGGTGGATTCTC AGCAGACGCTCCCAATAC 
STAT2 CCATCTCTGGCACCTTTC GAGCACCTTGTCGTCATC 
MSR1 GATCAACCGGAGGACACTGAC GCACCAGCACGACAAACAC 
β-ACTIN CCTCTCAGGCATGGAGTCCT CTGATGTCCACGTCGCACTT 
RPL19 AACTCCCGTCAGCAGATCC AGTACCCTTCCGCTTACCG 
HPRT1 GGACTTGAATCATGTTTGTG CAGATGTTTCCAAACTCAAC 
 
3.2.4 Statistical analysis  
Statistical analyses were carried out using Graph-Pad Prism 6 software (GraphPad 
Software, San Diego, CA, USA). Differences in the fold change of gene expression were 
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identified using a non-parametric Kruskal-Wallis ANOVA test where Dunn’s multiple 
comparisons test was used post-hoc to identify statistically significant differences in gene 
expression. The letter code depicting significant differences in gene expression between groups 
are as follows: (a) CpG to PBS, (b) Emulsigen to PBS, (c) PCEP to PBS, (d) CpG to Emulsigen, 
(e) Emulsigen to PCEP, and (f) CpG to PCEP. Differences were considered statistically 
significant at p< 0.05 (*), p< 0.01 (**) and p< 0.001 (***) which are stated in the text.  
 
3.3 Results and Discussion 
3.3.1 Induction of chemokines, cytokine and Toll like receptor (TLR) genes expression in 
response to adjuvants 
Awate et al (2012) reported that CpG and PCEP induced expression of a set of adjuvant core 
response genes when injected into murine muscle (Awate et al., 2012). Using a similar 
experimental design, we injected adjuvants into pigs via an intradermal route and included 
Emulsigen as another adjuvant under investigation. Please note that unless specifically stated, 
statistically significant data will always indicate the adjuvant relative to PBS at each time point. 
3.3.1.1 Chemokines 
Chemokine (C-C motif) ligand (CCL-2) is a chemokine with chemotactic activity for 
monocytes and basophils (Wegscheider et al., 2005). Other studies have shown that the adjuvants 
alum, MF59, and CpG-ODN modulated a cluster of genes encoding cytokines, chemokines, 
innate immune receptors, interferon-induced genes and gene encoding adhesion molecules 
defined as ‘adjuvant core response genes’ when administered to the injection site in mice 
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following intramuscular administration in quadriceps muscles (Mosca et al., 2008). Similarly, the 
oil-in-water emulsion AS03 co-administered with antigen to stimulate colony-stimulating factor 3 
(CSF3) induced expression of chemokines CCL-2, CCL-3 and CCL-5 in vitro in mice dendritic 
cells (Morel et al., 2011).  
In the present study, CCL2 was significantly induced in response to Emulsigen at 24 
(b;***), 48 (***) and 96 hours (**) and it was significantly induced by PCEP at 96 hours (c; *) 
(Fig 4A). Thus, even though the magnitude was less robust in pigs our results show general 
agreement with results from Awate et al (2012) where PCEP was shown to induce CCL-2 
expression >100 fold after 24 hours, rising to > 400 fold after 96 hours in murine muscle (Awate 
et al., 2012). CpG failed to significantly induce expression of CCL-2 in pig skin or murine 
muscle over time (Awate et al., 2012).  
The chemokine CCL-5 activates T cells through a tyrosine kinase pathway (Bacon et al., 
1995; Wong & Fish, 1998), which leads to the secretion of IFN-γ (Appay et al., 2000) and may 
promote dendritic cell maturation (Fischer at al., 2001; Yamagami et al., 2005). In the present 
study, CCL-5 expression was significantly induced by Emulsigen at 24 (b; **), 48 (*) and 96 
hours (***; Fig 4B). Intradermal injection of CpG and PCEP into pigs failed to significantly 
increase expression of CCL-5 at any time point. In contrast, Awate et al (2012) showed that 
PCEP injection into murine muscle up-regulated the expression of CCL-5 gene at 24 hours 
whereas CpG injected into murine muscle was shown to promote CCL-5 expression at 12 and 48 
hours (Awate et al., 2012).  
CXCL10 binds and activates the CXCR3 receptor which is highly expressed in activated 
Th1 cells, B cells, NK cells, and DCs (Dufour et al., 2002). In the current study, CXCL-10 was 
significantly induced by CpG relative to both PBS and PCEP 24 hours (a; **, f; **) and 48 hours 
(a; ***, f; *) (Fig 4C). CpG induced a significantly higher expression of CXCL-10 relative to 
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Emulsigen at 6 hours (d; ***) but CXCL-10 expression rebounded to be induced in response to 
Emulsigen after 24 hours. Awate et al (2012) showed that murine muscle injected with CpG 
showed >500 fold induction of CXCL-10 after 6 and 48 hours and muscle injected with PCEP 
showed significant induction of CXCL-10 after 48 and 96 hours(Awate et al., 2012).  
 
Figure 3.1 Chemokines gene expression profiles in response to PCEP, CpG and Emulsigen at the 
site of intradermal administration in pigs. Skin punch biopsies were collected at 1, 6, 24, 48 and 
96 hours for chemokine genes expression by quantitative real-time PCR for CCL-2 (A), CCL-5 
(B), and CXCL-10 (C). Results shown are the mean ± SD of three to six replicates at each time 
point. Relative fold changes (y-axis) for each gene were calculated by the Ct method and are 
relative to the gene expression in PBS injected skin tissue and each gene was normalized to pig 
HPRT1 for each time point. The letter code depicting significant differences in gene expression 
between groups are as follows: (a) CpG to PBS, (b) Emulsigen to PBS, (c) PCEP to PBS, (d) 
CpG to Emulsigen, and (f) CpG to PCEP.  
 
3.3.1.2 Cytokines 
IL-6 is a proinflammatory cytokine that promotes the differentiation of B cells (Helle et 
al., 1988; Hilbert et al., 1989; Houssiau et al., 1988; Lue et al., 1991). In the current study, IL-6 
was significantly induced by Emulsigen at 6, 24 and 48 hours (b; *, *** and *, respectively). 
PCEP induced IL-6 expression after 48 and 96 hours (c; ***, **, respectively) and relative to 
CpG after 96 hours (f; *) (Fig 5A). CpG did not promote IL-6 expression at the site of injection 
in pigs. These results are in agreement with Awate et al (2012), which showed that PCEP 
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injected in murine muscle was a more potent activator of cytokine genes IL-6 at the site of 
injection (which peaked at >400 fold at 24 hours) compared to CpG (Awate et al., 2012). Tumor 
necrosis factor-α (TNF-α) is a cytokine involved in acute-phase inflammation and is produced 
chiefly by activated macrophages as well CD4+ lymphocytes, NK cells, neutrophils, mast cells 
and eosinophils (Brynskov et al., 2002; Locksley, Killeen, & Lenardo, 2001). TNF-α was 
induced less than 10 fold by Emulsigen at 24, 48 and 96 hours (b; **, **, *, respectively) 
whereas CpG induced TNFα expression after 6 hours (a; *) (Fig 5B). Awate et al (2012) showed 
that injection of CpG into murine muscle triggered a transient increase in TNFα expression at 3-6 
hours followed by reduced expression and finally increased expression again after 48 hours 
(Awate et al., 2012). Murine muscle injected with PCEP showed increased TNFα expression over 
time (Awate et al., 2012). There was no significant change in NFkB expression in pig skin in 
response to injection of any of the adjuvants (Fig 5C).  
CpG injection into pig skin significantly induced expression of the potent anti-
inflammatory cytokine, IL-10, after 24 and 48 hours (a; **, *) but no other adjuvant significantly 
induced expression of this gene in pigs (Fig 5D). IL-13 is an anti-inflammatory cytokine and a 
mediator of allergic inflammation (Cocks et al., 1993; Wynn, 2003). In the present study, IL-13 
was significantly repressed in response CpG relative to Emulsigen at 24 hours (d; *) and relative 
to PCEP at 48 hours (f; **) (Fig 5E). In contrast, Awate et al (2012) showed that CpG and PCEP 
injected into murine muscle triggered increased IL-13 expression over time. Finally, our results 
in pigs showed that CpG significantly reduced expression of IL-17 after 24 hours (a; *) (Fig 5F). 
In contrast, Awate et al (2012) showed that in murine muscle, PCEP upregulated Th17 type 
cytokines (IL-17 and IL-6) and Th2 type cytokines (IL-4, IL-10, and IL-13) with expression 
generally increasing over time. Our data shows that in pig skin, adjuvants PCEP and promote 
Th2 stimulation through induction of IL-13 expression but that CpG inhibited IL-13 and IL-17 
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expression and it induced expression of IL-10. Together these data suggest that these adjuvants 
do not share conserved expression profiles of innate immune response genes in pig skin relative 
to murine muscle.  
 
 
 
Figure 3.2 Induction of cytokine gene expression profiles in response to PCEP, CpG and 
Emulsigen at the site of intradermal administration in pigs. Skin punch biopsies were collected at 
1, 6, 24, 48 and 96 hours and subjected to quantitative real-time PCR to quantify gene expression 
levels for IL-6 (A), TNF-α (B), NFkB (C), IL-10 (D), IL-13 (E) and IL-17 (F). Results shown are 
the mean ± SD of six replicates at each time point. Relative fold changes (y-axis) for each gene 
were calculated by the Ct method and are relative to the gene expression in PBS injected skin 
tissue and each gene was normalized to pig HPRT1 for each time point. The letter code depicting 
significant differences in gene expression between groups are as follows: (a) CpG to PBS, 
Emulsigen to PBS, (c) PCEP to PBS, (d) CpG to Emulsigen, and (f) CpG to PCEP.  
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3.3.1.3 Toll-Like Receptors 
The proteins coded for by the Toll-Like Receptors TLR4 and TLR9 genes are members of 
the TLR family (Du et al., 2000), which recognizes LPS and unmethylated CpG DNA/ 
oligodeoxynucleotides, respectively and they trigger the activation of an innate immune response 
(Medzhitov & Janeway, 1997). In the present study, none of the adjuvants significantly induced 
expression of the TLR4 gene in response to PBS (Fig 6A) but the TLR9 gene was induced by 
Emulsigen after 24 hours (b; ***) and 48 hours (***). No other adjuvant induced expression of 
TLR9 induction at any other time point (Fig 6B). In contrast, Awate et al (2012) showed that 
murine muscle injected with PCEP up-regulated TLR4 and TLR9 at the injection site (Awate et 
al., 2012).  
 
Figure 3.3 Induction of TLR gene expression profiles in response to PCEP, CpG and Emulsigen 
at the site of intradermal administration in pigs. Skin punch biopsies were collected at 1, 6, 24, 48 
and 96 hours and subjected to quantitative real-time PCR to quantify gene expression levels for 
TLR4 (A) and TLR9 (B). Results shown are the mean ± SD of three to six replicates at each time 
point. Results shown are the mean ± SD of six replicates at each time point. Relative fold changes 
(y-axis) for each gene were calculated by the Ct method and are relative to the gene expression in 
PBS injected skin tissue and each gene was normalized to pig HPRT1 for each time point. The 
letter code (b) depicts significant differences in gene expression between Emulsigen and PBS.  
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3.3.2. Induction of interferon induced genes and immune cell receptor gene expression by 
adjuvants 
IFN-α, a viral response gene, was not induced in response to any of the adjuvants relative 
to PBS when administered to pig muscle but its expression was significantly repressed in 
response to Emulsigen after 48 hours (b;*) (Fig 7A). The protein coded for by IFNAR2 gene is a 
type I membrane protein (Domanski et al., 1995). IFNAR2 was induced less than 10-fold by 
Emulsigen at 48 and 96 hours (b; *) but no induction was observed in response to CpG or PCEP 
at any time points (Fig 7B). STAT2 is a transcriptional activator, which responds to cytokines 
such as IFN-α, and growth factors by being phosphorylated which triggers homo- or heterodimers 
and translocation to the nucleus (Holloway et al., 2014; Steen et al., 2013). CpG injected into pig 
skin induced expression of STAT2 at 6, 24 and 48 hours (a; *, ***, **) (Fig 7C) but no other 
adjuvant induced expression of this gene at any time points Awate et al (2012) showed that 
murine muscle injected with PCEP showed significant expression of STAT2 relative to tissue 
injected with PBS after 96 hours. Interferon regulatory factors (IRFs) are transcription factors 
that regulate expression of target cytokines such as interferon (IFN)-β and other innate immune 
response genes (Nehyba et al., 2009; Nehyba et al., 2002; Takaoka et al., 2008). IRF7 expression 
was repressed in pig skin in response to CpG relative to PBS (a; *) and relative to PCEP (f; *) 
after 1 hour but it was significantly induced in response to CpG relative to PBS after 24 and 48 
hours (a; ***, ***) (Fig 7D) induced expression of IRF7 after 24, 48 and 96 hours (b; *, *, *, 
respectively) (Fig 7D). PCEP did not induce expression of IRF7 expression over time. The results 
of the present study are consistent with another study, which showed that, in response to injection 
of MF59 oil-in-water emulsion, CpG, and alum into murine muscle, IRF7, STAT1, and STAT2 
gene expression were induced (Mosca et al., 2008). 
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IFN-stimulated genes IFIT2 and IFIT3 code for proteins which mediate protein-protein 
and protein-RNA interactions (Fensterl & Sen, 2011). IFIT2 gene was significantly induced in 
response to CpG for 24 and 48 hours (Fig 7E: a; **, *)) and CpG induced IFIT2 expression 
relative to PCEP at 6, 24 and 48 hours, respectively (Fig 7E: f; *, **, *). IFIT3 gene was 
significantly induced in response to CpG (Fig 7F: a; ***, **) for 24 and 48 hours, respectively. 
CpG induced IFIT3 expression relative to PCEP at 48 hours (Fig 7F: f; (*)). Both genes showing 
peak expression relative to PBS of > 30 fold at 24 hours but both PCEP and Emulsigen did not 
significantly induce IFIT2 and IFIT3 gene expression over time in pigs. These results of the 
present study differ from the responses observed where PCEP was shown to increase IFIT2 and 
IFIT3 gene expression over time after intramuscular administration in mice (Awate et al., 2012).  
MX1 is an Interferon-induced dynamin-like GTPase with antiviral activity against a wide 
range of RNA viruses and some DNA viruses (Jin et al., 1998; Verhelst et al., 2012). In the 
present study, CpG induced MX1 at 24 and 48 hours (a; ***, ***) (Fig 7G). In contrast, Awate et 
al (2012) showed that CpG and PCEP up-regulated expression of MX1 gene after injection into 
murine muscle but CpG induced a more rapid response and PCEP induced a >100 fold induction 
of MX1 after 48 hours (Awate et al., 2012). MX2 is known as an Interferon-induced dynamin-
like GTPase with potent antiviral activity (Aebi et al., 1989). Others have shown that when CpG 
and Emulsigen were used as adjuvants in a foot and mouth disease vaccine, the vaccine triggered 
an increased transcription of MX1 when injected into pigs (Alves et al., 2009). In the present 
study, CpG significantly induced MX2 at 24 and 48 hours (a, ***, ***) (Fig 7H). Emulsigen 
induced the expression of MX2 after 48 hours (b; *). CpG significantly induced expression of 
MX1 (Fig 7G, f; *) and MX2 (Figure 7H: f;*) relative to PCEP. Awate et al (2012) showed that 
neither PCEP nor CpG induced expression of MX2 gene in murine muscle (Awate et al., 2012). 
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LGALS3 is an IFN-inducible gene that encodes a member of the galectin family of 
carbohydrate binding proteins. This protein plays a role in numerous cellular functions including 
apoptosis, innate immunity, cell adhesion and T-cell regulation (Chen et al., 2015). CpG induced 
LGALS3 gene expression after 24 hours and 48 hours (a; ****, **) and Emulsigen induced 
expression of this gene after 48 hours (b; *) (Fig 7I). In contrast to murine muscle, pig skin 
injected with PBS did not trigger a strong induction of LGALS3 gene expression over time 
(Awate et al., 2012). PSMB8 is an IFN-inducible gene whose corresponding protein is present in 
professional antigen presenting leucocytes and it is involved in the enzyme regulatory functions 
and proteosomal degradation. PSMB8 gene expression was induced in response to CpG at 24 
hours (a; ***) (Fig 7J). PCEP and CpG were shown to up-regulate the expression of PSMB8 
gene expression in mice muscle tissue at 48 and 96 hours (Awate et al., 2012). Our findings are 
consistent with the others that demonstrated that CpG was an efficient inducer of IFN-α related 
genes when injected intramuscularly.  
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Figure 3.4 Induction of Interferon response genes in response to PCEP, CpG and Emulsigen at 
the site of intradermal administration in pigs. Skin punch biopsies were collected at 1, 6, 24, 48 
and 96 hours and subjected to quantitative real-time PCR to quantify gene expression levels for 
IFN-α (A), IFNAR2 (B), STAT2 (C), IRF7 (D), IFIT2 (E), IFIT3 (F), MX1 (G), MX2 (H), 
LGALS3 (I) and PMSB8 (J). Results shown are the mean ± SD of three to six replicates at each 
time point. Results shown are the mean ± SD of six replicates at each time point. Relative fold 
changes (y-axis) for each gene were calculated by the Ct method and are relative to the gene 
expression in PBS injected skin tissue and each gene was normalized to pig HPRT1 for each time 
point. The letter codes depicting significant differences in gene expression between groups are as 
follows: (a) CpG to PBS, (b) Emulsigen to PBS, (c) PCEP to PBS, and (f) CpG to PCEP.  
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Figure 8 shows differential gene expression in response to adjuvants alone relative to PBS time 
matched controls. Expression data >2 are green and >10 are dark green. Gene expression less 
than 0.6 (-1.6 fold) relative to PBS are red and gene expression less than 0.4 (-2.5 fold) are dark 
red. Expression between 0.6 and 2 fold are yellow. With the exception of IL-17 which is induced 
at 1 hour (green) and then repressed in response to CpG (red) at later time points, the majority of 
genes tested showed peak gene induction or repression in response to CpG at 24 hours. The 
majority of genes showed induction in response to Emulsigen with expression peaking at 24 
hours after stimulation. The response was not immediate, as the majority of genes were not 
induced after 1 or 6 hours. Approximately ⅓ of the genes (such as chemokines and IL-6, IL-10, 
and IL-13) showed a > 2 fold induction of expression within 1 hour after exposure to PCEP with 
approximately ¼ of the genes showing induced expression over time with IL-17 gene expression 
being the exception. Finally, we observed that CpG, and to a much lesser extent, Emulsigen, were 
inducers of IFN response genes (IFIT2, IFIT3, MX1, MX2, IRF7, LGALS3, PMSB8, and 
STAT2) but IFNα itself was repressed and IRNAR2 was induced at later time points in response 
to Emulsigen. The results of the present study suggest that differences exist in the mechanisms 
mediating the adjuvant activities of PCEP, Emulsigen and CpG. Most genes were not stimulated 
or repressed in response to time matched average response to saline. Further studies are required 
to confirm whether the PCEP, Emulsigen or CpG trigger recruitment of innate immune cells at 
the site of injection or draining lymph nodes and whether they trigger differences in expression of 
local cytokines and IFN response genes. Understanding the mechanisms of action of adjuvants 
will provide critical information on how innate immunity influences the development of adaptive 
immunity in response to PCEP. Such knowledge will facilitate the rational development of new 
vaccine adjuvants.  
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Figure 3.5 Heat map of relative mRNA expression in pig skin induced by administration of CpG, 
Emulsigen, PCEP or PBS at the site of injection. Each column represents one time point and each 
row represents the relative fold change gene expression for each gene at that time point. The 
colour scheme for the relative gene expression is as follows: <0.5 is dark red, between 0.4 and 
0.6 is red, between 0.61 and 1.8 is yellow, between 1.8 and 10 is green, > 10 is dark green. Gene 
names are listed on the left of panel and time points and treatment are indicated across the top of 
each panel. 
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Chapter 4. Innate immune response profiles in pigs injected with vaccine adjuvants 
polydi(sodium carboxylatoethylphenoxy)phosphazene (PCEP) and Emulsigen 
(Veterinary Immunology Immunopathology, 2019: 209, 7-16 ) 
Royford Magiria,b, Ken Laib,, Yanyun Huangc, George Mutwiria,b, Heather L. Wilsona,b 
a Vaccinology & Immunotherapeutic Program, School of Public Health, University of 
Saskatchewan, Saskatoon, SK, Canada 
b Vaccine & Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac), 
University of Saskatchewan, Saskatoon, SK, Canada 
c Prairie Diagnostic Services, 52 Campus Drive, Saskatoon, SK ,Canada	
Relationship of this study to the dissertation  
In chapter 3, we have shown that PCEP is a strong modulator of immune response genes. 
In this chapter we evaluate whether gene expression translate to protein transcription by 
accessing local production of cytokines after intradermal injection in pigs and whether cytokines 
induce recruitment of immune cells at the site of injection. In this study, we examined PCEP-
induced immune cell recruitment at the injection site and changes in cell composition in the 
draining lymph nodes. Additionally, we determined the cytokine responses at the site of injection. 
Taken together, PCEP induced significant production of interleukin IL-1β, and IL-13 at the site 
of injection which leads to recruitment of distinct immune cells to the site of injection site 
suggesting that PCEP stimulated early innate immune responses at the injection site by creating 
an immunocompetent environment that may contribute to increased immunogenicity of the co-
administered antigens. 
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responded to reviewer’s comments as appropriate. 
 
4.1 Introduction 
Effective adjuvants enhance the immunogenicity of highly purified or recombinant 
antigens but despite being used for decades in vaccines, MOA of many adjuvants remain 
unknown. This lack of clarity regarding adjuvant MOA is one of the factors that has limited 
development and approval of new adjuvants for human use (Calabro et al., 2011). Vaccination 
with antigen alone often triggers little or no specific immune responses unless formulated with an 
adjuvant that activates the innate immune responses (Calabro et al., 2011; Levitz & Golenbock, 
2012; Liang & Loré, 2016; McKee et al., 2009; Pasquale et al., 2015; Schijns, 2002; Wang & 
Singh, 2011). Studies in mice indicate that vaccine adjuvants enhance the immunogenicity of the 
antigen by activating early innate immune responses and promoting a strong immunostimulatory 
environment at the site of injection (Gupta & Chaphalkar, 2015; Kanzler et al., 2007; Milligan, 
2014).  
We previously reported that PCEP, a high-molecular weight, water-soluble polymer, 
enhanced long lasting immune responses when co-administered with a variety of viral and 
bacterial antigens in mice, pigs and cattle (Awate et al., 2012; Eng et al., 2010; Magiri et al., 
2018b; McNeal et al., 1999; Mutwiri et al., 2008; Mutwiri et al., 2007). We recently reported on 
PCEP MOA in a series of studies. In mice similar to other adjuvants, PCEP induced recruitment 
of immune cells to the site of injection and promoted transport of antigen to the draining lymph 
73		
node (Awate et al., 2014; Dupuis et al., 2001). The cells recruited following intramuscular (i.m.) 
injection of PCEP to the site of injection and the draining lymph nodes in mice constituted 
largely of neutrophils but also macrophages, CD4+ T cells, CD8+ T cells and CD19+ B cells, 
monocytes and DCs (Awate et al., 2014). Further, PCEP promoted cytokine and chemokine 
production as well as regulation of a number of ‘adjuvant core response genes’ at the 
intramuscular injection site in mice and pigs (Awate et al., 2012; Magiri et al., 2016; Mutwiri et 
al., 2008). Specifically, studies with mice and pigs revealed species-specific differences in 
polyphosphazenes induced stimulation of innate immune responses (S. Awate et al., 2012; Magiri 
et al., 2016). Intramuscular injection of PCEP induced time-dependent changes in the gene 
expression of many “adjuvant core response genes” (Mosca et al., 2008a) such as chemokine 
genes CCL-2, CCL-4, CCL-5, CCL-12 and CXCL-10 in mice (Awate et al., 2012) and CCL2 and 
CXCL10 (but not CCL- 5) in pigs (Magiri et al., 2016). Major transcription factor NF-kB gene 
and the inflammatory cytokine TNF-α genes were up-regulated in response to PCEP in mice 
(Awate et al., 2012) but not in pigs (Magiri et al., 2016). Additionally, in pigs, PCEP induced IL-
6 gene expression but not IL-10, IL-17 or IFN-α (Magiri et al 2016). PCEP injection in mice 
increased the expression of TLR4 and TLR9 at the site of injection (Awate et al., 2012) whereas 
PCEP did not induce significant expression any of the TLR genes in pigs suggesting differences 
in activation of immune responses in different animal species (Magiri et al., 2016). However, 
across species, PCEP may modulate antigen-specific immune responses by activating early innate 
immune responses and promoting a strong immunostimulatory environment at the site of 
injection. By promoting induction of transient innate immune responses, adjuvants may promote 
antigen-specific immunity.  
Very little is known about MOA of adjuvants in pigs. We recently reported that PCEP 
induced the expression of chemokines and proinflammatory cytokines genes when injected 
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intrademally in pigs (Magiri et al., 2016) suggesting that PCEP may promote recruitment of 
immune cells at the site of injection. Further unlike what was observed in mice, PCEP did not 
induce significant expression any of the TLR genes in pigs suggesting species specific 
differences in activation of innate immune responses (Magiri et al., 2016). We hypothesize that 
PCEP induces an innate immune response at injection sites and thus creates an immune 
microenvironment to facilitate vaccine triggered adaptive immunity. In the current study, we 
investigated whether PCEP activates cytokine production and recruitment of immune cells in pigs 
by evaluating changes at the site of injection and the draining lymph nodes. A known commercial 
adjuvant for pig vaccines, Emulsigen was included for comparative purposes.  
 
4.2 MATERIALS AND METHODS 
4.2.1 Animal experiments 
The animal experiments were approved by the University of Saskatchewan’s Animal Research 
Ethics Board, and adhere to the Canadian Council on Animal Care guidelines for humane animal 
use. Groups consisted of 2 control groups (naïve, unimmunized animals and pigs injected with 
PBS) and 2 treatment groups (pigs injected with PCEP or emulsigen). The animals were 3-4 four 
weeks old commercial cross breed pigs (20 animals per group with n=5 animals euthanized at 4 
specific time points (Days 1, 4, 7 and 14)) were administered intradermal (I.D.) injection on the 
neck region left and right side (250 µl per side) with sterile phosphate-buffered saline (PBS), 500 
µg PCEP, or 20% Emulsigen and an additional group without any injection as naive. The body 
temperature, and clinical observations & score for local reactions in all groups at both injections 
sites were taken through out the study period. The local reaction scores microscopically were 
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from 0 - 3 with 0 = normal, 1 = minor, 2 = moderate & 3 = severe. Additionally, markings of 
injection site were reapplied every day so that they can be visible at all time point. An 8 mm skin 
punch plug biopsy and the corresponding draining lymph nodes were collected from five animals 
per group at 1, 4, 7, and 14 days post injection. Biopsies were treated with 10% formalin for 
histopathology or incubated with RPMI supplemented with 5% FBS for tissue homogenisation 
and subsequent cytometric bead assay. Fifty microliters of peripheral blood was collected into 
serum separation tubes (SST) for cytokines cytometric bead assay at each time point in the 
serum.  
4.2.2 Adjuvants preparation 
PCEP was synthesized by the Idaho National Laboratory (Idaho Falls, ID, USA) using 
methods previously described in (Andrianov et al., 2004; Mutwiri et al., 2007b) and its endotoxin 
level was determined to be less than 0.034 ng/ml as assessed by the Limulus Amebocyte Lysate 
assay (Biowhittaker, Walkersville, MD, USA). PCEP and an “oil-in-water” formulation 
(Emulsigen) (MVP Laboratories, OM, USA) were dissolved in endotoxin-free, sterile PBS, pH 
7.4 (Life Technologies, Carlsbad, CA, USA) prior to injection.  
4.2.3 Histopathololgy preparation 
Skin punch biopsy and the draining lymph nodes tissues were prepared for 
histopathological evaluations as follows: Tissues were fixed with 10% formalin, then incubated 
for 24 hour in 70% ethanol, 100 % ethanol and finally 100% xylol. Tissues were then embedded 
in paraffin block for easier sectioning in the microtome and sliced to 3 to 5 µm thickness. Slides 
were stained using standard Haematoxylin-eosin method following the standard operating 
procedures. Histopathological changes of the skins that were evaluated included granuloma 
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formation, lymphocytes infiltration, epithelial necrosis, and suppurative inflammation. 
Histopathological changes in the draining lymph nodes included granuloma formation and 
suppurative inflammation. Scoring was performed by a pathologist blinded to the treatment and 
the scoring was as follows:  A) No pathological changes = 0, B) Patchy pathological changes = 1, 
C) Moderate pathological changes = 2, D) Severe pathological changes = 3 as described 
previously by (Magiri et al., 2018a; Mikalsen et al., 2012).   
4.2.4 Cytometric bead assay 
Cytokine concentrations were assayed in sera as well as from tissue homogenates from 
the injection site and the draining lymph nodes. Skin punch biopsy and draining lymph nodes 
were homogenized in 1 ml PBS with protease inhibitor cocktail tablet (Roche Diagnostics 
GmbH, Mannheim, Germany) with 2.3 mm Zirconia silica microbeads (Biospec Products Inc., 
Bartlesville, OK, USA) in a mini-beadbeaterTM (Biospec Products, Inc.) via six 10 second pulses 
interspersed with cooling at 4°C. The homogenates were centrifuged at 20,000 ×g for 10 min at 
4°C, and supernatants stored at -20°C before analysis.  Cytokine levels were measured by 
cytometric bead assay (BioRad) according to the manufacturer’s recommendations. 
Bioplex cytokine assays: Bioplex bead coupling was performed as per the manufacturer’s 
instructions. The reagents used are described in table 1. BioPlex cytokine assays antibodies 
against porcine IFN-α, IFN-γ, IL-1-β, IL-6, IL-8, IL-10, IL-12, IL-13, and IL-17A were coupled 
to BioRad multiplex assay microsphere beads using the BioRad BioPlex  following 
manufacturer’s instructions. Sera and tissue homogenates were tested for IFN-α, IFN-γ, IL-1-β, 
IL-6, IL-8, IL-10, IL-12, IL-13, and IL-17A secretion. The multiplexassay was carried out in a 96 
well Grener Bio-One Fluotrac 200 96Fblack (VWR, #82050-754), which allows washing and 
retention of the Luminex beads. The bead sets conjugated with all the cytokine to be analyzed 
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were vortexed for 30 seconds followed by sonication for another 30 seconds to ensure total bead 
dispersal. The bead density was adjusted to 1200 beads per µl in PBSA (1x PBS + 1% BSA 
(Sigma-Aldrich) + 0.05 % sodium azide (Sigma-Aldrich), pH 7.4) and 1 µl of each bead set was 
added to 49 µl of the PBSA + 1% New Zealand Pig Serum (Sigma-Aldrich P3484) +0.05 % 
sodium azide (Sigma-Aldrich) which was then added to each well. Plates ware washed using the 
Bio-Plex Pro II Wash Station (Bio-Rad) to allow soaking for 20 s then washing with 100 µl 
PBSA. The porcine cytokine protein standards were added to the wells at 50 µl per well at a final 
concentration as described in table 1 below and the serum (prediluted 1:4) and tissue homogenate 
(injection sites and draining lymph nodes; prediluted 1:2) were added to the wells at 50 µl per 
well. After sealing the plates with plate sealer (Thermo Fisher Scientific, #232702), the plates 
were agitated at 800 rpm for 1 hour at room temperature. After 1 hour incubation with serum, the 
plates were washed using the Bio-Plex Pro II Wash Station (Bio-Rad; soak 30 s, wash with 150 
µl PBS plus 1% Tween-20). A 50 µl volume of biotin cocktail consisting of biotinylated porcine 
antibodies (as described in table 1) was added to each well. The plates were again sealed, covered 
and agitated at 800 rpm for 30 minutes at room temperature then washed again as described 
above. A 50 µl of Streptavidin RPE (Cedarlane PJRS20; diluted to 5 µg/ml) was added to each 
well. The plate was again sealed, covered and agitated at 800 rpm for 30 minutes at room 
temperature and washed as indicated above. A 100 µl of 1xTris-EDTA (TE buffer-10 mM Tris, 
bring to pH 8.0 with HCl and 1 mM EDTA) was added to each well and then the plate was 
vortexed for 5 minutes before reading on the Luminex100 xMAP™ instrument following the 
manufacturer's instructions). The fluorescence on the beads was read on a BioRad BioPlex 200 
reader (60 µl volume, 50 beads per region). 
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Table 4.1 List of antibodies, bead, detection (secondary antibodies) and suppliers 	
Cytokine standards 
Standard 
concentration range 
Cytokine Supplier/ Catalog number  (pg/ml) 
rPorc IFN alpha 
Genentech  
200-1 pg/mL 
rPorc IFN gamma 
CG 
2000-8 pg/mL 
rPorc IL-1β 
R&D 681PI010 (10 µg) 
5000-20 pg/mL 
rPorc IL-6 
R&D 686PI025 (25 µg) 
5000-20 pg/mL 
rPorc IL-8 Kingfisher RP0109S-005 (5 
µg) 
200-1 pg/mL 
rPorc IL-10 
Invitrogen PSC0104 (10 µg) 
5000-20 pg/mL 
rPorc IL-12 
R&D 912PL025 (25 ug) 
5000-20 pg/mL 
rPorc IL-13 Kingfisher RP0007S-005 (5 
µg) 
5000-20 pg/mL 
rPorc IL-17A Kingfisher RP0128S-005 (5 
µg) 
2000-8 pg/mL 
Coating antibodies to Coupled beads 
  
Cytokine Catalog number 
Bead region (all from 
BioRad) 
MAb anti IFN alpha 
 
GeneTex GTX11408 
 
45 (BioRad MC10045-
01) 
MAb anti porc IFN gamma  Fisher PIMP700 
 
43 (BioRad MC10043-
01) 
MAb anti porc IL-1b/IF2 
R&D MAB6811 
26 (BioRad MC10026-
01) 
Goat anti porcine IL-6 
R&D AF686 
65 (BioRad MC10065-
01) 
MAb anti sheep IL8 (86.9% homology) 
 AbD Serotec MCA1660 
 
27 (BioRad MC10027-
01) 
 
MAb anti swine IL10 Invitrogen ASC0104 
 
28 (BioRad MC10028-
01) 
Porc IL-12 MAb anti porc IL12 
 
36 (BioRad MC10036-
01) 
Goat anti swine IL-13 
 
Kingfisher PB0094S-100 
 
52 (BioRad MC10052-
01) 
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Rabbit anti porcine IL-17A 
 Kingfisher KP0498S-100 
 
62 (BioRad MC10062-
01) 
 
Detection antibodies (all biotinylated) 
Cytokine Catalog number 
Desired starting conc 
(ug/ml) 
MAb anti pig IFN alpha (biotin in 
house) 
 
R&D 27105-1 
 
1/5000 
Rabbit anti porc IFN gamma (biotin in 
house) 
 
Fisher PIPP700 1/400  
Goat anti porc IL-1b/IF2 biotin 
 
R&D BAF681 (50 µg) 
 
0.5 µg/mL 
Goat anti porcine IL-6 biotin 
 
R&D BAF686 (50 µg) 
 
0.5 µg/mL 
MAb anti porc CXCL8/IL8 (biotin in 
house) 
 
R&D MAB5351 (500 µg) 
 
1/500 
MAb anti swine IL10 biotin 
 
Invitrogen ASC9109  0.5 µg/mLfor cell sups, 1 
µg/mLfor sera 
MAb anti porc IL12/IL23 p40 biotin 
 
R&D BAM9122  
 
0.5 µg/mL 
Goat anti swine IL-13 biotin 
 
Kingfisher PBB0096S-050 
 
0.5 µg/mL 
Rabbit anti porcine IL-17A biotin 
 
Kingfisher KPB0499S-050 
 
0.5 µg/mL 
 
4.2.5 Data analysis 
Statistical analyses were performed using Graph-Pad Prism 7 software (GraphPad 
Software, San Diego, CA, USA). Differences between groups were identified using a non-
parametric Kruskal-Wallis ANOVA test where Dunn’s multiple comparisons test was used post-
hoc to identify statistically significant differences between the two adjuvants and saline control 
80		
relative to each time point. Differences were considered statistically significant at p< 0.05, p< 
0.01, p< 0.001 which are stated in the text. 
 
4.3 Results  
4.3.1 Histopathological changes of the skin and draining lymph nodes after i.d. Injection with 
PCEP and Emulsigen  
Pigs were injected i.d. with PBS, PCEP or Emulsigen. Body temperature was taken and 
injection sites were examined for gross changes. In all the animals, body temperatures remained 
normal throughout the study period suggesting that the adjuvants did not induce a systemic 
response (data not shown). The local inflammatory reaction did not induce gross ulceration at the 
site of injection as observed macroscopically (data not shown).  
Sites of injection and draining lymph nodes were excised and evaluated for evidence of an 
inflammatory response and cytokine production. We evaluated changes in histopathology 
including granuloma formation (microscopic aggregation of macrophages transformed into 
epithelium like cells surrounded by a collar of mononuclear leukocytes, principally lymphocytes, 
and plasma cells), lymphocytes infiltration (infiltration of tissue by T and B lymphocytes), 
epithelial necrosis (death of cells and living tissues), and suppurative inflammation (forms as a 
result of the action of polymorphonuclear leukocytes e.g. neutrophils) (Fig 9). Representative 
photomicrographs show a typical cellular infiltrate observed in the skin at the site of injection 
(Fig 9 left) and the draining lymph nodes (Fig 9 right) on day 14 post injection. The top panel 
shows normal skin (Fig 9A) or draining lymph nodes (Fig 9B) after injection with saline at 200x 
magnification. In the skin PCEP (Fig 9C) induced multifocal to coalescing inflammation and a 
mixture of macrophages (blue arrow), lymphocytes (yellow arrow) and some neutrophils (red 
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arrow, centre image) with many necrotic debris in the inflammation (blue arrows). In the draining 
lymph nodes, PCEP (Fig 9D) induced multifocal infiltration of macrophages, with multinucleated 
giant cells (blue arrow) and sparse neutrophils (red arrow). In the skin, Emulsigen (Fig 1E) 
induced diffuse infiltration of inflammatory cells, composed of macrophages and lymphocytes 
and small granuloma. In the draining lymph nodes, Emulsigen (Fig 9F) induced coalescing areas 
of granulomatous inflammation (blue arrows) and inflammation is composed of mostly 
macrophages. Collectively, these data show the ability of adjuvants to promote local 
inflammation, which may be important for the initiation of the innate and acquired immune 
response.  
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Figure 4.1 Representative images of the cellular infiltrate at the injection site and lymph nodes 
draining of the site injected with either saline, PCEP or Emulsigen adjuvants at a magnification 
of X200. Top panel shows normal skin injected with saline at the skin site of injection (left) and 
the draining lymph nodes (right). On the skin PCEP (middle left panel) induced multifocal to 
coalescing inflammation and a mixture of macrophages (blue arrow), lymphocytes (yellow 
arrow) and some neutrophils (red arrow, centre image) with many necrotic debris in the 
inflammation (blue arrows) while on the draining lymphnodes PCEP (middle right panel) 
induced multifocal infiltration of macrophages, with multinucleated giant cells (blue arrow) and 
sparse neutrophils (red arrow). On the skin site of injection, Emulsigen (lower left panel) induced 
diffuse infiltration of inflammatory cells (left), composed of macrophages and lymphocytes and 
small granuloma while on the draining lymph nodes, Emulsigen (lower right panel) induced 
coalescing areas of granulomatous inflammation (blue arrows) and inflammation is composed of 
mostly macrophages. 
  
83		
Histopathological scoring was performed by a pathologist who was blinded to the sample 
identification. At the site of injection, adjuvants induced significant granuloma formation, 
lymphocytes infiltration, suppurative inflammation and necrosis compared to the skin of pigs 
injected with saline as a control. Interestingly, no granulomas were observed until after 14 days 
with pigs injected with Emulsigen (p< 0.05) and PCEP (p<0.01) showing significant granuloma 
formation at the injection site relative to time-matched saline control animals (Fig 10A). Further, 
pigs injected with PCEP showed significant lymphocytic infiltration 4 (p<0.05) and 14 days (p< 
0.01) post administration relative to the saline control pigs (Fig 10B). Pigs injected with 
Emulsigen showed significant lymphocytic infiltration 14 days (p< 0.05) post administration (Fig 
10B). PCEP and Emulsigen induced significant tissue necrosis 1, 4 and 7 days post 
administration (p< 0.01, p<0.01, p<0.01 for PCEP); p<0.05, p<0.05, p<0.01 for Emulsigen, 
respectively) at the site of injection relative to time-matched saline controls (Fig 10C). However, 
signs of necrosis were resolved by 14 days suggesting rapid resolution of the tissue reaction. 
PCEP induced significant suppurative inflammation with predominant eosinophil and neutrophil 
infiltration for 1 (p<0.01), 4 (p<0.05), 7 (p<0.01) and 14 (p<0.01) days post injection relative to 
the saline controls (Fig 10D). Emulsigen induced significant suppurative inflammation on days 1 
(p<0.05), 4 (p<0.01) and 7 (p<0.05) post injection (Fig 10D).  
In the draining lymph nodes, Emulsigen induced significant granuloma formation at day 4 
(p<0.05) and day 14 (p<0.05) and PCEP induced significant granuloma formation at 7 days (p< 
0.05) post innoculation relative to the saline control animals (Fig 10E). Finally, PCEP induced 
significant suppurative inflammation in the draining lymph nodes 1 day post injection relative to 
lymph nodes from saline control animals (p<0.05) but the response was not significantly different 
from controls at other time points suggesting rapid resolution of the inflammation (Figure 10F). 
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PCEP and Emulsigen induced histopathological changes in skin and draining lymph nodes 
relative to pigs with saline as a control. 
 
 
Figure 4.2 The histopathological changes of in the skin and draining lymph nodes in response to 
intradermal injection of PCEP or Emulsigen. The site of injection at the skin and the draining 
lymph nodes were collected from the draining lymph nodes at 1, 4, 7, and 14 days post injection. 
The lines indicate the median value of five replicates at each time point. All tissues are compared 
to time-matched skin or lymph nodes tissues from saline-injected control animals. 
Histopathological changes in the skin included assessment of granluloma formation, lymphocyte 
recruitment, necrosis, and signs of inflammation whereas histopathology of draining lymph nodes 
included assessment of granuloma formation and suppurative inflammation. Scoring was 
performed by blinded pathologist. 
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4.3.2 Cytokine profile in the pig skin, draining lymph nodes and peripheral blood after i.d. 
injection with PCEP and Emulsigen. 
Punch biopsies were obtained from the site of intradermal injection was collected after 1, 
4, 7 and 14 days in pigs inoculated with saline, PCEP and Emulsigen. Cytometric bead cytokine 
analysis was performed on homogenates of the biopsies. Emulsigen triggered significantly 
increased production of IL-6 (p<0.05; Fig 11D) and IL1β (p<0.05; Fig 11C) after 4 days and of 
IL-12 (p<0.05; Fig 11G) after 7 days. PCEP triggered increased local production of IL1β 
(p<0.01; Fig 11C) and IL-13 (p<0.01; Fig 11H) after 4 days relative to the control skin tissue. 
These data indicate that despite the evidence of microscopic histopathological evidence at the site 
of injection in response to PCEP and Emulsigen, only acute inflammatory cytokines IL-6 
(Emulsigen only) and IL1β (PCEP and Emulsigen) were transiently induced at the site of 
injection in pigs 4 days post injection. Neither of the adjuvants triggered local production of IFN-
α (Fig 11A), IFN-γ (Fig 11B), IL-8 (Fig 11E), IL-10 (Fig 11F) or IL-17 (Fig 11I) relative to the 
biopsies from the saline injection sites.  
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Figure 4.3 Cytokine responses in the skin at the injection site. The injection site were collected 
from one of the sites at 1, 4, 7, and 14 days post injection incubated with RPMI supplemented 
with 5% FBS for tissue homogenisation in PBS and cytometric bead assay using Bioplex. Results 
shown are the mean ± SD five replicates at each time point compared to PBS  
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When cytokine analysis was assessed at the draining lymph nodes, PCEP induced 
secretion of interleukin IL-1β (p< 0.01; Fig 12A) and IL-6 (p< 0.01; Fig 12B) on day 1 post 
injection but this elevation of these returned to baseline levels by day 4 post injection (figure 11). 
Further, neither PCEP nor Emulsigen induced secretion of IFN-α (Data not shown), IFN-γ (data 
not shown), IL-8 (Fig 12C), IL-10 (Fig 4D), IL-12 (Fig 12E), IL-13 (Fig 12F) or IL-17 (Fig 12G) 
at the draining lymph nodes over time.  
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Figure 4.4 Cytokine responses in lymph nodes draining the injection site. The lymph 
nodes were collected from one of the sites at 1, 4, 7, and 14 days post injection incubated with 
RPMI supplemented with 5% 
 
Finally, serum cytokine profiles were assessed over time in pigs i.d. injected with PCEP, 
Emulsigen and saline. None of the immunostimulants resulted in elevated production of serum 
IFN-α, IL-8, IFN-γ, IL-17, IL-6, IL1β, IL-10, IL-12 or IL-13 (Data not shown) indicating that the 
effects of the PCEP and Emulsigen as immunostimulants were observed locally but not 
systemically.  
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4.4 Discussion 
Vaccination continues to be a very important public health tool in the control of infectious 
diseases in the world. The main goal of vaccination is to stimulate potent immunological 
responses which promotes protection against specific pathogens (Kaech et al., 2002). 
Immunostimulatory adjuvants can direct innate and adaptive immune responses by promoting 
DC maturation and the concomitant release of pro-inflammatory cytokines (Liang & Loré, 2016; 
Mizumoto et al., 2005). Together, these effects significantly impact the overall efficacy of 
vaccines when immunostimulatory adjuvants are included (Coler et al., 2011). Our study 
attempts to elucidate the impact that immunostimulants PCEP and Emulsigen have at sites of 
injection and draining lymph nodes in pigs over a two week period. The impact on the innate 
immune and inflammatory response is instructive of how the adjuvants will influence the 
immune response when used as part of a vaccine.  
We selected the i.d. route of administration for our analysis because we showed it was 
more superior than i.m and it is a common route for administration of vaccines in livestock 
(Zhang et al., 2017, Magiri et al., 2018a) and recently, we showed that i.d. administration of a 
H1N1 vaccine which included PCEP as adjuvant gave a superior immune responses compared to 
pigs immunized with the same vaccine but administered via the intramuscular route (Magiri et 
al., 2018b). Skin-associated lymphoid tissue consists mainly of Langerhans cells and dermal 
APCs which circulate between the skin and the lymph nodes (DeBenedictis et al., 2001; Ray & 
Gately, 1996). Some reports suggest that i.d. vaccines induce superior protective immune 
responses and required less antigen relative to vaccines administered i.m. or subcutaneously 
(Herbert et al., 1989; Itzchak et al., 1992; Magiri et al., 2018a). Overall, our results showed that 
PCEP and Emulsigen induced strong inflammatory response at the site of injection and the 
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draining lymph node, suggesting that inflammation may be critically important for the initiation 
of the innate immunity and the promotion of acquired immunity.  
We investigated histopathological changes such as granuloma formation with presence of 
macrophages, lymphocytes infiltration with T and B cells, epithelial necrosis, and suppurative 
inflammation (characterised predominantly as neutrophils and eosinophils). Interestingly, no 
macroscopic changes were observed for either adjuvant but PCEP induced significant 
macrophages infiltration, lymphocyte infiltration, leucocyte infiltration and necrotic debris at the 
site of injection and the draining lymph nodes whereas Emulsigen induced diffuse infiltration of 
leucocytes, macrophages, and lymphocytes at both sites. PCEP-induced signs of necrosis were 
resolved after 14 days post injection of the immunostimulants. These results are consistent with 
results from other authors who have described adjuvants induce a local microscopic 
inflammatory reaction at an injection site (Calabro et al., 2011; Schijns, 2000) without gross 
macroscopic ulcerations (das Dores Moreira et al., 2009). Early stages of inflammation can occur 
through the activation of pattern-recognition receptors on many cells including lymphocytes, 
granulocytes, and endothelial cells (Faure et al., 2001; Muzio et al., 2000). Tissue necrosis 
induced by adjuvants as in “danger signal” hypothesis advanced by (Matzinger, 1994), who 
proposed that apart from self/non-self discrimination against infection, danger signals from 
damaged cells can trigger activation of the immune system through activation of inflammasome 
leading to release of proinflammatory cytokine such as IL-1β. Molecules associated with tissue 
damage such as uric acid, nucleotides, adenosine triphosphate (ATP), reactive oxygen 
intermediates, and cytokines are released at the injection site due to tissue damage (Shi et al., 
2003). These non-infectious damage signals have now been named DAMPs to distinguish them 
from PAMPs. Particulate adjuvants cause local tissue damage and cell death at the injection site 
and release of DAMPs thereby activating inflammasome (Kool et al., 2008). In addition, many 
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adjuvants induce release of pro-inflammatory cytokines at the site of injection including PCEP 
(Awate et al., 2012; Calabro et al., 2011; Didierlaurent et al., 2009). These damage signals trigger 
non-specific activation of the innate immune system, subsequently stimulating adaptive 
immunity. Recently inflammasomes have been one of the most widely investigated topics due to 
their potential role in adjuvant activity.  
The role of neutrophils in adjuvant activity is not completely understood but increased 
neutrophils at the site of injection may attract other immune cells due to chemokine release 
ultimately resulting in increased antigen uptake, processing and transport to the draining lymph 
nodes (Calabro et al., 2011; Morel et al., 2011). In agreement with the current findings, PCEP 
injection was shown to lead to robust local infiltration by T and B lymphocyte in mice (Awate et 
al., 2014). Studies in mice have shown that PCEP is a potent inducer of cell recruitment at the 
injection site with lymphocytes, neutrophils and macrophages being the most abundant cells, 
followed by monocytes and DCs in mice (Awate et al., 2014a). 
Although the adjuvants PCEP and Emulsigen were able to influence the immune 
response, their mechanism of action that can differentiate the intensity or duration of the required 
immune response may not be conserved. Thus, we also evaluated the cytokine profile to clarify 
how early events relate to precise immune response to adjuvants. Many adjuvants induce release 
of pro-inflammatory cytokines at the site of injection in mice (Awate et al., 2012; Calabro et al., 
2011; Didierlaurent et al., 2009). Other studies have shown the ability of oil-in-water emulsion 
AS03 co-localize with antigen to trigger colony-stimulating factor 3 (CSF3) and IL-6, and 
leukocyte- recruiting chemokines CCL2, CCL3, and CCL5 at the site of injection (Morel et al., 
2011) and draining lymph nodes (Morel et al., 2011). Studies in mice and pigs showed that PCEP 
induced strong expression of adjuvant core response genes coding for multiple cytokines and 
chemokines and immunomodulatory proteins (Awate et al., 2012; Magiri et al., 2016). In the 
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current study, we observed that PCEP and Emulsigen induced secretion of proinflammatory 
cytokines acute inflammatory cytokines IL-1β and IL-6 (Emulsigen only). IL-6 is a 
proinflammatory cytokine that is involved in the initiation of an immune response and it also 
promotes the differentiation of B cells (Helle et al., 1988; Hilbert et al., 1989; Houssiau et al., 
1988). PCEP may therefore direct the immune response towards a Th2 type of adaptive response. 
IL1β cytokine is an important mediator of the inflammatory response, and is involved in a variety 
of cellular activities, including cell proliferation and differentiation, and apoptosis. IL1β cytokine 
is proteolytically processed to its active form by caspase 1 activating multiprotein 
inflammasomes which assemble in the cytoplasm of cells. Activated caspase-1 cleaves the pro-
forms of the interleukin-1 cytokine family members leading to their activation and secretion of 
active form of IL1β (Bennouna et al., 2003; Brereton et al., 2011; Gris et al., 2010; Latz, 2010). 
PCEP and Emulsigen-induced inflmmasome activation may play an important role in activating 
innate immunity thus contributing to adjuvant activity in pigs. Results from in vitro experiments 
with murine cells indicate that PCEP stimulated significant production of the innate immune 
response cytokines IL-12 and IFN-γ (Garlapati et al., 2011; Mutwiri et al., 2008). Activated DCs 
produce cytokines such as IL-12 which stimulates development of T helper cells that produce 
IFN-γ and promote cell-mediated immunity (Th1 cells). These results in mice are in contrast to 
our findings in pigs wherein we observed transient induction of IL-6 and IL-1β at draining lymph 
nodes. At the skin, PCEP induced transient expression of IL-1β as well as IL-13, an anti-
inflammatory cytokine, and a mediator of allergic inflammation and its secreted by many cells 
including T helper type 2 (Th2) cells (Cocks et al., 1993; Wynn, 2003).  
Overall, our data suggest that PCEP and Emulsigen induced cell recruitment which 
culminated in adjuvant-specific cytokine profiles. These changes may be important in 
establishing and integrating the immune-competent environment for favorable for antigen 
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processing, presentation, and subsequent stimulation of antigen-specific immune responses. 
However, further studies are still needed to evaluate and identify which cell types are essential to 
induce the appropriate response for any given pathogen. The mechanism of action of vaccine 
adjuvants must be fully eluciated in vivo to make clear how different cell types cooperate in 
establishing an integrated immunocompetent environment (Mosca et al., 2008b). This 
information will be critical for the design of new effective vaccines. 
Even so, our data reinforces the importance of activating the innate immune responses to 
establish a robust inflammatory responses which may be beneficial to induction of specific 
immune response after an immunization. As with Emulsigen, PCEP induced acute but not 
chronic inflammatory responses at the injection site and the draining lymph nodes when injected 
into pigs indicating that this adjuvant may be regarded as safe for use in pigs. We speculate that 
induction of innate immune responses at the site of injection may be an important mechanism 
through which adjuvant PCEP exert it adjuvant activity in pigs.  
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Chapter 5. Impact of dose reduction of adjuvant 
poly[di(sodiumcarboxylatoethylphenoxy)phosphazene] (PCEP) on inflammatory 
resposnses, immunogenicity and safety when co-administered with inactivated swine 
influenza virus vaccine in pigs 
Relationship of this chapter to the dissertation 
In chapter 4, we have provided evidence that adjuvant poly[di(sodiumcarboxylatoethyl-
phenoxy)phosphazene] (PCEP) induces cytokine production leading to inflammation at the site 
of injection. However, too much inflammation can render a vaccine unsafe. If the dose of an 
adjuvant can be reduced without impacting vaccine efficacy, the results could be improved 
vaccine safety (less signs of inflammation at the site of injection) and reduced vaccine cost. 
Because i.d. injection of PCEP induced signs of necrosis (cell death), we investigated whether 
reduction of the adjuvant dose reduced tissue damage without negatively impacting the antigen- 
specific immune responses. To address this issue we performed two studies.  In the first study, 
we injected i.d. varying doses of PCEP alone as follows: 500 µg, 100 µg, or 20 µg PCEP into 
piglets and evaluated the inflammatory responses (granuloma formation, lymphocytic infiltration, 
necrosis, and suppurative inflammation) at the injection site and the draining lymph nodes over a 
period of 14 days. When PCEP was injected alone, we observed that only 500 µg consistently 
induced significant necrosis and suppurative inflammation. However, the medium dose (100 µg) 
PCEP did induce significant skin granulomas and lymphocyte infiltration, where as the only 
significant response induced in the skin by the lower dose (20 µg) PCEP was lymphocyte 
infiltration. In the draining lymph nodes, only 500 ug PCEP significantly higher suppurative 
inflammation. No necrosis or granuloma was observed in the lymph nodes in all the doses. Thus, 
the high dose of adjuvant triggered the most significant pathological signs of tissue damage at 
both sites (skin and draining lymph nodes).   
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In the second study, we co-injected the varying doses of PCEP 500 µg, 100 µg, 20 µg, or 
4 µg with an inactivated swine influenza virus H1N1 antigen and evaluated the four parameters of 
inflammatory response (granuloma formation, lymphocytic infiltration, necrosis, and suppurative 
inflammation) at days 20 and 41 after a single injection at each site and also assayed SIV H1N1-
specific antibody titers.  We observed that the highest dose of the adjuvant PCEP (500 µg) 
induced significant inflammatory responses in 3 of the 4 parameters assessed at day 20, and by 
day 41, this high dose of adjuvant had caused significant inflammatory response in all the four 
parameters assessed. Interestingly, only 500 µg of PCEP induced significant granuloma 
formation and necrosis (the more severe lesions) at both time points. Of the lower doses, 100 µg 
and 20 µg of PCEP both induced significant lymphocytic infiltration but their responses were 
similar. The lowest dose, 4 µg of PCEP did not induce any significant inflammatory response in 
any of the four parameters assessed. When SIV H1N1-specific antibody titers were assessed in 
immunized animals, the three higher doses (500 µg, 100 µg and 20 µg) of PCEP induced 
significant antibody responses when compared to SIV H1N1, confirming that these doses had 
adjuvant activity. In contrast, the lowest dose (4 µg) of PCEP did not induce significant titers, 
indicating that this dose did not have adjuvant activity.  These results suggest that induction of 
inflammatory responses at the site of injection is necessary for adjuvant activity. However, not all 
responses assessed may be required for adjuvant activity as very severe inflammatory responses 
seen with 500 µg of PCEP was not associated with any additional increase in antibody responses. 
Thus, the quality of the inflammatory response is important but severe inflammation was not 
beneficial to antigen-specific immune responses. 
In this manuscript my primary role was conception of ideas, design, planning and conducting 
experiments, analysis and interpretation of the data. I also wrote the initial drafts of the 
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manuscript, and revised the manuscript based on feedback from other authors. We plan to submit 
a manuscript of this work for publication. 
5.1 Introduction 
  Because subunit vaccines contain highly purified antigens, they are often poorly 
immunogenic and require the addition of adjuvants to induce protective immune responses. The 
ideal adjuvant should maximize vaccine immunogenicity without compromising tolerability or 
pose undue risk to the recipient of the vaccine. Unfortunately, adjuvant research has lagged 
behind other vaccine areas such as antigen discovery, with the consequence that only a very 
limited number of adjuvants based on aluminum salts, monophosphoryl lipid A and oil emulsions 
are currently approved for human use (Wang & Singh, 2011). Despite their critical role in 
vaccines, adjuvant safety and toxicity remain poorly understood which is a barrier to rational 
development of safe and effective vaccines. The inflammatory or danger-signal model of 
adjuvant action implies that increased vaccine reactogenicity at the site of injection is a price for 
improved immunogenicity (Petrovsky & Aguilar, 2004a).  
Polyphosphazenes are high-molecular weight, water-soluble polymers that promote and 
enhance long lasting immune responses with a variety of viral and bacterial antigens (Awate et 
al., 2012; Eng et al., 2010; Magiri et al., 2018b; McNeal et al., 1999; Mutwiri et al., 2008; 
Mutwiri et al., 2007). PCEP has been shown to promote a stronger mixed Th1/Th2 type of 
responses relative other polyphosphazene derivatives and therefore PCEP may promote a more 
broad-spectrum immunity (Mutwiri et al., 2008; Mutwiri et al., 2007). PCEP promotes cytokine 
and chemokine production as well as regulation of a number of ‘adjuvant core response genes’ at 
the intramuscular injection site in mice and pigs (Awate et al., 2012; Magiri et al., 2016; Mutwiri 
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et al., 2008). These responses may contribute to immune cell recruitment to the injection site and 
transport of antigens to draining lymph nodes (Awate et al., 2014a).  
      Inflammatory responses induced by tissue necrosis at the site of injection by adjuvants was 
advanced by (Matzinger, 1994) in her ‘danger signal' hypothesis. Danger signals from damaged 
cells can trigger activation of the immune system through activation of inflammasome leading to 
release of pro-inflammatory cytokine such as IL-1β (Kool et al., 2008). Molecules such as uric 
acid, nucleotides, adenosine triphosphate (ATP), reactive oxygen intermediates, and cytokines 
are released from cells if there is tissue damage (Krysko et al., 2011). This sterile/semi-sterile 
inflammation can be induced in response to injection of adjuvants and release of these 
endogenous molecules can attract inflammatory cells and promote induction of innate immunity 
(Chen et al., 2007; Kono et al., 2014; Shi et al., 2003). In addition, many adjuvants including 
PCEP induce release of pro-inflammatory cytokines at the site of injection (Awate et al., 2012; 
Calabro et al., 2011; Didierlaurent et al., 2009). The effectiveness of PCEP and its antigen dose 
sparing effects have been demonstrated with various vaccines (Andrianov et al., 2009b; 
Andrianov et al., 2011a; Mutwiri et al., 2007a). As highlighted by acellular pertussis vaccines, 
the improved safety of subunit vaccines comes at the price of reduced immunogenicity (Poolman, 
2014). There is a need to draw a clear distinction between acceptable range of adjuvant-related 
side effects and optimal immune response (Gupta & Siber, 1995). It is important to receive 
sufficient vaccine for the induction of immune response but not to exceed the maximal safe dose 
as some adjuvants can cause adverse effects at the site of injection such as pyrexia, muscle 
weakness, arthralgia, myalgia and erythema (Cerpa-Cruz et al., 2013; Petrovsky & Aguilar, 
2004a). 
    There is a general consensus that local inflammation contributes to adjuvant activity. 
However, details of the relationship between local inflammation and antigen-specific immune 
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responses have not been investigated. Our previous research established that a high dose of PCEP 
(500 µg) or a low dose of PCEP (20 µg) co-administered with swine influenza antigen H1N1 
antigen triggered equivalent antibody responses (Magiri et al., 2018b). In the current study, we 
investigated the effect that reduction of adjuvant dose had on the local inflammatory responses 
and the antigen-specific immune response to inactivated swine influenza vaccine. Further, we 
investigated whether reduced dose of PCEP reduced pathological tissue damage at the injection 
site and the draining lymph nodes as a measure of safety of adjuvant PCEP. We hypothesized 
that induction of inflammatory responses at the site of injection is an important mechanism 
through which PCEP exert its adjuvant activity in pigs and that reduced adjuvant doses may lead 
to less histopathological damage without impacting the immune response to swine influenza 
vaccine. 
5.2 Materials and methods 
5.2.1 Adjuvant and vaccine preparation 
  PCEP was synthesized by the Idaho National Laboratory (Idaho Falls, ID, USA) using 
methods previously described in (A. K. Andrianov et al., 2004; Mutwiri et al., 2007b) and 
dissolved in endotoxin-free, sterile phosphate-buffered saline (PBS), pH 7.4 (Life Technologies, 
Carlsbad, CA, USA). Inactivated SIV H1N1 and PCEP were diluted with sterile PBS, pH of 7.4. 
The highest dose of PCEP (500 µg per dose) was chosen based on the previous experiments in 
pigs (Dar et al., 2012; Magiri et al., 2016; Magiri et al., 2018b). 
5.2.2 Animal experiments  
All animal experiments were conducted according to the Guidelines for the Care and Use 
of Laboratory Animals as indicated by the Canadian Council on Animal Care and was approved 
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by the Animal Care Committee of the University of Saskatchewan. For all the trials, three to four 
weeks old Landrace commercial crossbreed pigs were used.  
In the first study, we assessed whether the dose of PCEP impacted the inflammatory 
responses in absence of the antigen. Six groups (n=5 pigs/group) injected i.d. with 4 µg (lowest), 
(20 µg (low), 100 µg (moderate), 500 µg (high) PCEP or PBS. The injection volume to dissolve 
the adjuvant was consistently 250 µl per sites. An 8 mm skin punch plug biopsy was collected at 
1, 4, 7, and 14 days post injection in 10% formalin for histopathology evaluation to determine 
whether PCEP induces inflammatory responses in a dose dependent manner. 
The purpose of the second trial was to determine the optimal constant dose of antigen to 
be used in subsequent experiments. Piglets (n=5) were immunized i.d. with either 4x104, 2x105, 
1x106 SIV H1N1 HAU with 500 µg PCEP with PBS or naive as control. Serum was collected 0, 
21, 30 and 35 days post vaccination for assay of antibody response against SIV H1N1. The 4x104 
Inactivated SIV H1N1 HAU dose was selected for subsequent experiments. 
The purpose of the third trial was to further optimize the antigen dose with reduced PCEP 
co-formulated with the vaccine. Piglets (n=6) were immunized i.d. with 4x104 and 8x103 
inactivated SIV H1N1 HAU with 100 µg PCEP, or PBS or naive animals as controls. Serum was 
collected 0, 21, 30 and 35 days post vaccination for assay of antibody response against SIV 
H1N1. The 4x104 Inactivated SIV H1N1 HAU dose was selected for subsequent experiments. 
 In the fourth study, to determine adjuvant dose response to swine influenza virus vaccine 
and the injection responses with constant doses of antigen, piglets were divided into 6 test groups 
(n = 6 in each group). Pigs were immunized i.d. with constant 4x104 inactivated SIV H1N1 HAU 
alone or with 4, 20, 100, 500 µg PCEP or PBS. Vaccination was performed on day 0 and a 
booster vaccination was given on day 21. Serum was collected 0, 21, 28 and 35 days post 
vaccination for assay of antibody response against SIV H1N1. The piglets were anaesthetised 
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with 5% isoflurane and anaesthesia maintained using 2% isofluorane then an endotracheal tube 
was inserted to about 2/3 of the trachea length just above the bifurcation and challenged with 4 
mL of 8E+05 PFU H3N2 in MEM media/pig. Animals were euthanized 5 days post-infection (41 
days post primary immunization) using Euthanyl (25 mg sodium pentobarbital) administered 
intravenously (I.V.). The i.d. injection site at initial and booster vaccination site were collected in 
formalin for histopathology evaluation to assess whether reduction in the dose of the adjuvants 
lead to the reduction in tissue damage and whether the tissue damage was resolved 41 days after 
vaccination. 
5.2.3 Assessment of intradermal site reaction  
Skin punch biopsy tissues were prepared for histopathological evaluations as follows: 
Tissues were fixed with 10% formalin for 2 weeks then incubated for 24 hour in 70% ethanol, 
100 % ethanol and finally 100% xylol to clear the tissues. Tissues were then embedded in 
paraffin block for easier sectioning in the microtome and sliced to 3 to 5 µm thickness. Slides 
were stained using standard Haematoxylin-eosin method following the standard operating 
procedures. We evaluated changes in histopathology including granuloma formation 
(microscopic aggregation of macrophages transformed into epithelium like cells surrounded by a 
collar of mononuclear leukocytes, principally lymphocytes, and plasma cells), lymphocytes 
infiltration (infiltration of tissue by T and B lymphocytes), epithelial necrosis (death of cells and 
living tissues), and suppurative inflammation (forms as a result of the action of 
polymophonuclear leucocytes e.g. neutrophils). The histopathological changes of the skin 
included granuloma formation, lymphocytes infiltration, epithelial necrosis, and suppurative 
inflammation whereas histopathological changes in the draining lymph nodes included 
granuloma formation and suppurative inflammation. Scoring was performed by a pathologist 
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blinded to the treatment groups. Scoring was as follows: A) No pathological changes = 0, B) 
Patchy pathological changes = 1, C) Moderate pathological changes = 2, D) Severe pathological 
changes = 3 as described by (Magiri et al., 2018b; Mikalsen et al., 2012) 
5.2.4 Detection of Swine Influenza Virus H1N1 antibodies in porcine serum by enzyme-linked 
immunosorbent assay (ELISA). 
Purified SIV H1N1 was inactivated by mixing one part virus with one part 5% N-lauroyl 
sarcosine sodium salt (Sigma-Aldrich Canada Co. Oakville, Ontario) and 8 parts PBSA + 0.1% 
sodium azide for 30 min at room temperature. Virus was diluted to 0.5 µg/mL in 0.5 M 
bicarbonate buffer then applied to Immulon 2 96U plates (Thermo Lab systems #3655) at 100 µL 
per well and the plates were incubated at 4°C overnight. Coated plates were washed extensively 
with tris-buffered saline plus 0.05% Tween-20 (TBST; Sigma). Serum samples and control were 
diluted in TBST, transferred into coated plates, and diluted serially 4-fold serially. Antigen-
specific total IgG were detected with alkaline phosphatase conjugated KPL goat anti-swine IgG 
(H+L) (Invitrogen) and developed using PNPP substrate. Optical density was read at λ405 nm 
and the final titers were calculated using an excel spreadsheet.  
5.2.5 Statistical analysis 
Statistical analyses were assessed using Graph-Pad Prism 7 software (GraphPad Software, 
San Diego, CA, USA). Analysis of site reaction scores values between different treatment groups 
were compared using non-parametric Kruskal-Wallis ANOVA test where Dunn’s multiple 
comparisons test was used post-hoc to identify statistically significant differences between 
different adjuvant test groups. ELISA antibody and serum antibody titers were ranked using 
repeated measures, before comparison of treatment groups using the above mentioned statistical 
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analysis were utilized. P< 0.05 values was considered to be statistically significant.  
 
5.3 Results  
5.3.1 Dose dependent inflammatory responses induced by adjuvant PCEP in absence of the 
antigen. 
We evaluated by histopathology how the dose of adjuvant impacted inflammatory 
responses including granuloma formation (microscopic aggregation of macrophages transformed 
into epithelium-like cells surrounded by a collar of mononuclear leukocytes, principally 
lymphocytes, and plasma cells), lymphocytes infiltration (infiltration of tissue by T and B 
lymphocytes), epithelial necrosis (death of cells and living tissues), and suppurative inflammation 
(which forms as a result of the action of recruited polymorphonuclear leucocytes e.g. 
neutrophils). High (500 µg) and medium (100 µg), and low (20 µg) doses of PCEP (or PBS) were 
injected i.d. into pigs to assess inflammatory responses at the injection site and the draining 
lymph nodes on 1, 4, 7 and 14 day post injection. Body temperature was recorded and injection 
sites were examined for signs of lesions. In all the animals, no macroscopic lesions at the sites of 
injection were observed and body temperatures remained normal throughout the study period 
suggesting that the adjuvants PCEP did not induce a systemic immune response (data not shown). 
We observed that only 100 µg PCEP induced significant granuloma formation 14 days post-
administration (p<0.01) compared to PBS. All the other groups were not significantly different 
from each other at all the time points (Fig 13A). With regard to necrosis, the high dose of PCEP 
(500 µg) induced significant necrosis at 1, 4, and 7 days (p< 0.01) post-administration relative to 
PBS controls (Fig 13B). This high dose of PCEP (500 µg) was significantly higher than low dose 
(20 µg) at day 1 post injection (Fig 13B; p<0.01) but all other groups were not significantly 
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different from each other at all the time points. With regard to suppurative inflammation, the high 
dose of PCEP (500 µg) induced significant suppurative inflammation from day 1, 7 and 14 days 
post injection (p<0.01, p<0.01 and p<0.01 respectively) relative to the PBS controls (Fig 13C) 
while the medium dose of PCEP (100 µg) induced significant suppurative inflammation at 4 days 
(p<0.05) post administration relative to the PBS controls (Fig 13C). The low dose (20 µg) of 
PCEP induced significant suppurative inflammation 4 days (p<0.05) post administration relative 
to the PBS controls (Fig 13C). This high dose of PCEP (500 µg) was significantly higher 
suppurative inflammation than low dose (20 µg) at day 1 post injection (Fig 13C; p<0.01) but all 
other treatment groups were not significantly different from each other at all the time points. 
With regard to lymphocytic infiltration, the Medium dose (100 µg) of PCEP induced significant 
infiltration at 1, 7 and 14 days post-administration (Fig 13D; p<0.05) and low dose (20 µg) of 
PCEP induced significant infiltration at 4, and 7 days post-administration relative to PBS controls 
(Fig 13D; p<0.01 p<0.05). The high dose PCEP (500 µg) induced significant lymphocytic 
infiltration at 14 days (p< 0.01), post-administration relative to saline controls but all the 
treatment groups were not significantly different from each other at all the time points (Fig 13D).  
At the draining lymph nodes, on granuloma formation we observed that all treatment 
groups were not significantly different from each other at all the time points (data not shown). 
The high dose of PCEP (500 µg) had significantly higher suppurative inflammation than the low 
dose (20 µg) at day 1 post injection but all other treatment groups were not significantly different 
from each other at all the time points (data not shown).  
Generally, the higher adjuvant dose (500 µg of PCEP) triggered the most significant 
pathological signs of tissue damage at both the injection sites in the skin and the draining lymph 
nodes. 
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Figure	5.1	A	and	B	The	histopathological	changes	of	the	skin	injection	site	in	response	to	PCEP	at	the	site	of	intradermal	administration	in	pigs.	An	8	mm	skin	punch	plug	biopsy	was	collected	from	one	of	the	sites	at	1,	3,	7,	and	14	days	post	injection.	Results	shown	are	the	SEM	 of	 five	 replicates	 at	 each	 time	 point	 compared	 to	 PBS	 injected	 skin	 tissue.	 The	histopathological	 changes	 of	 the	 skin	 included	 were	 granuloma	 formation,	 lymphocytes	infiltration,	 epithelial	 necrosis,	 and	 suppurative	 inflammation.	 The groups with different 
letters are significantly different from each other at that time point (P< 0.05). 
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Figure	5.1	C	and	D	The	histopathological	changes	of	the	skin	injection	site	in	response	to	PCEP	at	the	site	of	intradermal	administration	in	pigs.	An	8	mm	skin	punch	plug	biopsy	was	collected	from	one	of	the	sites	at	1,	3,	7,	and	14	days	post	injection.	Results	shown	are	the	SEM	 of	 five	 replicates	 at	 each	 time	 point	 compared	 to	 PBS	 injected	 skin	 tissue.	 The	histopathological	 changes	 of	 the	 skin	 included	 were	 granuloma	 formation,	 lymphocytes	infiltration,	 epithelial	 necrosis,	 and	 suppurative	 inflammation.	 The groups with different 
letters are significantly different from each other at that time point (P< 0.05). 
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5.3.2 Selection of the dose of antigen.	
To determine the dose of antigen for subsequent experiments, piglets were injected with 
i.d. with a vaccine consisting of either 4x104, 2x105, 1x106 SIV H1N1 HAU with 500 µg PCEP 
or with PBS and pigs without injection (i.e. naïve pigs) were used as controls. A booster 
immunization was administered 21 days after the primary immunization and sera were collected 
0, 21, 30 and 35 days post vaccination to assess antigen-specific antibody response. Piglets 
immunized with 4x104, 2x105, 1x106 SIV H1N1 HAU formulated with 500 µg PCEP showed 
significantly higher (P<0.05, p<0.01 and p<0.01, respectively) serum antibody titres (Fig 14).  
 
Figure 5.2 To determine the constant dose of antigen to be used in subsequent experiments. 
Piglets (n=5) were immunized i.d. with either 4x104, 2x105, 1x106 SIV H1N1 with 500 µg PCEP 
with PBS or naive as control. ELISA antibody and serum antibody titers were ranked using 
repeated measures. The area under the curve (AUC) was calculated using a non-parametric non-
parametric Kruskal-Wallis ANOVA test where Dunn’s multiple comparisons test was used post-
hoc to identify statistically significant differences between different adjuvant test groups. P< 0.05 
values was considered to be statistically significant. 
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To optimize the antigen dose, piglets were immunized with 4x104 and 8x103 inactivated 
plus 100 µg PCEP. Both 4x104 and 8x103 vaccine doses showed significantly higher (P<0.01, 
P<0.05) serum antibody titres relative to the negative controls animals (Fig 15) so the 4x104 
inactivated SIV H1N1 HAU dose was selected for subsequent experiments. 
 
 
 
Figure 5.3 Antigen dose titration of inactivated SIV H1N1 for use in subsequent experiments. To 
optimize the dose of the antigen piglets were immunized with 4x104 and 8x103 inactivated plus 
100 µg PCEP i.d. Serum was collected 0, 21, 30 and 35 days post vaccination for assay of 
antibody response against SIV H1N1. ELISA antibody and serum antibody titers were ranked 
using repeated measures. The area under the curve (AUC) was calculated using a non-parametric 
non-parametric Kruskal-Wallis ANOVA test where Dunn’s multiple comparisons test was used 
post-hoc to identify statistically significant differences between different adjuvant test groups. P< 
0.05 values was considered to be statistically significant 
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5.3.3 Reduced doses of PCEP induces immune responses against inactivated swine influenza 
virus H1N1. 
Pigs were injected i.d. with PBS or 4x104 Inactivated SIV H1N1 HAU alone or plus 4, 20, 
100, 500 µg PCEP at day 0 then boosted 21 days later. Serum samples were collected over a 
period of 35 days and antigen-specific serum antibody titres were assayed by ELISA. Negligible 
antibody titres were detected in piglets immunized with inactivated SIV alone or in the presence 
of adjuvants by day 20 prior to the second immunization suggesting that the primary 
immunization was not sufficient (Fig 16). After 35 days, pigs immunized with 4x104 inactivated 
SIV H1N1 HAU plus 20, 100, 500 µg of PCEP showed significantly higher (P<0.01 P<0.001, 
P<0.01, respectively) serum antibody titres relative to the negative controls animals. 
Interestingly, reduction in the dose of adjuvant did not alter the magnitude of immune response as 
20 µg, 100 µg and 500 µg of PCEP triggered similar antigen-specific immune responses to SIV 
H1N1 antigen (P<0.01, P<0.01, respectively. These findings indicate that a reduced amount of 
PCEP was still successful in inducing significant antibody responses without significant 
pathological reaction at the site of injection.  
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Figure 5.4 Reduced doses of PCEP induce immune responses against inactivated swine influenza 
virus H1N1. Pigs were injected i.d. with PBS or 4x104 Inactivated SIV H1N1 HAU alone or plus 
4, 20, 100, 500 µg PCEP at day 0 then boosted 21 days later. Serum samples were collected over 
a period of 35 days and antigen-specific serum antibody titres were assayed by ELISA. ELISA 
antibody and serum antibody titers were ranked using repeated measures. The area under the 
curve (AUC) was calculated using a non-parametric non-parametric Kruskal-Wallis ANOVA test 
where Dunn’s multiple comparisons test was used post-hoc to identify statistically significant 
differences between different adjuvant test groups. P< 0.05 values was considered to be 
statistically significant 
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5.3.4 Pathological reaction at the site of injection following vaccination with Inactivated SIV 
H1N1 HAU with varying doses of adjuvant the primary and booster immunization sites. 
Pigs were injected i.d. with a constant dose antigen 4x104 inactivated SIV H1N1 HAU 
formulated with either 4, 20, 100, 500 µg PCEP of adjuvant per injection in 250 uL sterile PBS. 
The sites of injection were collected in formalin for histopathology evaluation. Animals were 
immunized and euthanized such that one immunization site was collected 41 days post injection 
and another immunization site was collected 20 days post-injection (See Fig 17).  
 
Figure 5.5  Immunization protocol 
 
We observed that, on day 20, 500 µg PCEP induced significantly higher granuloma 
formation than all other groups (Fig. 18A). All other groups were not significantly different from 
each other at day 20. Similar observations were made on 41, where 500 µg of PCEP induced 
significantly higher granuloma formation than all other groups. All other groups were not 
significantly different from each other (Fig. 18A). Thus only 500 µg of PCEP induced significant 
granuloma formation time points. 
When necrosis was assessed, only 500 µg PCEP induced significantly higher necrosis 
than all other groups on day 20 (Fig. 18B). All other groups are not significantly different from 
each other at day 20. Similar findings were observed at day 41 where 500 µg PCEP induced 
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significantly higher necrosis formation than all other groups. All other groups are not 
significantly different from each other (Fig. 18B) 
On day 20, only 100 µg of PCEP induced significantly higher suppurative inflammation 
than 4 µg PCEP, SIV and PBS while all other groups were similar (Fig. 18C). On day 41, 500 µg 
PCEP induced significantly higher suppurative inflammation than all other groups. All other 
groups were not significant different from each other.  Interestingly, on day 20, only 100 µg 
PCEP induced a significant response, which subsided by day 41. In contrast, this response was 
delayed till day 41 in animals injected with 500 µg PCEP (Fig. 18C) 
On lymphocytic infiltration on day 20, 500 µg, 100 µg and 20 µg of PCEP induced 
significantly higher lymphocyte infiltration than 4 µg PCEP, SIV and PBS. 4 µg of PCEP did not 
induce significant lymphocyte infiltration compared to SIV and PBS. Additionally SIV did not 
induce significant lymphocyte infiltration compared to PBS. Therefore 500 µg, 100 µg and 20 µg 
PCEP induced similar lymphocytic infiltration responses that are significantly stronger than 4 µg 
PCEP, SIV and PBS. The latter 3 groups are similar with no significant lymphocytic infiltration 
(Fig. 18D). Interestingly, on day 41, only 500 µg PCEP induced significantly higher lymphocyte 
infiltration than all other groups. All other groups were not significantly different from each other 
hence lymphocytic infiltration had subsided by day 41 in all groups except 500 µg PCEP (Fig. 
18D)  
In summary, the highest dose of the adjuvant PCEP (500 µg) induced significant 
inflammatory responses in 3 of the 4 parameters assessed at day 20, and day 41, this high dose of 
adjuvant caused significant tissue response in all four parameters assessed. Interestingly, only 
500 µg of PCEP induced significant granuloma formation and necrosis (the more severe lesions) 
at both time points. Of the lower doses, 100 µg and 20 µg of PCEP both induced significant 
lymphocytic infiltration but their responses were similar.  
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The lowest dose, 4 µg of PCEP did not induce any significant inflammatory response in 
any of the four parameters assessed. Decreased granulomatous inflammation, necrosis, 
lymphocyte infiltration and suppurative inflammation was observed with decreasing 
concentration of PCEP in the i.d. vaccine indicating that reduction of the dose of adjuvant in 
vaccine can lead to reduction in tissue damage without reduction in the magnitude of the antigen-
specific immune response. 
When SIV H1N1-specific antibody titers were assessed in immunized animals, only 500, 
100 and 20 µg of PCEP which had significant inflammatory responses had also developed 
significant antibody responses when compared to SIV H1N1, confirming that these doses had 
adjuvant activity (Fig. 16). However, 4 of PCEP did not induce significant inflammatory 
responses and SIV H1N1-specific antibody titers, indicating that this dose did not have adjuvant 
activity. 
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Figure 5.6 A and B Pathological reaction at the site of injection following vaccination with 
Inactivated SIV H1N1 with varying doses of adjuvant the primary and booster immunization 
sites. Pigs were injected i.d. with a constant dose antigen 4x104 inactivated SIV H1N1 HAU and 
formulated with 20, 100, 500 µg PCEP of adjuvant per injection. The sites of injection were 
collected in formalin for histopathology evaluation. The primary site of injection was therefore 
collected 41 days later and the booster injection site was collected only 20 days post-injection. 
The groups with different letters are significantly different from each other at that time point (P< 
0.05). 
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Figure 5.6 C and D Pathological reaction at the site of injection following vaccination with 
Inactivated SIV H1N1 with varying doses of adjuvant the primary and booster immunization 
sites. Pigs were injected i.d. with a constant dose antigen 4x104 inactivated SIV H1N1 HAU and 
formulated with 20, 100, 500 µg PCEP of adjuvant per injection. The sites of injection were 
collected in formalin for histopathology evaluation. The primary site of injection was therefore 
collected 41 days later and the booster injection site was collected only 20 days post-injection. 
The groups with different letters are significantly different from each other at that time point (P< 
0.05). 
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5.4 Discussion 
Adjuvants are crucial components in vaccines that broadens the immune responses, 
particularly for the poorly immunogenic subunit protein antigens (Reed et al., 2013b). Subject to 
the adjuvant’s nature, immune responses can be enhanced and/or skewed towards a particular 
cellular and/or humoral responses and promote infiltration of specific cell populations (Guy, 
2007). Improving the benefits (efficacy) of immunization while decreasing their potential risks 
(adverse reactions) is essential in the development of all new vaccines and is a key factor driving 
new technologies and sophisticated vaccine design. By counteracting the poor immunogenicity of 
purified antigen, the addition of adjuvants to vaccines may lead to an increase in pain, redness, 
and swelling at the site of injection and sometimes general symptoms such as fatigue, malaise, 
myalgia and fever (Garçon et al., 2011; Garçon et al., 2011). Vaccine reactogenicity is regarded 
as a dose-dependent phenomena reflecting local tissue damage and systemic inflammation 
induced by activation of innate immune receptors (Petrovsky & Aguilar, 2004a). The 
reactogenicity profile of any adjuvanted vaccine is specific to the antigen and the target 
population studied (Kosalaraksa et al., 2014; Mark & Granström, 1994; Waddington et al., 2010). 
Should an adjuvant induce excessive reactogenicity in a vaccine that cannot be resolved by 
reducing the dose of the reactogenic component, then the adjuvanted vaccine could be regarded 
as potentially unsafe.  
Local vaccine side effects may reflect direct chemical irritation due to non-physiological 
pH, osmolarity, salt concentrations or direct cell toxicity. Such local irritant effects are typically 
associated with immediate severe injection site pain followed by an inflammatory response 
triggered by the tissue damage. Examples of adjuvants that induce local reactogenicity include 
saponins (e.g. Quil A, QS21, ISCOMS, ISCOMATRIX) and oil emulsions (e.g. CFA, IFA, 
Montanide, MF59, AS03)(Aguilar & Rodriguez, 2007; Aucouturier et al., 2001; Petrovsky & 
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Aguilar, 2004a; Zhu et al., 2013). In the present study, we investigated whether reduction of 
PCEP dose had any effect on reactogenicity to the vaccine at the site of injection. Further, we 
investigated whether reduced dose of PCEP could lead to reduced evidence of pathological tissue 
damage at the injection site and the draining lymph nodes as a measure of safety. We show that 
when adjuvant alone was injected i.d., inflammatory cells (dominated by neutrophils at first, 
followed by lymphocytes and later macrophages) were recruited to the injection site between 4 
and 14 days after injection in all the PCEP doses. Interestingly, only 500 µg PCEP induced 
significant necrosis that persisted past 7 days suggesting that reduction of adjuvant dose led to 
reduced tissue damage. When PCEP was co-administered with inactivated swine influenza virus 
antigen, the vaccine induced systemic antibody production even at low doses. Other studies have 
shown induction of inflammation by aluminium-containing adjuvants is important for the 
recruitment of antigen-presenting cells and the release of cytokines and other mediators that 
induce maturation and activation of dendritic cells has been reported (Greaves, 2011). Overall, 
the results of other studies that have compared vaccines with and without adjuvant have shown a 
consistent trend toward increased reactogenicity, mainly at the injection site with adjuvanted 
formulations (Garçon et al., 2011; Garçon et al., 2011). We suggest that adjuvant PCEP appears 
to be responsible for the inflammatory responses at the site of injection that are critical in 
initiation of the immune responses even with reduced doses. Indeed, our recent studies have 
indicated that PCEP plays a role in the recruitment of neutrophils, natural killer cells, 
macrophages, eosinophils and immature dendritic cells to the site of injection and draining lymph 
nodes (Awate et al., 2012; Awate et al., 2014; Magiri et al., 2016) which in turn promotes the 
adaptive immune response to a vaccine (Magiri et al., 2018a). 
When tissue is damaged, the period of time in which residual inflammation and the 
associated cellular debris is restored to normal structure is called ‘recovery’ (Perry et al., 2013; 
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Thuilliez et al., 2009). In the second study, intradermal injection sites were evaluated after 
injection with varying doses of PCEP as part of a SIV H1N1vaccine and the four parameters of 
inflammatory response (granuloma formation, lymphocytic infiltration, necrosis, and suppurative 
inflammation) assessed at days 20 and 41 after a single injection at each site. The highest dose of 
the adjuvant PCEP (500 µg) induced significant inflammatory responses in 3 of the 4 parameters 
assessed at day 20, and by day 41, this high dose of adjuvant caused significant tissue response in 
all four parameters assessed. Interestingly, only 500 µg of PCEP induced significant granuloma 
formation and necrosis (the more severe lesions) at both time points. Of the lower doses, 100 µg 
and 20 µg of PCEP both induced significant lymphocytic infiltration compared to PBS but 
responses of the two adjuvants groups were similar. The lowest dose of PCEP (20 µg) did not 
induce any significant inflammatory response in any of the four parameters assessed.  
When SIV H1N1-specific antibody titers were assessed in immunized animals, only 500, 
100 and 20 µg of PCEP induced significant antibody responses when compared to SIV H1N1, 
confirming that these doses had adjuvant activity. However, the 4 µg of PCEP did not induce 
significant titers, indicating that this dose did not have adjuvant activity. Similar to our finding, 
aluminum-adjuvanted vaccines induced inflammatory nodules at the injection site, which 
expanded into the intramuscular space without any muscle degeneration or necrosis, whereas 
non-adjuvanted vaccines did not. These nodules consisted of polymorphonuclear neutrophils with 
some eosinophils present in the nodes within the initial 48 h, followed by the presence of 
monocytes/macrophages 1 month post injection (Kashiwagi et al., 2014).  
We report that reduction of the dose of adjuvant PCEP led to reduction in tissue reaction 
in a dose-dependent fashion but did not compromise the immune response to swine influenza 
virus vaccine (or antigen). Additionally, signs of decreased granulomatous inflammation, 
necrosis, lymphocyte infiltration and suppurative inflammation were observed with decreasing 
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concentration of PCEP in the vaccine without negatively impacting the magnitude of the immune 
response. Recently we also observed that 500 µg PCEP adjuvanted inactivated SIV H1N1 
vaccine immunized i.d. triggered some evidence of protective immunity (i.e. neutralizing 
antibody production and reduced viral load) against homologous challenge even with reduced 
adjuvant of PCEP by 25 folds in the formulation (Magiri et al., 2018b).  
In this study, we show that PCEP concentration of 20 µg (5 folds decrease in dose relative 
to the highest dose) induced immune responses similar to those seen with 500 µg concentration in 
swine influenza vaccine, which is consistent with other studies showing that the typical (2.3%) 
oil dose of the MF59 adjuvant could be reduced by half (but not 4-fold) without compromising 
immunogenicity and still meet the European criteria for pandemic vaccine licensure (Keitel et al., 
2010).  
 Others showed that reduction of emulsion dose from 2% to 1% or 0.5% (vol/vol) 
squalene in GLA-SE did not compromise immunogenicity in malaria vaccine (Fox et al., 2012) 
but they did not report on the effect on tissue reactogenecity. Interestingly, they reported that 
reduction of the emulsion dose in GLA-SE from 2% to 1% or 0.5% led to higher IgG2a antibody 
and IFN-γ production hence elicit a strong Th1 type of immune response in mice (Fox et al., 
2012). In contrast to our findings with PCEP, a study employing seasonal influenza virus antigen 
and MF59 at doses of 0.125, 0.25, 0.5, and the full dose in 6- to 36-month-old children found no 
difference in reactogenicity between the different adjuvant doses (Della Cioppa et al., 2011). In 
contrast, two different doses of AS03 [AS03A, containing the full dose of 2.5% squalene and 
2.5% tocopherol, versus AS03B, containing a half dose (1.25% squalene and 1.25% tocopherol)] 
when evaluated in another influenza vaccine clinical trial reported that initial immune responses 
elicited by the two different adjuvant doses were equivalent but the durability of the response 
measured at 182 days post vaccination was better with the higher adjuvant dose (Langley et al., 
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2010). 
In conclusion, when the PCEP dose was reduced, we generally observed less histopathological 
damage without impacting the immune response to an influenza vaccine. These results suggest 
that induction of inflammatory responses at the site of injection is necessary for adjuvant activity. 
However, not all responses assessed may be required for adjuvant activity as induction of a very 
severe inflammatory response was not associated with any additional increase in antibody 
responses. Thus, the quality of the inflammatory response is important but severe inflammation 
was not beneficial to antigen-specific immune responses.  
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CHAPTER 6. GENERAL DISCUSSIONS AND CONCLUSIONS 
Vaccination continues to be a very important public health tool in the control of infectious 
diseases in the world (Andre et al., 2008).Vaccines are estimated to prevent approximately 2.5 
million deaths and many more illnesses each year. Vaccines mimic natural infection in the body 
leading to activation of the immune system so that subsequent encounter with similar antigens 
will trigger activation of the memory immune responses (Pasquale et al., 2015). PAMPs are 
constitutively present in infectious agents and can act as vaccine adjuvants that activate PRRs on 
local innate immune cells such as APCs at the injection site. PRR activation on APCs leads to 
initiation of a series of signaling events and eventually induction of protective adaptive immune 
responses to the vaccine antigens (Pashine et al., 2005). Subunit vaccines contain highly purified 
antigens which themselves are poorly immunogenic (presumably because they lack PAMPs) and 
require addition of adjuvants to induce protective immune responses (Ulmer et al., 2006). Despite 
their critical role in vaccines and their use in billions of doses of vaccines for many decades, the 
MOA of many adjuvants remain poorly understood. The lack of detailed information on how 
adjuvants work is a barrier to their rational use in vaccines especially in the development of safe 
and effective vaccines.  
Immunoadjuvants enhance and modulate antigen specific immune responses and serve as 
key components in the development of modern vaccines. This term may generally include either 
specific immunostimulating molecules, which directly activate innate immune receptors, or 
delivery systems, which consist of non-immune stimulating components that function as 
adjuvants by promoting more effective antigen presentation to lymphocytes. Immunostimulatory 
adjuvants enhance the quality and magnitude of the adaptive immune responses by activating 
innate immune responses induced by antigens through increased inflammatory responses at the 
injection site, which are localized, short lived, and without systemic responses (Bachmann & 
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Jennings, 2010). Secondly, by activating and inducing maturation of APCs, which then traffic to 
the draining lymph nodes where they direct the type, magnitude and quality of the adaptive 
immune responses (Dinarello, 2009).  
Due to increasing understanding of pathogen interaction with the immune system, the role 
of adjuvants in modern vaccines is increasingly being understood. Polyphosphazenes are high-
molecular weight, water-soluble polymers that have been shown to promote and enhance long 
lasting immune responses with a variety of viral and bacterial antigens in several animal models 
(Eng et al., 2010; McNeal et al., 1999; Mutwiri et al., 2008). PCEP promote mixed Th1/Th2 type 
of immune responses hence leading to broad-spectrum immunity (Mutwiri et al., 2007). Research 
in our laboratory revealed that the adjuvant PCEP enhances immune responses in various animal 
species including mice, pigs, sheep and cattle (Eng et al., 2010; Mutwiri et al., 2008). 
Recent advances in murine immunobiology indicate that most adjuvants including PCEP 
act by stimulating the innate immune responses leading to induction of cytokine and chemokine 
production at the site of injection (Mutwiri et al., 2008), recruitment of immune cells and 
transport of antigen to the draining lymph node in mice (Awate et al., 2014), increased antigen 
uptake by DCs and activation and maturation of APCs. Recent reports suggest that PCEP injected 
either via the i.m. or i.d. routes induced expression of a set of common genes referred to as 
"adjuvant core response genes" at the site of injection in mice (Awate et al., 2012) and pigs 
(Magiri et al., 2016). In vitro, PCEP stimulates significant production of the innate cytokines IL-
12 and IFN-γ suggesting that activation of innate immunity may be important in mediating its 
adjuvant activity (Mutwiri et al., 2008).  
Understanding the mechanisms by which adjuvants mediate their effects will provide 
critical information on how innate immunity influences the development of adaptive immunity. 
Despite being a critical vaccine component, the mechanisms by which adjuvants work are not 
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fully understood and this is especially true when they are used in large animals. This lack of 
understanding limits our ability to design effective vaccines. As part of this thesis, we 
administered PCEP or PBS via an i.d. injection into pigs and assessed the impact on the 
expression of reported ‘adjuvant response genes’ over time and compared the responses to a 
previously reported study with mice. Studies with mice and pigs revealed species-specific 
differences in PZ-induced stimulation of innate immune responses (Awate et al., 2012; Magiri et 
al., 2016). Intramuscular injection of PCEP induced time-dependent changes in the gene 
expression of many ‘adjuvant core response genes’ (Mosca et al., 2008a) such as chemokine 
genes CCL-2, CCL-4, CCL-5, CCL-12 and CXCL-10 in mice (Sunita Awate et al., 2012) and 
CCL-2 and CXCL-10 (but not CCL- 5) in pigs (Magiri et al., 2016). Major transcription factor 
NF-kB gene and the inflammatory cytokine TNF-α genes were up-regulated in response to PCEP 
in mice (Awate et al., 2012) but not in pigs (Magiri et al., 2016). At the protein level, PCEP 
promoted significant local production of Th1-type proinflammatory cytokines (IL- 1β, Il-6, IL-18 
IFN-γ and TNF-α) and Th2-type cytokines (IL-4 and monocyte chemoattractants CCL-2 and 
CXCL-10) at the site of injection in mice but not systemically (Awate et al., 2012). However, in 
pigs, PCEP induced IL-6 gene expression but not IL-10, IL-17 or IFN-α (Magiri et al., 2016). 
PCEP injection in mice increased the expression of TLR4 and TLR9 at the site of injection 
(Awate et al., 2012) whereas PCEP did not induce significant expression of any of the TLR genes 
in pigs suggesting differences in activation of immune responses in different animal species 
(Magiri et al., 2016). These results suggest that PCEP may modulate antigen-specific immune 
responses by activating early innate immune responses and promoting a strong 
immunostimulatory environment at the site of injection. Our studies provide evidence that the 
effect that adjuvants have on innate immune responses can differ remarkably between species 
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  We previously reported that in mice, injection of PCEP increased cell recruitment and 
cytokine production at the site of injection with PCEP adjuvant. In this study presented in this 
thesis, we evaluated whether PCEP induced similar innate immune responses in pigs. Piglets 
were injected with either PCEP or Emulsigen i.d. and the local cellular infiltration and cytokine 
production were evaluated at the site of injection and the draining lymph nodes. PCEP induced 
infiltration of macrophages, T and B cells, leucocytes and necrotic debris at the site of injection 
as well as PCEP-induced leucocyte infiltration in the draining lymph nodes. Emulsigen induced 
diffuse infiltration of leucocytes, macrophages, and lymphocytes at the site of injection as well as 
at the draining lymph nodes. PCEP induced significant production of interleukin IL-1β, and IL-
13 at the site of injection and IL-1β, and IL-6 at the draining lymph nodes. Emulsigen promoted 
production of IL-1β, IL-6, and IL-12 at the site of injection but not in the draining lymph nodes. 
These results from pigs are consistent with results in mice from other authors who have 
determined that adjuvants induce a local microscopic inflammatory reaction at an injection site 
(Calabro et al., 2011; Schijns, 2000) without gross macroscopic ulcerations (das Dores Moreira et 
al., 2009). Early stages of inflammation can occur through the activation of PRRs on many cells 
including lymphocytes, granulocytes, and endothelial cells (Faure et al., 2001; Muzio et al., 
2000). Tissue necrosis induced by adjuvants as in ‘danger signal’ hypothesis advanced by 
(Matzinger, 1994), who proposed that apart from self/non-self discrimination against infection, 
danger signals from damaged cells (now referred to as “Damage signals”  can trigger activation 
of the immune system through activation of inflammasome leading to release of proinflammatory 
cytokine such as IL-1β. Molecules associated with tissue damage such as uric acid, nucleotides, 
ATP, reactive oxygen intermediates, and cytokines are released at the injection site due to tissue 
damage (Shi et al., 2003). 
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Recent evidence suggests that induction of inflammation and recruitment of immune cells 
to the site of injection are important mechanisms of action for PCEP as an adjuvant. Adjuvants 
can be expensive components in vaccines. If the dose of an adjuvant can be reduced without 
impacting vaccine efficacy, the results could be improved vaccine safety (less signs of 
inflammation at the site of injection) and reduced vaccine cost. We injected varying doses of 
PCEP [(high (500 µg) and medium (100 µg), and low (20 µg) into piglets and evaluated the 
inflammatory responses (granuloma formation, lymphocytes infiltration, epithelial necrosis, and 
suppurative inflammation) at the injection site and the draining lymph nodes and the antigen –
specific immune responses when administered alone or as part of an swine influenza virus H1N1 
vaccine. When PCEP was injected alone, inflammatory cells appeared at the injection site 
between 4 and 14 days after injection, dominated initially by neutrophils, followed by 
lymphocytes and later macrophages in all the PCEP doses. PCEP induced localized and 
controlled cell death in the skin, suggesting that the danger signals released from dead cells 
contributed to the enhanced immunogenicity. We suggest that PCEP appears to be responsible for 
the inflammatory responses at the site of injection that are critical in initiation of the immune 
responses even with reduced doses. Indeed, our recent studies have indicated that PCEP plays a 
role in the recruitment of neutrophils, natural killer cells, macrophages, eosinophils and immature 
dendritic cells to the site of injection and draining lymph nodes (Awate et al., 2012; Awate et al., 
2014; Magiri et al., 2016 ) which in turn promotes the adaptive immune response to a vaccine 
(Magiri et al., 2018a). 
 
In conclusion, we suggest that PCEP directly activates the innate immune responses at the 
site of injection. PCEP induced activation of innate immune responses at the injection site 
involves activation of adjuvant core response genes, production of cytokines and chemokines, 
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recruitment of various immune cells. All these events promote a strong immunocompetent 
environment at the injection site that may significantly contribute to the adjuvant activity of 
PCEP. In general, activation of innate immunity appears to be an important mechanism through 
which PCEP mediates its adjuvant activity. We propose a MOA model whereby PCEP induces 
tissue damage at the site of injection and the subsequent release of damage associated molecular 
patterns (DAMPs) which may activate the inflammasome and contribute to increased 
immunogenicity of the co-administered antigens. 
 
Future directions.  
The trend in vaccine development is moving away from the use of whole-cell or virus 
vaccines to subunit vaccines because of the long track record of safety of such vaccines. 
However, purified antigens often lack sufficient immunogenicity and therefore require addition 
of potent adjuvants to induce protective immune responses. The growing number of immune 
potentiators under investigation targets diverse innate immune mechanisms. Thus, the long-term 
goal should focus on selection of the optimal platforms and identification of key innate immune 
targets for induction of potent, but safe, immune responses.  
We have demonstrated that PCEP induces expression of cytokine, chemokines and 
immune receptors genes, which then lead to secretion of pro-inflammatory cytokines at the site of 
injection thus causing inflammatory responses and immune cells recruitment. Further 
investigations are necessary to comprehend the diverse contribution of this immunostimulatory 
environment at the site of injection to the development of adaptive immune responses and 
identify the immune cells involved by flow cytometry 
The contribution of the antigen to the inflammatory response still remains unclear. We 
have shown that PCEP induced acute but not chronic inflammatory responses at the injection site 
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and the draining lymph nodes when injected i.d. indicating that this adjuvant may be regarded as 
safe for use in this species. Further, When the PCEP dose was reduced, we generally observed 
significantly less histopathological changes without impacting the immune response to an 
influenza vaccine. There are many questions that need to be addressed. For example, does 
adjuvant activity of PCEP depend on the nature of antigen? Some antigens may have microbial 
components that have adjuvant activity, which may results in a synergistic effect hence 
increasing PCEP activity. Does the tissue damage caused by PCEP at the site of injection activate 
the inflammasome though DAMPs?  And if the inflammasome is activated does it contribute to 
the adjuvant activity of PCEP? Are there other possible mechanisms involved in the adjuvant 
activity of PCEP? The mechanistic understanding of the innate immune system in regard to 
adjuvants and the tools to manipulate it are growing, and together these will make a significant 
impact on vaccine development in future.  
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